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Abstract 
 
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder, for which there is 
no effective treatment. Clinical trials in ALS are hindered by the lack of reliable biomarkers to 
enable an early diagnosis and monitoring of disease progression. There is therefore an 
urgent need to develop biomarkers for ALS. In this Thesis, I examined the possibility that 
plasma Neurofilament levels may be a biomarker of disease progression in mouse models 
and ALS patients. 
 
I first developed an enzyme-linked immunosorbent assay (ELISA) method that overcomes a 
well-known technical obstacle, the NfH ’Hook Effect’, to enable accurate quantification of 
plasma Neurofilament Heavy Chain (NfH). Using this ELISA, I next examined the 
longitudinal changes in plasma NfH levels in SOD1G93A mice that model ALS. I observed a 
significant increase in plasma NfH levels as disease progressed, which correlated with the 
decrease in functional and morphological read-outs of neuromuscular function and motor 
neuron survival. Moreover, treatment of SOD1G93A mice with different disease-modifying 
agents, Arimoclomol, Cogane and Riluzole, was found to not only ameliorate disease but 
also reduce plasma NfH levels compared to untreated controls. Plasma NfH levels may 
therefore be of use in monitoring drug efficacy and disease progression in clinical trials. 
Examination of plasma NfH levels in an alternative ALS model with a slower disease 
progression, the SOD1G93Adl mouse, confirmed that plasma NfH levels increase during 
disease progression in models other than the rapidly progressing SOD1G93A model. The 
relevance of these findings of increased plasma NfHs in SOD1 mice as a biomarker of 
disease progression in the human disease were examined in the final Results Chapter using 
serial samples longitudinally collected from a cohort of 136 ALS patients with follow-up up to 
three years. 
 
To sum up, the results presented in this Thesis detail the investigation of plasma NfH levels 
as a disease progression marker in SOD1 mice and in ALS patients.  
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                                0.25mg EDTA per litter of distilled water 
BBB: blood-brain barrier 
BDNF: brain-derived neurotrophic factor 
bNfH: bovine neurofilament heavy chain subunit 
BSA: bovine serum albumin 
BSCB: blood-spinal cord barrier 
bvFTD: behavioural variant frontotemporal lobar degeneration 
BW: body weight 
C9orf72: chromosome 9 open reading frame 72 
CAFS: Combined Assessment of Function and Survival 
CC: corpus callosum 
cDNA: complementary deoxyribonucleic acid  
CMAP: compound muscle action potential 
CNS: central nervous system  
CSF: cerebral spinal fluid 
CST: corticospinal tract 
CV: coefficient of variation 
DNA: deoxyribonucleic acid 
dNTP: deoxyribonucleotide triphosphate 
DTI: diffusion tensor imaging 
ECF: extracellular fluid 
EDL: Extensor Digitorum Longus muscle 
EDTA: ethylene diamine tetraacetic acid 
EGTA: ethylene glycol tetraacetic acid 
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EI: echo intensity 
EIM: Electrical impedance myography 
ELISA: Enzyme-linked immunosorbent assay 
EMG: electromyography 
ER: endoplasmic reticulum 
FA: fractional anisotropic 
fALS: familial ALS 
FDA: U.S. Food and Drug Administration 
fMRI: Functional magnetic resonance imaging 
FTD: frontotemporal dementia 
FTLD: frontotemporal lobar degeneration  
FUS: fused in sarcoma 
FVC: forced vital capacity 
GDNF: glial cell-derived neurotrophic factor 
GEP: gene expression profiling 
GLT1: Glial glutamate transporter 1 
GS: Grip strength 
GS/BW: the ratio of grip strength and body weight 
GTPase: a hydrolase enzyme of guanosine triphosphate  
GWAS: genome-wide association studies 
HC: healthy controls 
HHD: handheld dynamometry 
Hib: Haemophilus influenza type b 
HRP: horseradish peroxidase 
HSE: heat shock element 
HSF1: heat shock transcription factor 1 
Hsp: heat shock protein 
HSR: heat shock response 
IgG: immunoglobulin G 
i.p.: intra-peritoneal 
IQR: interquartile range 
LMN: lower motor neuron 
microRNA: small non-coding RNA molecule 
MN: motor neuron                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
MND: motor neuron disease 
MRC: UK Medical Research Council 
MRI: magnetic resonance imaging 
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mRNA: messenger RNA 
MRSI: magnetic resonance spectroscopy imaging 
MS: multiple sclerosis 
mSOD1: mutant SOD1  
MU: motor unit 
MUNE: motor unit number estimation 
MUS: muscle ultrasonography 
MW: molecular weight 
NC: neurological disease controls 
NCS: nerve conduction studies  
Nfs: neurofilament proteins 
NfL: neurofilament light chain subunit 
NfM: neurofilament median chain subunit 
NfH: neurofilament heavy chain subunit 
NfHSMI34: hyperphosphorylated NfH detected by using SMI-34R (Covance, USA) as  
                primary antibody 
NfHSMI35: variably-phosphorylated NfH detected by using SMI-35R (Covance, USA)  
               as primary antibody 
NI: neurophysiological index  
NMJ: neuromuscular junction 
NOD: normalised optical density 
OD: optical density 
P-body: processing body 
PBP: progressive bulbar palsy 
PCR: polymerase chain reaction 
PD: Parkinson’s disease 
PET: positron emission tomography  
PFA: paraformaldehyde 
PLS: primary lateral sclerosis 
PLMN: pure lower motor neuron 
PMA: progressive muscular atrophy 
PNFA: progressive non-fluent aphasia 
pNfH: phosphorylated Neurofilament heavy chain subunit 
PRL: prolactin 
PUMN: pure upper motor neuron 
RNA: ribonucleic acid 
RNP: RNA-binding protein 
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ROS: reactive oxygen species 
RT: room temperature 
sALS: sporadic ALS  
SDS gel: sodium dodecyl sulphate polyacrylamide gel 
SELDI: surface-enhanced laser desorption/ionization 
S.E.M.: standard error of mean 
SD: semantic dementia 
SG: stress granules 
S-MUP: single motor unit potential 
SNP: single nucleotide polymorphism 
SOD1: superoxide dismutase 1 
TA: Tibialis Anterior muscle 
TDP-43: Tar DNA-binding protein 43 
TIF: translation initiation factor 
TMB: 3, 3’, 5, 5’-tetramethylbenzidine 
TMS: transcranial magnetic stimulation 
UMN: upper motor neuron 
UPR: unfolded protein response 
VEGF: vascular endothelial growth factor 
WB: western blot 
WT: wild-type 
wtSOD1: wild-type SOD1 
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Chapter 1 
General Introduction 
 
 
In this Thesis, I undertook a series of experiments aimed at developing a plasma-based 
biomarker of disease progression in the neurodegenerative disease Amyotrophic Lateral 
Sclerosis (ALS). 
 
In this Introduction, I will first review the recent advances in our understanding of the 
genetics and molecular pathomechanisms involved in ALS. In addition, I will review the 
recent progress in clinical trials and discuss possible solutions to improve the design of 
clinical trials in ALS. An overview of the current status of biomarker development in ALS is 
also presented.  
1.1 Amyotrophic Lateral Sclerosis 
Amyotrophic Lateral Sclerosis (ALS) is an adult-onset, fatal neurodegenerative disorder, 
characterised by the selective degeneration of motor neurons in the spinal cord, brainstem 
and motor cortex, resulting in muscle paralysis and death, usually within 3-5 years of 
symptom onset. At present, there is no specific diagnostic test or biomarker for ALS, and the 
diagnosis relies on the fulfilment of clinical criteria defined by the main clinical manifestations 
of each disease stage (Brooks et al., 2000). This lack of diagnostic aids results in a typical 
gap of 9-15 months between symptom onset and diagnosis, a delay that not only reduces 
the patient’s chance of maximising benefit from Riluzole, the only therapeutic agent currently 
available for ALS, but also hinders the early recruitment of ALS patients into clinical trials, 
thereby reducing the likelihood of success (Cellura et al., 2012; Chio et al., 2009; Iwasaki et 
al., 2002). Despite extensive efforts to develop effective treatments, Riluzole remains to date 
the only FDA-approved drug for ALS. This drug prolongs survival in ALS patients by 3 
months after 18-month treatment (Miller et al., 2007). Other supportive treatments deal with 
the consequences of disease progression, such as immobility, malnutrition and respiratory 
failure (Kiernan et al., 2011; Miller et al., 2007).  
 
The mean incidence of ALS is approximately 1.7-3.0 cases per 100,000 per year, and men 
have a slightly higher incidence than women (1.2-1.5:1). The age of clinical onset of ALS is 
highly variable: peak age at onset is 58-63 years for sporadic ALS (sALS) and 47-52 for 
familial ALS (fALS). The incidence of ALS decreases after 80 years of age. The prevalence 
of ALS is around 6 per 100,000 per year, and the life time risk for ALS is 1:400 in women 
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and 1:350 in men in the European population (Beghi et al., 2006; Hardiman et al., 2011; 
Johnston et al., 2006; Logroscino et al., 2010).  
1.1.1 Clinical phenotypes of ALS 
The clinical presentation of ALS is the presence of upper motor neuron (UMN) and lower 
motor neuron (LMN) signs, resulting from motor neuron (MN) degeneration in the motor 
cortex, brainstem and spinal cord. Patients can present with bulbar onset (25%), limb onset 
(70%) or trunk/respiratory onset (5%), followed by subsequent spreading to the adjacent 
regions (Vucic et al., 2007). UMN involvement in the limbs leads to spasticity, muscle 
weakness, brisk deep tendon reflexes, while UMN involvement in the bulbar region causes 
spastic dysarthria, brisk gag and jaw jerk. LMN involvement in the limbs features muscle 
weakness, wasting and fasciculation, whilst bulbar LMN dysfunction results in flaccid 
dysarthria, dysphagia, as well as weakness, wasting, and fasciculations in the tongue 
(Kiernan et al., 2011). 
   
Thus, the phenotype of ALS is highly heterogeneous due to the varying involvement of 
spinal and bulbar UMNs and LMNs, site of onset, and rate of progression (Ravits and La 
Spada, 2009). In general, the main presentations of ALS can be sub-classified as i) limb-
onset ALS with a combination of UMN and LMN signs in the limb, ii) bulbar-onset ALS, with 
speech and swallowing difficulties first and followed by later limb involvement; iii) the less 
common pure UMN involvement of primary lateral sclerosis (PLS), and iv) the pure LMN 
involvement of progressive muscular atrophy (PMA) (Kiernan et al., 2011).  
 
According to a recent study, the ALS phenotypes reported in the literature can be further 
sub-classified into 8 sub-groups, with distinct epidemiological and clinical characteristics 
(Chio et al., 2011a). These phenotypes were determined from 1132 ALS patients, and are 
defined as follows: 
i) Classic (Charcot’s) phenotype: onset of symptoms in the upper or lower limbs, with clear 
but not predominant pyramidal signs;  
 
ii) Bulbar phenotype: a bulbar onset with dysarthria and/or dysphagia, tongue wasting and 
fasciculation for the first 6 months, followed by limb involvement later on;  
 
iii) Flail arm phenotype:  progressive, predominantly proximal, weakness and wasting in the 
upper limbs, may or may not present with pathological deep tendon reflexes or Hoffman sign 
23 | P a g e  
 
in the upper limbs. Functional involvement had to be confined to the flail limbs for at least 12 
months after symptom onset;  
 
iv) Flail leg phenotype: progressive distal onset of weakness and wasting in the lower limbs, 
with or without pathological deep tendon reflexes or Babinski sign. However, 
symptoms/signs beginning proximally in the legs without distal involvement at presentation 
were classified as classic ALS;  
 
v) Pyramidal phenotype (UMN predominant ALS): dominant pyramidal signs of severe 
spastic para/tetraparesis, associated with Babinski or Hoffmann sign, hyperactive reflexes, 
clonic jaw jerk, dysarthric speech and pseudobulbar signs, are accompanied by clear cut 
features of LMN impairment from onset of the disease and by the presence of EMG findings 
of acute and chronic denervation in at least two different sites;  
 
vi) Respiratory phenotype: predominant respiratory involvement at onset with orthopnoea or 
dyspnoea at rest or during exertion, accompanied by only mild spinal or bulbar signs in the 
first 6 months. UMN involvement is evident; 
 
vii) Pure LMN (PLMN): clinical and electrophysiological evidence of progressive LMN signs. 
Clinical UMN signs are excluded;  
 
viii) Pure UMN (PUMN): pure UMN involvement. Patients with clinical and 
electrophysiological involvement of LMN signs are excluded.   
The epidemiological and clinical characteristics of these sub-groups are summarised in 
Table 1.1. Classic and bulbar phenotypes are the most common sub-groups and have 
similar annual incident rates. Men are predominant in classic, flail arm, respiratory, PLMN 
phenotypes. Age at onset is significantly lower in pyramidal, PLMN and PUMN phenotypes, 
while bulbar phenotype has the highest age at onset. In addition, the better outcome in 
tracheostomy-free survival are found in PLMN, pyramidal, PUMN, and flail arm phenotypes, 
whist the bulbar phenotype has the worst outcome. Factors influencing outcomes include 
age at onset, certain phenotypes and co-morbidity of frontotemporal dementia (FTD) (Chio 
et al., 2011a).This sub-classification might render in full the clinical heterogeneity of ALS, 
which may be relevant to the underlying pathogenesis of ALS and of use in the design of 
clinical trials.  
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Table 1.1. Summary of epidemiological and clinical characteristics of ALS phenotypes. 
Phenotype No of 
cases 
(%) 
Annual 
incidence 
rate  
Mean 
Men to 
women 
incidence 
rate ratio 
Age at 
onset 
(years) 
Mean (SD)* 
Median 
(IQR)
‡
 
Diagnostic 
latency 
(months) 
Mean (SD)* 
Median (IQR)
‡
 
Cases 
with FTD 
(%)
†
 
Classic 404 
(30.3) 
0.94 1.65:1 62.8 (11.3) 
64.6 (56.1, 
70.6) 
10.9 (9.6) 
8 (5,13) 
16 (4.0) 
Bulbar 456 
(34.2) 
1.05 0.98:1 68.8 (9.7) 
69.9 (62.9, 
75.0) 
9.8 (7.0) 
8 (5,12) 
41 (9.0) 
Flail arm 74 (5.5) 0.17 4:1 62.6 (11.8) 
63.3 (54.8, 
72.2) 
12.8 (11.0) 
9 (5, 15) 
1 (1.4) 
Flail leg 173 
(13.0) 
0.40 1.03:1 65.0 (9.6) 
65.6 (58.5, 
71.2) 
13.1 (10.1) 
11 (7, 17) 
7 (4.1) 
Pyramidal 120 
(9.1) 
0.28 1.04:1 58.3 (13.5) 
60.1 (49.2, 
68.3) 
15.9 (13.4) 
12 (6, 22) 
3 (2.5) 
Respiratory 14 (1.1) 0.03 6:1 62.2 (8.6) 
62.0 (58.3, 
65.3) 
6.4 (4.3) 
5 (3, 9) 
- 
PUMN 38 (2.9) 0.08 2.04:1 56.2 (11.3) 
55.2 (45.7, 
61.3) 
15.5 (12.4) 
14 (10, 19) 
- 
PLMN 53 (4.0) 0.12 0.98:1 58.9 (10.9) 
56.5 (48.3, 
62.6) 
15.9 (14.3) 
15 (10, 19) 
2 (3.8) 
Overall ALS 1322 3.07 1.29:1 64.3 (11.3) 
65.3 (59.7, 
71.8) 
10.8 (10.4) 
9 (5,14) 
70 (5.4) 
Adapted from Chio et al., 2011  
* sd: Standard deviation, ANOVA test, p=0.0001 
‡ IQR: Interquartile range 
† chi-Squared test, p=0.0001 
 
 
 
 
 
 
 
 
 
 
 
 
25 | P a g e  
 
1.1.2 Cognitive involvement in ALS                                                                          
Cognitive changes in ALS were not described in Charcot’s original description of ALS and 
cognition was regarded to be largely spared in ALS until recent years following the 
development of consensus on clinical diagnostic criteria of frontotemporal lobar 
degeneration (FTLD) (Neary et al., 1998) and the findings of the connection between ALS 
and FTLD   (Achi and Rudnicki, 2012; Neary et al., 2000). 
1.1.2.1 Frontotemporal lobar degeneration (FTLD) 
FTLD is defined by focal neurodegeneration in the frontal and anterior temporal lobes of the 
brain and is one of the leading causes of dementia, particularly in patients before 65 years of 
age. The incidence rate of FTLD is 3.5-4.1 per 100,000 population and its prevalence rate is 
10-20 per 100,000 population among the population aged between 45-65 years of age (Van 
Langenhove et al., 2012). The median disease duration of FTLD is 6-8 years (Hodges et al., 
2003). According to its clinical manifestations, FTLD can be divided into three sub-types, 
which can gradually overlap as disease progresses (Kertesz et al., 2005; Van Langenhove 
et al., 2012). The three sub-types of FTLD are:  
 
i) Behavioural variant FTLD (bvFTD): the most frequently diagnosed variant, with 
predominant prefrontal neurodegeneration. Patients present with marked changes in 
behaviour and personality; 
 
ii) Progressive non-fluent aphasia (PNFA): predominant left perisylvian atrophy. Patients 
present with loss of motor speech fluency and agrammatism, but language comprehension 
is relatively preserved;   
 
iii) Semantic dementia (SD): pathology is mainly in the anterior temporal lobes. Patients 
develop progressive comprehension deficits and naming errors in speech.  
1.1.2.2 The clinical spectrum of ALS and FTLD 
The association between dementia or psychiatric disturbances and ALS has become 
increasingly important during the last decade (Bak and Hodges, 2001). It is now known that 
of the total population of ALS patients, 15-18% also have FTLD with TAR deoxyribonucleic 
acid (DNA)-binding protein 43 (TDP-43)-positive inclusions in cortical neurons (Lomen-
Hoerth et al., 2003; Mackenzie et al., 2007; Ringholz et al., 2005), and at least 50% have 
evidence for more subtle cognitive and/or behavioural dysfunction (Ringholz et al., 2005). 
FTD symptoms in ALS patients are usually those of bvFTD (Lillo et al., 2010), and typically 
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precede the onset of ALS (Hu et al., 2009). On the other hand, of patients with FTLD, 15% 
have ALS and many more have only some lower motor neuron involvement (Burrell et al., 
2011; Lomen-Hoerth et al., 2002). Patients with ALS-FTD typically have onset of symptoms 
in their 50’s, which, in most cases, present first with cognitive changes. The interval between 
cognitive symptoms and weakness varies, with a mean of 2 years (Lillo et al., 2010), and 
bulbar onset is found more often than in pure ALS patients in some studies (Bak and 
Hodges, 2004; Lillo et al., 2010). Survival in patients with ALS-FTLD is worse than those 
with ALS alone or FTLD alone, particularly in those with dysexecutive function (Elamin et al., 
2011; Lillo et al., 2010). These findings suggest that ALS and FTLD are at two ends of a 
clinical continuum. Table 1.2 summarises the diagnostic categories of the FTLD-ALS 
disease spectrum. It is now known that genetics and underlying molecular mechanism may 
explain the relationship between ALS and FTLD (Van Langenhove et al., 2012). Figure 1.1 
shows the molecular relationships between ALS and FTLD. 
1.1.3 Cognitive and clinical characteristics in ALS patients with the chromosome 9 
open reading frame 72 gene (C9orf72) expansion 
The hexanucleotide repeat expansion in the C9orf72 gene accounts for a significant 
proportion of fALS (34.2%), sALS (5.9%), familial FTLD (25.9%) and sporadic FTLD (5.1%) 
and is currently the major genetic cause of ALS and/or FTLD (Cooper-Knock et al., 2012a; 
DeJesus-Hernandez et al., 2011; Majounie et al., 2012; Renton et al., 2011; van Blitterswijk 
et al., 2012). Although the function of C9orf72 remains to be established, it appears that ALS 
patients carrying this repeat expansion present a recognisable phenotype among the ALS 
population (Byrne et al., 2012). ALS patients with the C9orf72 repeat expansion have an 
earlier onset, more co-morbid FTLD and a shorter survival, compared to those without the 
expansion (Byrne et al., 2012; Cooper-Knock et al., 2012a).   
1.2 Genetics of Amyotrophic Lateral Sclerosis 
Although the majority of ALS cases are sporadic ALS (sALS), approximately 10% of cases 
are familial (fALS) with a Mendelian pattern of inheritance. fALS cases are clinically 
indistinguishable from and share similar pathological features with sALS cases. Identifying 
causative fALS genes offers a direct approach to investigate the underlying 
pathomechanisms of ALS and thus may help identifying therapeutic targets. However, there 
is also growing evidence that sALS may also have a genetic basis. Although the genetic 
effect in sALS might be smaller than those in fALS, such so called ‘susceptibility’ genes, 
together with possible environmental factors may predispose the development of sALS 
(Sreedharan and Shaw, 2009). 
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Table 1.2. Diagnostic categories of FTLD-ALS disease spectrum. 
Disease Subtypes Main clinical characteristics 
FTLD bvFTD Disinhibition, apathy, lack of emotional concern, hyperorality, 
stereotypic behaviour and executive dysfunction 
 PNFA Laboured speech, agrammatism with relatively spared 
comprehension 
 SD Comprehension deficits, naming errors with fluent speech 
FTLD-MND  FTLD with minor motor system dysfunction 
ALS-FTLD  FTLD and ALS  
ALSci  ALS with minor cognitive impairment 
ALSbi  ALS with minor behavioural impairment 
ALS  Pure ALS motor symptoms 
Adapted from van Langenhove et al., 2012. 
Abbreviations: ALSbi: ALS with a mild behavioural impairment; ALSci: ALS with a mild 
cognitive impairment; bvFTD: behavioural variant FTLD; PNFA: progressive non-fluent 
aphasia; SD: semantic dementia; MND: Motor neuron disease. 
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Figure 1.1 
 
 
 
 
Figure 1.1. Clinical disease continuum and molecular relationships between FTLD and 
ALS. Pure FTLD and pure ALS are the two ends of a clinical disease continuum. Patients 
who present clinical features of both disorders are classified as ALS-FTLD. ALS patients 
showing some cognitive or behavioural changes but not meeting the criteria for FTLD are 
classified as ALSci (ALS with cognitive impairment) or ALSbi (ALS with behaviour 
impairment). FTLD patients who show minor motor neuron involvement without developing 
ALS are classified as FTLD-MND like. Pathological proteins involved in ALS and FTLD are 
shown in ovals, while causal genes are shown in rectangles. Black solid and dashed 
between diseases and pathological proteins/genes indicate strong and putative correlations, 
respectively. Pink solid lines show the correlations between genes and pathological proteins. 
Adapted from van Langenhove et al., 2012. 
 
 
 
 
 
 
 
29 | P a g e  
 
1.2.1 Causative genes for ALS 
To date, at least 20 genes and chromosomal loci have been associated with fALS (Al-
Chalabi et al., 2012; Andersen and Al-Chalabi, 2011; Beleza-Meireles and Al-Chalabi, 2009; 
Ferraiuolo et al., 2011), and these genes are summarised in Table 1.3.  
 
Mutations in the superoxide dismutase 1 (SOD1) gene account for 20% of fALS cases 
(Rosen et al., 1993), and can be found in approximate 2-7 % sALS cases (Ticozzi et al., 
2011). To date, over 165 different genetic mutations spanning the entire SOD1 gene have 
been discovered (http://alsod.iop.kcl.ac.uk/Als/index.aspx). Transgenic mice carrying a 
mutant human SOD1 gene develop motor dysfunction, muscle wasting and death, reflecting 
the symptoms of human ALS, and have contributed enormously to our understanding of the 
underlying pathophysiology of ALS and as the test bed of preclinical drug trials (Gurney et al., 
1994).  
 
Furthermore, recent genetic discoveries have identified a number of new important ALS-
causing genes, including genes involved in protein quality control (UBQLN2, VCP), 
endosomal trafficking and cell signalling (ALS2, VAPB, FIG4, OPTN), cytoskeletal 
function (MAPT, PFN1) and glutamate excitotoxicity (DAO). However, the most 
significant mutations have been identified in genes that code for proteins involved in RNA 
(ribonucleic acid) processing, specifically TARDBP, FUS, SETX, ANG, HNRNPA1 and 
C9orf72, as shown in Table 1.3. The identification of these new ALS-causing genes has 
widened our understanding of the underlying molecular pathophysiology in ALS.  
 
Mutations in the Tar DNA-binding protein 43 (TARDBP) and in the Fused in Sarcoma (FUS) 
genes (Neumann et al., 2009; Neumann et al., 2006), which have been identified in both 
sALS and fALS patients, account for 5% and 4% of the fALS cases respectively. Moreover, a 
hexanucleotide repeat expansion in the C9orf72 gene has recently been identified in more 
than half of fALS cases in a Finnish cohort and may indeed account for more than 30-40% of 
all fALS cases in the USA and North England and for about 10% of the overall sporadic ALS 
population (Cooper-Knock et al., 2012a; DeJesus-Hernandez et al., 2011; Renton et al., 
2011). These most recent genetic discoveries have also revealed important links between 
ALS and other neurodegenerative diseases, in particular FTLD, as well as important clues 
regarding the pathomechanisms of disease, which can be used in developing novel 
therapeutic targets (Andersen and Al-Chalabi, 2011). 
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Table 1.3. Genes associated with familial ALS. 
Genetic subtype 
(Estimated % of fALS) 
Gene  
locus 
Gene Inheritance/ Onset Phenotypic MND variants Other features Reference 
Oxidative Stress 
ALS1 
(20%) 
21q22 Superoxide dismutase 1 (SOD1) AD/Adult ALS, PMA, PBP (rare) 
BFA (rare) 
Cognitive impairment, 
Autonomic dysfunction,  
FTD (rare);  
Cerebellar ataxia 
(Rosen et al., 1993) 
Endosomal trafficking and cell signalling 
ALS2 
(<1%) 
2q33.2 Alsin (ALS2) AR/Juvenile Juvenile PLS, juvenile ALS or 
infantile HSP 
Unknown (Hadano et al., 2001; 
Yang et al., 2001) 
ALS8 
(<1%) 
20q13.3 Vesicle-associated membrane 
protein-associated protein B 
(VAPB) 
AD/Adult ALS, PBP, or PMA Motor neuropathy (Chen et al., 2010; 
Nishimura et al., 2004) 
ALS11 6q21 Polyphosphoinositide phosphatase 
(FIG4) 
AD/Adult ALS, PLS, HSP CMT4J‡, Cognitive impairment (Chow et al., 2009) 
ALS12 
(<1%) 
10p13 Optineurin (OPTN) AD and AR /Adult ALS-FTD POAG‡, FTD (Maruyama et al., 2010) 
RNA binding and/or processing dysfunctions 
ALS4 9q34 Senataxin (SETX) AD/Juvenile ALS AOA2, cerebellar ataxia, motor 
neuropathy 
(Chen et al., 2004) 
ALS6 
(1-5%) 
16p11.2 Fused in sarcoma (FUS) AD/Adult ALS, ALS-FTD Parkinsonism, FTD (Kwiatkowski et al., 
2009; Vance et al., 
2009) 
ALS9 
(<1%) 
14q11.2 Angiogenin (ANG) AD/Adult ALS, PBP or ALS-FTD Parkinsonism  (Greenway et al., 2006; 
van Es et al., 2009) 
ALS10 
(1-5%) 
1p36.2 Tar DNA-binding protein 
(TARDBP) 
AD/Adult ALS, ALS-FTD PSP, PD, FTD, Chorea (Kabashi et al., 2008; 
Sreedharan et al., 2008) 
ALS-FTD 
(40-50%) 
 
9p21.2 Chromosome 9 open reading 
frame 72 (C9orf72) 
AD/Adult ALS, ALS-FTD, ALS-
Parkinsonism 
FTD, Psychosis, Parkinsonism (DeJesus-Hernandez et 
al., 2011; Morita et al., 
2006; Renton et al., 
2011; Vance et al., 
2006; Williams et al., 
2013) 
ND 12q13.13 Heterogeneous nuclear 
ribonucleoprotein A1 (HNRNP A1) 
AD/NA ALS IBM‡ (Kim et al., 2013) 
Ubiquitin/protein degradation 
ND 
(<1%) 
9p13-p12 Valosin-containing protein (VCP) AD/Adult ALS, ALS-FTD IBMPFD‡, Dementia, FTD (Johnson et al., 2010) 
ALSX 
(<1%) 
Xp11 Ubiquilin 2 (UBQLN2) X-linked/ Adult 
and Juvenile 
ALS, ALS/dementia Dementia, FTD (Deng et al., 2011) 
Cytoskeleton 
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ALS-dementia-PD 17q21 Microtubule-associated protein tau 
(MAPT) 
AD/Adult ALS-FTD FTD; PSP, PD, CBD (Hutton et al., 1998) 
ND 17p13.2 Profilin 1 (PFN1) AD/Adult ALS NA (Wu et al., 2012) 
Glutamate excitotoxicity 
ND 
(<1%) 
12q24 D-amino acid oxidase (DAO) AD/Adult ALS NA (Mitchell et al., 2010) 
Other genes 
ALS5 15q15-q21 Spatacsin (SPG11) AR/Juvenile Juvenile ALS NA (Orlacchio et al., 2010) 
ALS-FTD 9p13.3 Ơ Non-opioid receptor 1 (SIGMAR 
1) 
AD/Adult 
AR/Juvenile 
ALS, ALS-FTD FTD (Al-Saif et al., 2011; Luty 
et al., 2010) 
Unknown genes 
ALS3 18q21 Unknown AD/Adult ALS NA (Hand et al., 2002) 
ALS7 20ptel-p13 Unknown AD/Adult ALS NA (Sapp et al., 2003) 
 
Adapted from Andersen and Al-Chalabi, 2011 and Ferraiuolo et al., 2011. 
‡Clinical features reported in non-ALS patients with mutations not associated with ALS.  
Abbreviations: AD: autosomal dominant; ALS, amyotrophic lateral sclerosis; AOA2, ataxia with oculomotor apraxia type 2; AR: autosomal 
recessive; BFA, benign focal amyotrophy; CMT4J: Charcot-Marie-Tooth disease type 4J; FTD, frontotemporal dementia; HSP, hereditary 
spastic paraparesis; IBM, inclusion body myopathy; IBMPFD, Inclusion body myopathy with Paget disease and frontotemporal dementia; MND, 
motor neuron disease; NA, information not available; ND: not defined; PBP, progressive bulbar palsy; PD, Parkinson’s disease; PLS, primary 
lateral sclerosis; PMA, progressive muscular atrophy; POAG, Primary open-angle Glaucoma; PSP, progressive supranuclear palsy. 
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1.2.2 Susceptibility and modifier genes 
The search for susceptibility and modifier genes in sALS can be approached by a 
number of experimental approaches: 
i) Candidate gene-based approaches: Targets are chosen according to the 
molecular mechanisms identified through known causative genes in fALS such as 
cytoskeletal structure [neurofilament heavy chain subunit (NEFH), dynactin 
(DCTN1)], hypoxia and oxidative stress [vascular endothelial growth factor (VEGF), 
paraoxonase (PON)], motor neuron survival [survival motor neuron (SMN), ciliary 
neurotrophic factor (CNTF), leukaemia inhibitory factor (LIF)] and neurodegenerative 
disorders [hemochromatosis (HFE), apolipoprotein E4 allele (APOE4)] (Valdmanis 
and Rouleau, 2008);  
 
ii) Genome-wide association studies (GWAS): GWAS enables the identification of 
novel genes and pathways without any assumptions about the genomic nature or 
location of the casual variants (Sreedharan and Shaw, 2009). With large-scale 
GWAS, it has been possible to identify reliable single nucleotide polymorphism 
(SNPs) and copy number variants for sALS, which are then verified by replication in 
another cohort. This approach has identified five significant associations in sALS:  
 
a) FLJ10986: an uncharacterised gene (Dunckley et al., 2007);   
b) ITPR2: the inositol 1,4,5-triphosphate receptor 2 gene (van Es et al., 
2007);   
c) DPP6: dipeptidyl peptidase 6 gene (van Es et al., 2008); 
d) ELP3: elongator protein 3 gene (Simpson et al., 2009); 
e) KIFAP3: kinesin-associated protein 3 (Landers et al., 2009). 
The effect of these identified variants still requires further investigation (Dupre and 
Valdmanis, 2009). However, some subsequent GWAS in smaller German 
(FLJ10986 & ITPR2), Italian (DPP6), French-Canadian (DPP6 & FGGY) and 
Chinese (FLJ10986, ITPR2, DPP6 & KIFAP3) cohorts failed to replicate the 
association found in large-scale surveys (Chen et al., 2012; Daoud et al., 2010; 
Fernandez-Santiago et al., 2011; Fogh et al., 2011), whilst others confirmed the 
initial findings in KIFAP3 (Orsetti et al., 2011). These results suggest that a 
geography/population-specific effect may be present in these variants.   
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Table 1.4 summarises the susceptibility and modifier genes for ALS identified 
through candidate gene-based approaches and large-scale GWAS approach. 
1.3 Disease pathomechanisms in ALS 
ALS is a complex disease involving dysfunction of several cellular pathways in both 
motor neurons as well as neighbouring glial cells (Ferraiuolo et al., 2011). Several of 
the main molecular pathways that have been proposed to be affected in ALS include:  
i) Oxidative stress; ii) Mitochondrial dysfunction; iii) Excitotoxicity; iv) Endoplasmic 
reticulum (ER) stress; v) Protein aggregation; vi) Dysregulation of endosomal 
trafficking; vii) Aberrant axonal transport; viii) Dysregulated transcription and RNA 
processing; ix) Neuroinflammation and non-cell-autonomous processes. These 
pathways are summarised in Fig. 1.2.  
1.3.1 New insights into the pathogenesis of ALS 
Several recent breakthroughs in our understanding of the genetic and molecular 
pathology of ALS have led to important changes in our understanding of ALS 
pathomechanisms.  
1.3.1.1 A failure of proteostasis: new findings about this long-known 
mechanism 
Intracellular aggregates of mutant protein are established pathological hallmarks of 
a number of neurodegenerative disorders including ALS. Increased oxidative stress, 
excitotoxicity, mitochondrial dysfunction, neuroinflammation, and aberrant RNA 
metabolism all contribute to aberrant protein folding, facilitating the formation of 
aggregates, which can further cause downstream subcellular dysfunctions 
(Ferraiuolo et al., 2011). Hence, an effective protein quality control is an important 
cellular defence system to prevent toxic protein aggregation due to cellular stress. 
Figure 1.3 shows four main protein quality control machineries present in cells, 
which are protein refolding, proteasomal degradation, autophagy and ER unfolded 
protein response. 
1.3.1.1.1 Both mutant SOD1 and oxidised wild-type SOD1 misfold and result in 
increased cellular stress        
SOD1, a ubiquitous cytoplasmic and mitochondrial antioxidant enzyme, catalyses 
the harmful reactive oxygen species (ROS) products, hence prevents oxidative 
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Table 1.4 Summary of susceptibility and modifier genes in ALS. 
Genes Identified in 
patients 
group  
Nature of 
variation 
Function Effect of variation References 
GWAS 
FLJ10986 sporadic SNP* unknown unknown (Dunckley et al., 2007) 
ITPR2 sporadic SNP Glutamate-mediated neurotransmission,  
Intracellular Ca
2+
 homeostasis,  
Apoptosis. 
unknown (van Es et al., 2007) 
DPP6 sporadic SNP Neuropeptide homeostasis, 
Modulation of voltage-gated K
+
 channels 
unknown (van Es et al., 2008) 
ELP3 sporadic SNP RNA processing, Gene expression, 
Neuroprotection. 
unknown (Simpson et al., 2009) 
KIFAP3 sporadic SNP Kinesin motor subunit Reduced expression; longer survival (Landers et al., 2009) 
Candidate gene-based studies 
NEFH Sporadic 
/familial 
KSP in/del** Cytoplasmic type II intermediate filament Accumulation (Al-Chalabi et al., 1999; 
Figlewicz et al., 1994) 
PRPH Familial 
/sporadic 
SNP,  
In/del 
 
Type III intermediate filament Accumulation, Disruption of Neurofilament 
assembly 
(Corrado et al., 2011; 
Gros-Louis et al., 2004; 
Leung et al., 2004) 
VEGF sporadic SNP in 
promotor 
Mitogen involved in angiogenic activity Reduced expression (Lambrechts et al., 2003)  
PON1 sporadic SNP Anti-oxidant and detoxifying properties Reduced activity (Slowik et al., 2006) 
SMN sporadic Copy 
number 
mRNA metabolism, neuronal 
development and synapse formation 
unknown (Corcia et al., 2002) 
CNTF familial Null mutation Neurotrophic factor inactive (Giess et al., 2002) 
LIF sporadic SNP Neurotrophic factor unknown (Giess et al., 2000) 
HFE sporadic SNP Cellular iron regulation Decreased expression of Cu/Zn-SOD1, α-
tubulin and β-actin; 
Disruption of axonal transport 
(Wang et al., 2004) 
APOE sporadic Haplotype Lipid metabolism unknown (Li et al., 2004; Zetterberg 
et al., 2008) 
Adapted from Valdmanis and Rouleau 2008, Sreedharan and Shaw, 2004, Anderson and Al-Chalabi, 2011. 
Abbreviations: *SNP, single nucleotide polymorphism; **KSP in/del, lysine-serine-proline insertion/deletion
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Figure 1.2  
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Figure 1.2. Molecular pathogenesis of amyotrophic lateral sclerosis. ALS is a 
complex disease involving activation of several cellular pathways in motor neurons 
and surrounding neighbours. Up-regulated oxidative stress, aberrant RNA 
processing contribute to aberrant protein folding, resulting in aggregates which can 
lead to proteasome impairment, ER stress, activation of autophagy and apoptotic 
pathways. Mitochondrial dysfunction and dysregulation of calcium influx can also 
lead to apoptosis. The failure of axons, in cytoskeletal and in cargo transport, 
contributes to dying-back axonopathy, denervation and muscle atrophy. Astrocytes 
are involved in the expression of the glutamate reuptake transporter EAAT2 as well 
as the secretion of inflammatory mediators, while oligodendrocytes take part in the 
supply of lactate. Microglia activate a serious of inflammatory mediators and is a key 
player of neuroinflammation, which is associated with the function of T-cells. 
Adapted from Robberecht and Philips, 2013 and Kalmar et al., 2013. 
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Figure 1.3 
 
 
  
Figure 1.3. The protein quality control machinery. This Figure summarises 
schematically the protein quality control machineries and the chaperone-co-
chaperone network. Hsp70 is a crucial component of all pathways, including 
refolding, proteasomal degradation, autophagy and ER unfolded protein response. 
Abbreviations: ATF6, Activating transcription factor 6; BAG-3, Bcl-2-associated 
athanogene 3; Grp78, 78 kDa glucose-regulated protein; IRE1, inositol-requiring 
enzyme 1; LAMP2A, Lysosome-associated membrane protein 2A; PERK, protein 
kinase RNA-like endoplasmic reticulum kinase. Adapted from Kalmar et al., 2013. 
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stress. Mutant SOD1 (mSOD1) not only reduces the cellular antioxidant capacity but 
is also detrimental to the proteasomal and autophagy protein degradation pathways. 
Escaping from protein degradation, mSOD1 accumulates and forms oligomers and, 
eventually, aggregates, which then increase cellular stress and activate the unfolded 
protein response (UPR) in the ER (Saxena et al., 2009).  This can result in activation 
of ER-stress induced apoptosis. It is now known that these reactions occur not only 
in mSOD1-related fALS but also in non-mSOD1-related fALS and sALS, as oxidised 
wild-type SOD1 (wtSOD1) can acquire similar toxic properties to mSOD1 (Bosco et 
al., 2010b; Ezzi et al., 2007).  
1.3.1.1.2 Impaired protein degradation 
A failure of the protein degradation machinery in ALS has become more evident 
following the discovery of mutations in genes involved in proteostasis (Table 1.3 and 
1.4), including: 
 
i) Ubiquilin 2 (UBQLN2):  delivers ubiquitylated proteins to the proteasomal pathway, 
and is found in skein-like inclusions in fALS, sALS, non-UBQLN2-related fALS, and 
FTLD (Deng et al., 2011); 
 
ii) Valosin-containing protein (VCP): encodes a multifunctional ubiquitine-sensitive 
chaperone, which plays key roles in ER-, proteasomal- and autophagy-associated 
protein degradation (Johnson et al., 2010); 
 
iii) Charged multivesicular body protein 2b (CHMP2B): involved in the sorting of 
integral membrane proteins in multivesicular bodies and subsequent clearance in 
autophagy (Parkinson et al., 2006); 
 
iv) Phosphatidylinositol 3,5-bisphosphate 5-phosphatase (FIG4): located in vacuolar 
membrane and is essential for normal lysosome function (Chow et al., 2009).  
 
Motor neurons have high metabolic activity and intrinsically high energy demands in 
order to maintain a baseline physiological function, which makes them more 
vulnerable to cellular stress (Bento-Abreu et al., 2010). However, motor neurons 
have an extremely high threshold for the activation of the heat shock response (HSR) 
(Batulan et al., 2003), the first line of defence to cellular stress, which renders motor 
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neurons less able to cope with cellular stress and to handle misfolded proteins, 
hence increases their vulnerability to cell death (Kalmar and Greensmith, 2008).  
1.3.1.2 Dysregulated transcription and RNA processing 
The identification of mutations in genes encoding proteins involved in RNA 
metabolism and regulation, including TARDBP, FUS, TAF15, EWSR1, SMN, ANG, 
SETX, and C9orf72, has provided new hypotheses to be tested to unravel ALS 
pathogenesis. There is now emerging evidence for dysregulated RNA processing in 
ALS, including, i) Transcriptional regulation (Ayala et al., 2008; Greenway et al., 
2006; Kieran et al., 2008; Law et al., 2006; Polymenidou et al., 2011); ii) Alternative 
slicing (Bose et al., 2008; Polymenidou et al., 2011); iii) mRNA transport (Volkening 
et al., 2009);  iv) microRNA processing (Campos-Melo et al., 2013); v) Nucleus-
cytoplasm shuttling (Dormann et al., 2010; Lagier-Tourenne et al., 2010); vi) Stress 
granules (Dewey et al., 2012; Gal et al., 2011; McDonald et al., 2011). 
1.3.1.2.1 Loss-of-function mechanism of TDP-43 and FUS 
TDP-43 targets more than 6000 mRNAs, including a good number of long pre-
mRNAs that are enriched in motor neurons. Upon the loss of TDP-43, the 
abundance of more than 600 mRNAs and the splicing of more than 900 mRNAs are 
changed (Polymenidou et al., 2011). Similarly, FUS binds more than 5500 genes, 
most of which are different from the targets of TDP-43, and the loss of FUS also 
affects the abundance of other mRNAs (Lagier-Tourenne et al., 2012). These 
findings suggest a loss-of-function mechanism of TDP-43 and FUS.  
1.3.1.2.2 Gain-of-function toxicity of TDP-43 and FUS 
TDP-43 is mainly a nuclear protein, but translocates from the nucleus to the 
cytoplasm in response to stress, where it is incorporated into stress granules (SGs). 
This process allows the cell to prioritise protein synthesis in response to the stressor, 
such as heat shock proteins (Lindquist, 1986), whilst, simultaneously, the on-going 
translated mRNAs are held-up and directed into SGs and processing bodies (P-
bodies) (Li et al., 2013). P-bodies are also RNA-binding protein granules that serve 
key roles in mRNA homeostasis (Jain and Roy, 2013). P-bodies represent sites of 
mRNA degradation, translation repression, non-translating mRNAs, and RNA-
binding proteins. P-bodies mediate mRNA decay, including nonsense-mediated 
decay and RNA interference by serving as sites of co-localization for RNA 
processing components such as the RNA decapping machinery (Parker and Sheth, 
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2007). However, the relationship between TDP-43 and P-bodies remains to be 
established. 
 
Once the cellular stress is resolved, SGs disaggregate and allow TDP-43 to relocate 
back to nucleus and the RNA translation to be presumed or discarded (McDonald et 
al., 2011; Shorter, 2011). Figure 1.4 illustrates this proposed mechanism. Despite 
being a nuclear protein, FUS is also present in the cytoplasm and post-synaptic 
density via transportin-mediated nuclear import, which is perturbed in most of 
mutations in FUS (Dormann et al., 2010). Both TDP-43 and FUS contain a prion-like 
domain. This domain contains sequences which enable proteins to adopt a range of 
alternative structures, each capable of conformational self-replication. This is 
achieved through templating the conversion of other copies of the same protein in 
order to radically alter protein function (King et al., 2012). This prion-like domain is 
essential to form SGs and P-bodies and is prone to form aggregates, particularly in 
ALS-associated mutant forms (Johnson et al., 2009; Li et al., 2013). These insoluble 
mutant TDP-43 and FUS aggregates alter the SG dynamics even after the 
resolution of stress and result in persistent presence of SG that subsequently 
increase cellular stress due to aggregates at protein levels as well as prevention of 
the translation of mRNAs critical to cell survival and recovery, which consequently 
contribute to motor neuron vulnerability and death in a toxic ‘gain-of-function’ 
mechanism (Bosco et al., 2010a; Dormann et al., 2010; Johnson et al., 2009; Li et 
al., 2013; Liu-Yesucevitz et al., 2010) 
1.3.1.3 A failure of axons 
As observed in animal models and in ALS patients, muscle denervation and 
subsequent axonal retraction is one of the first pathological changes in ALS, which 
occurs prior to the death of motor neurons and the onset of symptoms (Fischer et al., 
2004; Frey et al., 2000). The failure involves structural and functional disruption in 
axons. This deficit has been reaffirmed by recent genetic (Table 1.3 & 1.4) and 
molecular findings, including: 
 
i) Structure proteins: NfH, Peripherin, Dynactin, Profilin1, Elongator complex protein 
3 and Kinesin-associated protein 3. Mutations in genes encoding these proteins 
have been shown to be causative or susceptibility genes in ALS (Al-Chalabi et al., 
1999; Figlewicz et al., 1994; Gros-Louis et al., 2004; Landers et al., 2009; Leung et 
al., 2004; Munch et al., 2004; Simpson et al., 2009; Wu et al., 2012);  
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Figure 1.4  
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Figure 1.4.  Stress granules and P-bodies are sites of RNA triage. Upon cellular stress, one of the cellular stress responses is to halt the 
translation initiation, leading to the formation of stress granules (SG). SGs are cytoplasmic RNA-protein complexes that contain RNA-binding 
proteins (RNPs), mRNAs, and translation initiation factors (TIF). Once the stress exposure is resolved, the SGs disassemble and RNA 
translation resumes. Nontranslating mRNAs can be directed to Processing bodies (P-bodies), which are sites of halted translation and mRNA 
degradation. SGs and P-bodies are independently regulated, but can interact with each other. RNPs such as TDP-43, FUS, TAF15, EWSR1, 
hnRNPA1, hnRNPA2B1, are predominantly nuclear proteins that can be recruited to SGs upon cellular stress. Adapted from Li et al., 2013.  
Abbreviations: Dcp1/2: mRNA-decapping enzyme 1/2, a decapping enzyme; Dhh1: DEAD box Helicase Homolog 1, a decapping activator; 
Edc3: Enhancer of mRNA decapping 3, a decapping activator; eIF4G1/2 Eukaryotic initiation factors 4G1/2, translation initiation factors and a 
scaffolding protein that interacts with eIF3; G3BP: GAP SH3 domain-binding protein, an hnRNA-binding protein and endoribonuclease. LSm1-7: 
like Sm (small) proteins 1-7, decapping activators; TIA1: T-Cell-Restricted Intracellular Antigen-1 Cytotoxic Granule-Associated RNA-Binding 
Protein, a 3'UTR mRNA binding protein; Xrn1: 5'-3' exoribonuclease 1. 
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ii) Axonal signalling: Vesicle-associated membrane protein-associated protein B/C 
(VAPB) and Alsin. VAPB normally interacts with ephrin A4, a receptor of the ephrin 
axonal repellent system via RHOA GTPase. Alsin also belongs to RHO-family 
GTPases (Linseman and Loucks, 2008; Nishimura et al., 2004; Tsuda et al., 2008; 
Yang et al., 2001);  
iii) Neurite outgrowth inhibitor: Nogo-A is up-regulated in muscles of ALS patients 
and SOD1 mouse models. It is currently a therapeutic target in a clinical trial in ALS 
(Dupuis et al., 2002; Jokic et al., 2006; NCT01753076); 
iv) Trophic factors: VEGF, a trophic factor for MNs and an axon guidance molecule. 
VEGF is a modifier gene in ALS, and either overexpressed or 
intracerebroventricularly administered of VEGF attenuates the phenotype in SOD1 
rat model (Lambrechts et al., 2003; Storkebaum et al., 2005).  
1.3.1.4 Neuroinflammation  
A common characteristic of ALS and other neurodegenerative disorders is the 
neuroinflammatory reaction involving activated glial cells (astrocytes, microglia, and 
oligodentrocyte) and T cells (Philips and Robberecht, 2011).  
 
Astrocytes provide trophic support for surrounding neurons, regulate extracellular 
neurotransmitter concentrations, such as glutamate, metabolic and ionic 
homoeostatic functions, repair and regulate immune response of CNS (Sofroniew 
and Vinters, 2010). Although astrocytes are not immune cells, upon activation they 
are able to recognise non-self and endogenous danger signals (via PRRs, the 
pattern-recognition receptors) and also secret soluble mediators, such as CXCL10, 
CCL2, Interleukin-6, and BAFF (B cell survival factor), which have an impact on both 
the innate and adaptive immune response (Farina et al., 2007). Selective knock-out 
of mSOD1 in astrocytes of SOD1 mice significantly slows disease progression 
(Yamanaka et al., 2008). Improved survival was observed in SOD1 rat model that 
have wild-type glial restricted precursor cells transplanted into cervical spinal cord, 
which later differentiated into wild-type astrocytes (Lepore et al., 2008). These 
findings suggest that regulating astrocyte function may be a therapeutic target for 
ALS.  
 
Microglia, the resident macrophages in the nervous system, are the first line of 
defence against infection or injury to the nervous system. Upon activation, microglia 
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secrete, firstly, proinflammatory molecules to protect against the injuries, and, 
subsequently, anti-inflammatory molecules to repair (Hanisch and Kettenmann, 
2007), events which are influenced by the subsets of surrounding astrocytes and 
inflammatory T-cell (Henkel et al., 2009). Microglia can therefore be induced to be 
detrimental M1 microglia or beneficial M2 microglia. Their contribution to motor 
neuron degeneration is T-cell dependent (Appel et al., 2010). In SOD1G93A mice, 
CD4+ T helper cells can modulate the inflammatory response through down-
regulation of the neurotoxic reaction of microglia and astrocytes (Beers et al., 2008; 
Chiu et al., 2008). Regulatory T-cells (Tregs) infiltrating the spinal cord are beneficial 
during early disease stages in SOD1G93A mice (Beers et al., 2011). Tregs are 
correlated with disease progression in ALS patients: i) reduction in numbers of 
Tregs in the blood are found in rapidly progressing ALS patients (Beers et al., 2011), 
and ii) early reduction in the expression of FOXP3 (forkhead box P3), the 
transcription factor for the development and function of Tregs, is predictive of rapid 
disease progression (Henkel et al., 2013).    
 
Recent evidence has also revealed that oligodendrocytes and their progenitor cells 
NG2 cells, play a crucial part in axonal maintenance by providing neurons with 
lactate through the monocarboxylate lactate transporter MCT1; loss of MCT1 is toxic 
to MNs both in vitro and in vivo  (Lee et al., 2012). However, the roles of 
oligodendrocytes in neuroinflammation are not yet well understood. 
1.4 ALS Therapeutics 
One of the most important steps forward in our understanding of the pathogenesis of 
ALS in the last two decades was the identification of the first mutations in the SOD1 
gene, which was rapidly followed by the discovery of other causal genetic mutations 
(Table 1.3). This important development led to the generation of transgenic mouse 
models engineered with human mutated genes, which have functioned as test beds 
for preclinical testing of potential therapeutic agents targeting underlying 
pathomechanisms in ALS. Figure 1.5 summarises the main molecular pathways 
which have been targeted by different compounds tested in recent clinical trials in 
ALS. Table 1.5 summarises novel therapeutic targets recently or currently under 
studies in clinical trials in ALS patients (Zinman and Cudkowicz, 2011). It is clear 
that quite a large number of Phase III clinical trials have failed despite the promising 
pre-clinical and Phase I/II results, including studies involving Gabapentin,  
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Figure 1.5 
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Figure 1.5. Novel therapeutic targets in recent or current clinical trials in ALS. 
A number of molecular pathomechanisms of ALS have been identified and 
therapeutically targeted in ALS. Glutamate-mediated excitotoxicity can be targeted 
by reducing presynaptic glutamate, for example by treatment with the only FDA-
approved drug Riluzole. Glutamate can also be reduced by increasing EAAT2 
expression to inactivate synaptic glutamate, as targeted by Ceftriaxone. For fALS 
patients with a known mutation, reducing the effects of the mutant protein by 
targeting the mRNA may be a novel approach and a slowing of disease progression 
has been achieved in animal models of ALS. A number of drugs targeting 
mitochondria have been tested, although all of these drugs failed in Phase III trials. 
Targeting skeletal muscle function may also improve quality of life. Stem cell 
transplantation may provide trophic support for motor neurons to reduce 
degeneration. Enhancement of the HSR may reduce the proteotoxic stress and 
prevent motor neuron degeneration. Adapted from Zinman and Cudkowicz, 2011. 
Abbreviation: siRNA, small interfering RNA 
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Table 1.5 Summary of ALS novel therapeutic targets recently or currently under test in clinical trials. 
Target (drugs) Mechanisms Stage of development Preliminary results References 
1. Glutamate 
1.1 Ceftriaxone Reduce synaptic glutamate 
by increase expression of 
EAAT2 
Phase III study Criteria for tolerability met, but insufficient efficacy at the Phase III 
stage.  The results raise key questions of trial design, the enrolment 
number! 
(NCT00349622; 
Pflumm, 2012) 
2. RNA/post-transcriptional modification  
2.1 Antisense 
SOD1 
oligonucleotides 
(ISIS 333611) 
Reduce expression levels 
of mutant SOD1 mRNA 
Phase I study 
completed. 
Phase 2B study 
underway. 
Criteria for safety and tolerability met in the Phase 1 study. (Miller et al., 2013; 
NCT01041222) 
2.2 
Pyrimethamine 
Reduce SOD1 levels, 
possibly through 
posttranscriptional 
modification 
Phase I/II study 
recruiting. 
Decreases levels of SOD1 in leukocytes and cerebrospinal fluid (CSF) 
of ALS patients in a Phase I pilot study; further investigation required. 
(Lange et al., 2013; 
NCT01083667) 
3. Protein misfolding 
3.1 Arimoclomol Augmentation of Heat 
Shock Response (HSR) 
Phase II/III study 
ongoing. 
Safe, well-tolerated and CSF penetration in placebo-controlled study. (Cudkowicz et al., 
2008; NCT00706147) 
3.2 
Immunisation 
Removal of misfolded 
SOD1 
Preclinical studies Promising preclinical data in both active and passive immunisation in 
SOD1 mouse model of ALS. 
(Gros-Louis et al., 
2010; Takeuchi et al., 
2010; Urushitani et 
al., 2007) 
4. Mitochondria 
4.1 
Dexpramipexol 
Improve mitochondrial 
function 
Phase III Phase II stage 1 study showed safety, tolerability, motor decline 
attenuation and dose-responsive improvement in survival. 
(Bozik et al., 2009; 
NCT00647296; 
NCT00931944; 
NCT01281189) 
4.2 Olesoxime 
(TRO19622) 
Mitochondria pore 
modulation 
Phase III terminated Preclinical animal data showed efficacy, but Olesoxime failed to meet 
endpoints in Phase III clinical trial. However, questions about trial 
designs might need to re-address in the future. 
(ALSTDI; 
NCT00868166; 
Sunyach et al., 2012) 
5. Growth factors 
5.1 VEGF 
(sNN0029) 
Angiogenesis and 
neuroprotection 
Phase II open-labelled 
study 
Intracerebroventricular injection. Initial safety and tolerability met; final 
report pending. 
(NCT00800501; 
NCT01384162) 
5.2 VEGF (SB-
509) 
A Zinc Finger Protein 
Transcription Factor (ZFP-
TF) of the VEGF  
Phase II completed Initial results showed criteria for safety and tolerability met, and slow in 
deterioration of muscle force in ALS.  
(BioSciences; 
NCT00748501) 
5.3 Cogane Neurotrophic factor 
inducer; neuroprotection 
Preclinical study Improved neuromuscular physiological function and motor neuron 
survival in SOD1
G93A
 mouse model of ALS 
(Kalmar et al., 2012a) 
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6. Immune 
6.1 NP001 transform macrophages 
from a neurotoxic state to a 
neuroprotective state 
Phase I and II studies 
completed. 
Phase III under way. 
Initial results show safe and tolerable. Beneficial effect observed in 
patients with high dose, enhanced by a post-hoc analysis.  
(NCT01091142; 
NCT01281631; 
Pflumm, 2012) 
7. Stem-cell (SC) 
7.1 Embryonic 
SC into CNS 
(Neuralstem) 
Neuroprotection Phase I study 
completed. 
The initial results of the Phase I study appear to be safe for the 
procedure itself, but note some serious adverse events to 
immunosuppressant drugs. Stem cells could last and be detected in the 
spinal cord of autopsied tissue of some trial participants. 
(Glass et al., 2012; 
NCT01348451) 
7.2 Induced 
pluripotent 
Stem Cells (iPS 
cells) 
Neuroprotection Phase I study pending. A trial using existing collections of cells to develop human iPS cells is 
due to complete soon. A new trial to set up a fibroblast bank for 
studying molecular, cellular and genetic pathology in fibroblast, iPS, and 
differentiated cells is recruiting. 
(NCT00801333; 
NCT01639391) 
8. Muscle 
8.1 Diaphragm 
pacing 
Promote diaphragm 
contraction 
Phase I study 
completed. 
Post-Approval study 
recruiting.  
The initial results show safety in DPS implantation and improved 
survival. 
FDA approval for humanitarian designation exemption pending. 
(NCT00420719; 
NCT01605006; 
Onders et al., 2010) 
8.2 GDF-8 
(myostatin) 
inhibitor (ACE-
031) 
Increase muscle growth Phase I study in 
healthy 
postmenopausal 
women completed, but 
phase II study for 
Duchenne Muscular 
Dystrophy terminated. 
Initial criteria for safety and tolerability in Phase I study met, but 
participants with muscular dystrophy experienced adverse effects such 
as increasing nosebleeds, gum bleeding, and small dilated blood 
vessels within the skin, which raised safety concern and led to its 
termination. 
(MuscularDystrophyC
ampaign; 
NCT00952887; 
NCT01099761) 
8.3 Skeletal 
muscle troponin 
activator (CK-
2017357;  
Tirasemtiv ) 
Improve fast muscle 
contraction 
Phase IIb trial 
recruiting. 
Initial criteria and tolerability met; need to reduce the dose of Riluzole 
when use in combination. 
(NCT01709149; 
Pflumm, 2012; 
Russell et al., 2012) 
8.4 Reticulon 4 
(Nogo-A) 
inhibitor 
(GSK1223249;  
Ozanezumab) 
Promote neurite outgrowth Phase II study 
recruiting. 
Initial criteria and tolerability met. (NCT01753076) 
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Ceftriaxone, Talampanel, Topiramate, and Lamotrigine (Cudkowicz et al., 2003; 
Miller et al., 2001; NCT00349622; Ryberg et al., 2003; Shefner et al., 2010). In light 
of these failed clinical trials, and considering the increasing demand of clinical trials 
in response to the significant advances which have uncovered the underlying 
molecular mechanisms of ALS, there is a clear need for clinical trials in ALS to be 
improved. The challenges faced to achieve this goal are multiple; the disease is 
clinically extremely heterogeneous with an unpredictable rate of progression, whilst 
the pharmacokinetics and bioavailability of most of the drugs examined to date is far 
from clear (Zinman and Cudkowicz, 2011). ALS is clearly not a prevalent disorder 
and patients often manifest concerns over being treated with placebo. All of these 
factors contribute to poor recruitment for clinical trials in ALS. The delay in providing 
a firm diagnosis of ALS reduces the already short treatment window and it is likely to 
have a major effect in reducing the efficacy of most test drugs since the spared and 
‘rescuable’ motor neuron population is likely to be significantly reduced the more 
advanced the disease is. In addition, the high costs, large sample size requirement, 
difficulty in retaining participants and the unavoidable missing data in the 
development of trials may all play a crucial role in the failure of most clinical trials in 
ALS. Possible solutions to improve trial design have been recently proposed 
(Zinman and Cudkowicz, 2011) and are summarised below: 
 
i) Time-to-event study design: enable participants cross-over to active treatment;  
 
ii) 2:1 randomisation: increase the proportion of participants being treated with active 
compound; 
 
iii) Replacement of the currently most used primary outcome, survival, by either one 
of the co-primary outcome measures, used for example in the Phase III 
Ceftriaxone study (EMPOWER) (Berry et al., 2013), or an alternative outcome 
measure such as the change in ALS functional rating scale_Revised (ALSFRS_R), 
used as a primary outcome measure in a recent study on Lithium and Riluzole 
(Aggarwal et al., 2010); 
 
iv) Randomised sequential trials with multiple interim analyses: traditionally, the 
sample size of clinical trials should be determined in advance, and data analysis 
should only proceed after the data collection is completed. The technique of 
sequential trials has enabled the examination of data at a series of interim analyses, 
so that a decision of whether to continue, stop or adjust therapy in the trials can be 
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formed (Todd et al., 2001; Whitehead, 1999). In this case, when a novel therapy is 
significantly effective, patients can receive the drug as soon as possible. In contrast, 
if a novel therapy is evidently not beneficial or even detrimental, patients should not 
be at any further risk testing with this drug and all other resources should be put into 
better use for other treatment strategies. A sequential trial design has become 
increasingly popular in ALS, and has been used to reduce the number of ALS 
patients required, for example to show that Creatine (Groeneveld et al., 2003), 
Valproic acid (Piepers et al., 2009) and Lithium (Verstraete et al., 2012b) are 
ineffective.  
 
It should be noted that the associated parameter measuring treatment difference 
and the stopping rule should be chosen appropriately. More flexible and 
sophisticated statistical tests for interim analysis to compare the effects between 
experimental and placebo groups should be employed. Lastly, the conclusion drawn 
from the interim analysis is only appropriate for deciding whether or not the trial 
should continue and a final analysis should still be carried out (Todd et al., 2001);  
 
v) Multidrug phase II selection studies considered as an effective way to speed up 
trials;  
 
vi) Multistage adaptive design by reducing the time and the costs for a drug with 
positive phase II to move on to a phase III of the study. 
1.5 Clinimetrics in ALS 
Clinimetrics are characterised as ‘…arbitrary ratings, scales, indexes, instruments or 
other expressions that have been created as ‘’measurements’’ for those clinical 
phenomena that cannot be measured in the customary dimensions of ‘’laboratory 
data’’.’ These rating scales have been developed in order to be used to describe the 
clinical condition of patients with a disease process (Feinstein, 1987). The clinical 
changes due to the disease progression can be covered by recording elements of 
impairment, disability and/or handicaps (Brooks, 1997). Clinimetric scales, as a 
measure of a complex clinical phenomenon, usually contain multiple items 
representing different aspects of a disease such as pathology, impairment, disability 
and handicap, the combination of which varies in the different ALS clinical functional 
rating scales developed over the last two decades (Brooks, 2002). Most of these 
scales require either the patient’s self-reporting or the clinician’s reporting of the 
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current functional state, referable to the four major anatomical domains involved in 
ALS (bulbar, breathing, arms and legs) in an ordinal-scaled questionnaire. In 
addition, attributes being measured in clinimetric scales need to vary over the entire 
range of clinical presentation among patients in order to provide adequate coverage 
of clinimetric scale score variability. Hence, limited variability of attributes may not 
be representative of the whole population (Brooks, 2002), although it might be more 
sensitive to reflect the change of function.  
 
Reliable clinimetric scales need to fulfil i) consistent intra-rater reliability (or so-called 
test-retest reliability) in assessments of a patients with stable condition by the same 
assessor at different occasions, either being tested in the clinic or via telephone, ii) 
consistent inter-rater reliability across examiners, iii) the ability to detect change over 
time within a patients, i.e. the clinimetric scale score responsiveness, and iv) good 
clinimetric scale score sensitivity to detect clinically differences between groups. 
Table 1.6 summarises markers related to function which are used in ALS trials 
(Cudkowicz et al., 2004).  
 
One of the most widely used clinimetric scale in ALS is the ALS Function Rating 
Scale_Revised (ALSFRS_R), a revised version of ALSFRS, which strengthens the 
ALSFRS with regard to the assessment of respiratory function (Cedarbaum et al., 
1999). In a study of 267 ALS patients in the clinic, 4.4-fold increased risk to death or 
tracheotomy was found in patients with baseline ALSFRS_R score below the 
median (38), suggesting ALSFRS_R score is a good predictor of survival (Kaufmann 
et al., 2005) and its progression rate at diagnosis was found to subordinate to the 
score itself in another study (Kimura et al., 2006).  
 
Progression rate measured by ALSFRS_R between i) First symptom to First 
examination, ii) the whole follow-up period, and iii) within 100 days during follow-up 
were all found correlate with survival time (Kollewe et al., 2008). Hence, the 
ALSFRS_R is currently widely used as a screening measure for entry into clinical 
trials and as a sensitive outcome measure with sufficient validation to be 
recommended as a primary endpoint (Leigh et al., 2004). Indeed, a new endpoint for 
ALS was recently introduced, which combines survival time and change in the 
ALSFRS_R score as co-primary endpoints, the Combined Assessment of Function 
and Survival (CAFS) (Berry et al., 2013). CAFS provides a balanced analysis of a 
drug which might have preferential benefit on function and survival, a powerful 
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Table 1.6 Summary of current clinimetrics in use in ALS. 
Measures Method Pros and cons Reference 
Muscle Strength 
Maximum 
Voluntary 
Isometric 
Contraction 
(MVIC) 
Quantify the 
strength of 
individual muscle 
groups and 
normalise the 
score to obtain 
megascores. 
Numerically 
continuous data.  
Fixed device with 
strain gauges 
Good intra- and inter-rater reliability; has been used as primary outcome 
measure in clinical trials. Inconsistent association with survival found in 
different trials. Long testing time (approximately 45 minutes), expensive 
equipment, vigorous training for evaluators required, nor applicable for 
home visit, not usable for very weak muscles, high dropout rate in the trials 
using MVIC as an outcome measure  
(Andres et al., 1986; 
Cudkowicz et al., 2004; 
Hoagland et al., 1997) 
Hand-held 
dynamometre 
Been validated against MVIC with good correlation; good intra-rater 
reliability; portable; inexpensive; shorter testing time. 
(Beck et al., 1999; 
Cudkowicz et al., 2004) 
Manual Muscle 
Testing (MMT) 
Using the Medical Research Council 
(MRC) grading scale. Ordinal qualitative 
data.  
Trained evaluators and standardised patient positioning required; speed, 
low cost, but low sensitive to change in muscle strength.  
(Cudkowicz et al., 2004; 
Lakes and Group, 2003) 
Pulmonary function 
Forced vital 
capacity (FVC) 
Volume of air forcefully expired in one 
breath, reported as a percentage of a 
predicted vital capacity based on the 
height, gender and age. 
Widely available, non-invasive, and portable. Baseline FVC and the rate of 
decline in FVC are predictive of survival. The decline of FVC overtime is a 
sensitive measure of disease progression. However, this test is difficult to 
perform in patients with significant bulbar symptoms.  
(Cudkowicz et al., 2003; 
Kaufmann et al., 2005; 
Magnus et al., 2002; 
Varrato et al., 2001) 
Maximal 
Inspiratory 
Pressure (MIP) 
The maximal negative pressure at the 
mouth after complete exhalation by single 
sustained maximal inspiratory effort 
against an occluded airway. 
Widely available, non-invasive, and portable, but increased variability in 
patients with bulbar involvements. 
(Black and Hyatt, 1969; 
Cudkowicz et al., 2004) 
Maximal Expiratory 
Pressure (MEP) 
The maximal positive pressure measured 
in the mouth after inhalation to total lung 
capacity followed by a maximal expiratory 
effort against an occluded airway 
Widely available, non-invasive, and portable, but increased variability in 
patients with bulbar involvements. 
(Black and Hyatt, 1969; 
Cudkowicz et al., 2004) 
Functional rating scales: access the activities of daily living (ADL)  
Appel ALS rating 
scale 
Evaluate 5 categories: Bulbar, 
Respiratory, Muscle Strength, Lower limbs 
and Upper limbs function, ranging from 30 
(normal) to 164 (maximum impairment). 
Simple, validated, sensitive. Rate of change in the score is a predictor of 
survival. Several team members required to finish the test; time-consuming. 
Difficult to use in severely affected patients. Unclear relation to function. 
(Appel et al., 1987; 
Haverkamp et al., 1995) 
ALS Functional 
Rating Scale 
(ALSFRS) 
Evaluate 4 motor areas (fine motor, gross 
motor, bulbar, and respiratory) in 10 
questions, score ranging from 40 (normal) 
The first functional scale independent to strength testing. Good correlation 
with survival and other measures. Disproportionate weighing of limb and 
bulbar measurements to respiratory dysfunction. 
(Guiloff, 2002; Mora, 2002) 
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to 0 (worst function) 
ALS Functional 
Rating 
Scale_Revised 
(ALSFRS_R) 
Evaluate 4 motor areas (fine motor, gross 
motor, bulbar, and respiratory) in 12 
questions, score ranging from 48 (normal) 
to 0 (worst function) 
The revised test of ALSFRS. Currently the most widely used functional test 
in ALS clinical trials. The rate of progression of ALSFRS_R from onset of 
disease is a predictor of survival time.  
(Cedarbaum et al., 1999; 
Gordon et al., 2010; 
Kaufmann et al., 2007) 
Combined 
Assessment of 
Function and 
Survival (CAFS) 
A recently developed endpoint which 
combines two primary outcomes: the 
ALSFRS_R and survival. 
Has been applied in a phase II and phase III study, and show CAFS may 
provide a balanced analysis for a testing drug with disproportionate effect 
on function and survival, which weights mortality as the most clinically 
important outcome. However, CAFS scores between treatment groups 
cannot be compared across trials directly and it requires sophisticated 
analysis of the data for function arm and survival arm.  
(Archibald et al., 2011; 
Berry et al., 2013; 
Cudkowicz et al., 2011; 
Ferreira-Gonzalez et al., 
2007; Rudnicki et al., 2013; 
Wittkop et al., 2010) 
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statistical analysis, and yet prevent false-positive results from drugs beneficial in 
function but detrimental in survival (Berry et al., 2013). If CAFS can be further 
validated in more trials, then it may help to improve design and outcome of clinical 
trials in ALS.  
1.6 Biomarkers for ALS 
If improving the trial design is one approach to improve clinical trials in ALS, the 
other rests on the development of disease biomarkers. A biomarker is defined as ‘an 
objective measurement that acts as an indicator of normal biological processes, 
pathogenic processes or pharmacologic response to therapeutic intervention’ by the 
UK Medical Research Council (MRC).  
1.6.1 Biomarkers for the development of disease-modifying treatments in ALS 
A biomarker should be able to reflect an important feature of the disease, so that it 
could be used for disease diagnosis, predict disease susceptibility, monitor disease 
progression, and evaluate treatment efficacy/toxicity (Ryberg and Bowser, 2008). 
Figure 1.6 shows the timeline of key clinical events and their relation to different 
types of biomarkers. 
 
Ideal biomarkers for ALS should have the following characteristics and positive 
effects in the conduct of trials (Turner et al., 2009; Zinman and Cudkowicz, 2011): 
 
i) speed up the diagnostic process of ALS, which would enable early participation in 
clinical trials; 
 
ii) help differentiation between clinical phenotypes, reducing the confounding effect 
that clinical heterogeneity has in clinical trials;  
 
iii) help to define the true efficacy of drugs designed to target specific pathogenic 
mechanism which are related to the biomarker itself; 
 
iv) change with the natural progression of the disease and hence help to monitor 
more efficiently drug efficacy, which would in turn reduce the size and time the trials 
need; 
 
v) expedite the drug screening process; 
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Figure 1.6 
 
 
 
Figure 1.6. Timeline of key clinical events and related types of biomarkers in 
ALS. As disease initiating events are usually genetically determined or occur long 
before the onset of symptoms, it is important to be able to identify these subjects as 
soon as possible. Therefore onset should be detected earlier and the diagnosis 
made quicker, so that treatment can be initiated as soon as possible. Biomarkers 
can be used to aid diagnosis and to help clarify disease phenotypes, thereby 
shortening the current lengthy diagnostic process and reducing heterogeneity in 
clinical trials. Biomarkers for disease progression can speed-up drug screening, 
monitor the drug efficacy/toxicity and predict poor prognosis, to allow appropriate 
treatment to be provided.  Adapted from Ryberg and Bowser, 2008 
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vi) predict poor prognosis and the rate of disease progression so that early 
intervention as well as adequate care can be planned; 
 
vii) provide new insights on pathogenesis; 
 
viii) be quantifiable with easy accessibility and affordable technology. 
 
And yet there are currently no validated biomarkers for diagnosis, phenotype 
determination, disease progression, or therapeutic monitoring in ALS, the current 
approaches to the development of biomarker identification in ALS are discussed 
below. 
1.6.2 Current strategies for the development of Biomarkers in ALS 
Biomarker discovery in ALS has been prioritised by the drive to develop new 
treatment strategies and strengthened by recent advances in technology. A number 
of leading candidates have been identified to date; however, there are currently no 
validated biomarkers for ALS. 
1.6.2.1 Physiological biomarkers 
Assessments of the physiological features of the neuromuscular structures involved 
in the disease process in ALS can provide direct information of disease progression 
in ALS patients. A number of tests have been developed to examine the motor 
deficits in both LMNs and UMNs.  
 
LMN function is routinely assessed using nerve conduction studies (NCS) and 
electromyography (EMG). UMN function can be assessed through transcranial 
magnetic stimulation (TMS). Loss of muscle strength is one of the most direct 
measures of disease progression in ALS, but the maximal compound muscle action 
potential (CMAP) amplitude, which reflects the function of the motor unit, will fall 
only when the extent of denervation exceeds the compensation of re-innervation, 
when approximately 50-80% of axons have been lost (Bromberg, 2004). Although 
routine EMG is essential in the diagnosis of ALS, it is not regarded as a good tool for 
monitoring disease progression due to its invasive nature and its poor correlation 
with pathological changes during disease progression. The development of non- 
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invasive, disease progression-related physiological measures would be highly 
desirable.       
1.6.2.1.1 Motor unit number estimation 
Motor unit number estimation (MUNE) is a non-invasive clinical neurophysiological 
measure that provides quantitative information on the number of intact motor units 
innervating a single muscle and on the size of individual motor units. MUNE is 
calculated by dividing the size of an average surface recorded single motor unit 
potential (S-MUP) into the maximal CMAP, and is not affected by collateral 
innervation (Bromberg, 2004; Bromberg et al., 1993; McComas, 1995).  
 
A number of analytical techniques have been employed to monitor motor unit loss 
during disease progression in ALS (Armon and Brandstater, 1999; Felice, 1997), 
amongst which statistical MUNE has been used more often in ALS clinical trials due 
to the feasibility of standardising results from site to site. A study assessing 
statistical MUNE in SOD1-related ALS patients showed that carriers are not different 
from controls at a pre-symptomatic stage (Aggarwal and Nicholson, 2001). However, 
in another longitudinal study where MUNE was assessed at 6-month intervals, two 
carriers were observed to have 12-23% reduction in MUNE in thenar or extensor 
digitorum brevis, while the muscle strength was still preserved (Aggarwal and 
Nicholson, 2002). MUNE has been used as a secondary endpoint measure in ALS 
clinical trials; a change of MUNE after 1 year was found to have a superior 
correlation with disease progression than other measures, such as CMAP, hand grip 
and vital capacity (Felice, 1997).  
 
However, the results from two more recent multicentre clinical trials raise concerns 
about using statistical MUNE as an outcome measure. In the multicentre drug trials 
for creatine, there was a 23% decline of MUNE over a 6-month study period, 
although S-MUP amplitude was found stable over the same period, in contrast to 
previous MUNE studies (Shefner et al., 2004). Several modifications of the statistical 
methods were implemented to address this problem before statistical MUNE was 
employed as a secondary outcome measure in a drug trial for Celecoxib over a 12-
month study period (Shefner et al., 2007). However, S-MUP amplitude still remained 
stable during the follow-up of Celecoxib/ALS trial. Meanwhile, it was also discovered 
that S-MUPs from ALS patients displayed increased amplitude variability when 
stimulated repeatedly (Jillapalli and Shefner, 2004). Therefore, the assessment of 
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the motor unit in ALS patients presents not only quantitative problems. It was 
previously assumed that the variability of response to a repeated stimulus detected 
by MUNE in ALS patients is due to the number of motor unit responding in an 
intermittent manner; the newly identified qualitative problem of motor unit suggests 
that this may be due to dysfunction of motor unit itself (Shefner et al., 2007). 
Although this problem could be addressed, it has reduced the potential for statistical 
MUNE to become a secondary outcome measure in a multicentre clinical trial 
(Shefner et al., 2007).     
1.6.2.1.2 Electrical impedance myography 
Electrical impedance myography (EIM) is a non-invasive electrophysiological 
technique in which low-intensity, high-frequency alternating current is applied 
through surface electrodes measuring the underlying muscle impedance (Rutkove et 
al., 2002). Two of the components of muscle impedance, the resistance (R) and the 
reactance (X) change in ALS. As R is reversely proportional to the cross-sectional 
area of the muscle, ALS patients will have increased R due to muscle atrophy. In 
contrast, X is decreased in ALS as a result of an increased total capacitance due to 
muscle atrophy (Tarulli et al., 2009). A third parameter, phase (θ), is then calculated 
from the formula: θ= arctan (X/R), which is used as the main outcome parameter for 
EIM studies as it is less sensitive on muscle shape and size (Rutkove et al., 2002), 
but sensitive enough to detect muscle abnormalities in ALS (Tarulli et al., 2009).  
 
A recent multicentre study has compared EIM with existing clinimetrics, the 
handheld dynamometry (HHD) and ALSFRS_R, to examine the potential of EIM to 
monitor disease progression in ALS (Rutkove et al., 2012). The three measures 
were compared by assessing the coefficient of variation (CV) in the rate of decline 
and each technique’s correlation with survival. All three measures correlated with 
survival, and EIM was found to be able to reduce the sample size needed for 
detection of a 20% treatment effect, plus 80% power for 95 subjects per arm, 
compared to 220 subjects per arm for ALSFRS_R (Rutkove et al., 2012). It appears 
EIM may therefore be a promising biomarker to accelerate Phase II clinical trials.  
1.6.2.1.3 Neurophysiological index 
The neurophysiological index (NI) was developed to quantify peripheral 
neuromuscular deficits in ALS, by mathematical derivation (NI=CMAP (mV) X F 
wave frequency/distal motor latency (ms)) from three combined standardised 
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neurophysiological measurements: compound motor action potential amplitude, 
distal motor latency and F-wave frequency, representing aspects of denervation and 
re-innervation (de Carvalho and Swash, 2000). This approach is non-invasive, and 
simple to measure from abductor digiti minimi (ADM). In subsets of ALS patients 
grouped according to the progression rate, NI was found to be the most sensitive 
measure of change among other existing clinimetrics such as MRC muscle strength 
scale, forced vital capacity (FVC) and ALSFRS scores (de Carvalho et al., 2003a). It 
has been shown that in patients progressing rapidly, NI can decline by as much as 
50% over 1 year (de Carvalho et al., 2003a, 2005). ALS patients with bulbar-onset 
disease were found to have a greater NI value (0.88) than patients with upper limb-
onset disease over a 12-week follow-up period, but the rate of decline was not found 
to be different among different phenotypes (averaged 0.04 per week). In addition, 
the change in NI was found to weakly correlate with the change of functional 
impairment (Cheah et al., 2011). Validation in multicentre studies is needed to 
further evaluate the utility of NI in ALS clinical trials.  
1.6.2.1.4 Transcranial magnetic stimulation 
Transcranial magnetic stimulation (TMS) provides the only neurophysiological 
assessment of UMN function and cortical abnormalities. This technique exploits 
electromagnetic induction, which in turn induces weak electric currents to measure 
activity and function of specific brain circuits. An UMN lesion is considered either if 
the response to cortical stimulation is absent or the central conduction time is 
delayed, while the peripheral conduction time and amplitude of the M-wave (evoked 
by supramaximal peripheral nerve stimulation) remains within the normal range 
(Urban et al., 1998). A number of TMS measurements have been performed in 
patients with ALS, including: 
 
i) Cortical motor threshold: The current needed to stimulate the motor cortex 
increases during disease progression in ALS (de Carvalho et al., 2002);  
 
ii) Cortical silent period: The pause in EMG activity after motor-cortex stimulation is 
reduced in ALS (Eisen and Swash, 2001; Siciliano et al., 1999);  
 
iii) Peri-stimulus time histograms: desynchronized, complex, primary peak that has 
an increased duration were observed, suggesting a supraspinal defect, as this 
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abnormality was not detected in Kennedy’s disease, a LMN disorder (Eisen and 
Swash, 2001; Eisen and Weber, 2000; Siciliano et al., 1999);  
 
iv) Central conduction time: The latency from cortex to a selected limb muscle is 
normal or modestly prolonged in ALS (Eisen and Swash, 2001); 
 
v) Motor evoked potentials: small or absent motor-evoked response is observed in 
ALS patients (de Carvalho et al., 2003b).  
 
Most of the findings in ALS patients using TMS suggested cortico-motor neuron 
pathways dysfunction and reduced inhibition (Winhammar et al., 2005). Indeed 
cortical hyperexcitability was found to precede the onset of SOD1-related fALS, 
when the short-interval intracortical inhibition was massively reduced in pre-
symptomatic carriers, but not in asymptomatic carriers (Vucic et al., 2008). Although 
validation through multicentre studies is still required, TMS may be a potential tool to 
allow early identification of symptom onset in carriers of fALS and hence allow early 
intervention in these patients.  
1.6.2.2 Neuroimaging 
Neuroimaging provides a non-invasive approach to monitor disease progression and 
to identify biomarkers for ALS. With the advance in magnetic resonance imaging 
(MRI), neuroimaging has contributed to ALS not only as a diagnostic tool to exclude 
ALS mimics (Brooks et al., 2000), but also as a mean of biomarker discovery 
(Turner and Modo, 2010). 
1.6.2.2.1 Magnetic Resonance Imaging  
ALS is a disease of upper motor neurons (UMN) and lower motor neurons (LMN). 
Recent progresses in ALS also demonstrate a clinicopathological overlap with FTLD. 
MRI neuroimaging therefore provides excellent non-invasive tools to investigate the 
UMN component of ALS, the involvement of the primary motor cortex and 
corticospinal tract (CST). 
1.6.2.2.1.1 Standard sequence 
Standard T1-weighted MRI imaging in general is not sensitive enough to detect 
subtle changes of brain atrophy in ALS patients apart from those patients with an 
extensive FTD phenotype (Turner and Modo, 2010). With the development of voxel-
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based morphometry, subtle volumetric changes in both grey-matter and white-
matter tissue compartments can be identified when compared to healthy controls 
(Abrahams et al., 2005; Chang et al., 2005), and atrophy in the right precentral 
gyrus is the most consistent finding in ALS patients (Chen and Ma, 2010). This 
technique has largely improved the detection power of the standard T1-weighted 
clinical MRI in detecting brain atrophy.  
1.6.2.2.1.2 Diffusion tensor imaging 
Diffusion tensor imaging (DTI) is sensitive to the movement of water, which moves 
as a highly directional element (fractional anisotropic; FA) and behave as freely 
diffusible (isotropic; diffusivity, ADC: Apparent Diffusion Coefficient) in intact and 
damaged white matter tract, respectively. DTI image acquisition can then 
reconstruct the connectivity of white matter tracks, as diffusion tensor tractography 
(Ciccarelli et al., 2008). This technique has demonstrated the involvement of the 
CST and corpus callosum (CC) in ALS and other forms of UMN degeneration, such 
as primary lateral sclerosis and hereditary spastic paraparesis (Ellis et al., 1999; 
Filippini et al., 2010; Iwata et al., 2011; Muller et al., 2012; van der Graaff et al., 
2011). Therefore DTI might be a potential biomarker to help the early identification 
of UMN failure, which would ultimately speed up the diagnosis of ALS. In addition, 
longitudinal DTI studies have showed significant UMN progression (decreased FA) 
over a period of 6-8 months, and also correlated with the clinimetric ALS Functional 
Rating Scale_Revised (ALSFRS_R) score and decline of ALSFRS_R score (Keil et 
al., 2012; Zhang et al., 2011b). These results indicate that DTI might be a promising 
diagnostic and disease progression marker for ALS. 
1.6.2.2.1.3 Functional MRI 
Functional MRI (fMRI) examines the differential magnetic properties of oxygenated 
and deoxygenated haemoglobin which is a by-product of neuronal activation in 
response to specific tasks. Expanded areas of cortical activation have been shown 
in ALS patients in a number of studies (Lule et al., 2009). Moreover, 
interhemispheric disconnection has been demonstrated in resting-state fMRI 
(Jelsone-Swain et al., 2010; Mohammadi et al., 2009), which echoes the findings in 
DTI tractography.  
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1.6.2.2.1.4 Magnetic resonance spectroscopy imaging  
The magnetic resonance spectroscopy imaging (MRSI) allows the quantification of 
proton-containing cerebral metabolites within areas of interests. Metabolites most 
studied to date are the ratio of N-Acetylaspartate to choline or creatine (NAA/Cho or 
NAA/Cr ratios). A longitudinal study focused on the motor cortex showed a 
significant change in absolute concentration and ratio of metabolites in ALS patients. 
These changes also correlated to the lateralisation of clinical symptoms, to disease 
duration, and to disease progression (Pohl et al., 2001). A recent advance is the 
availability of whole-brain MRSI which enables metabolic profile from the whole 
brain to be studied during a single scan and also provides a stronger correlation with 
the ALSFRS_R score than the correlation found in DTI studies with the same rating 
scale (Stagg et al., 2013). Hence MRSI might also be considered a potential source 
of biomarker for ALS, particularly if a multimodal analysis is chosen combining 
different techniques of imaging. 
1.6.2.2.2 Positron emission tomography scan 
The use of positron emission tomography (PET) scans in ALS studies relies on the 
development of ligands for more accessible neuronal receptors, so that monitoring 
ALS progression can be carried out, similar to the used of PET amyloid images in 
Alzheimer’s disease (AD) (Quigley et al., 2011). The requirement for intravenous 
injection and radiation exposure are inherent disadvantages in the development of a 
PET-based biomarker. However, using PK11195, a ligand for a microglia specific 
peripheral benzodiazepine receptor, PET scanning has been used to demonstrate 
the widespread cerebral neuroinflammatory activity in ALS patients (Turner et al., 
2004), an increasingly important pathomechanism in ALS.  
1.6.2.2.3 Muscle ultrasonography 
Muscle ultrasonography (MUS), a safe and non-invasive diagnostic tool performed 
in a more relaxing environment compared to MRI and PET imaging, can visualise 
muscle pathology, record muscle contraction and detect fasciculations caused by 
neuromuscular disorders (Pillen et al., 2008). Affected muscles present with 
diminished muscle thickness and increased echo intensity (EI), which are also 
associated with aging and gender. With a quantification based on age and gender, 
MUS can differentiate neuromuscular disorders with a high specificity and sensitivity 
(Arts et al., 2010; Pillen et al., 2008). Studies have shown MUS can differentiate 
ALS and controls with a sensitivity of 96.3% and a specificity of 84.4% and is 
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superior in detection of regional LMN degeneration (fasciculations) than EMG (Arts 
et al., 2012; Misawa et al., 2011), which can be used to improve diagnostic certainty.  
 
MUS has been used to predict survival in ALS in a cross-sectional study (n=31) 
which showed the combination of EI and the ALSFRS_R pre-slope (Change in 
ALSFRS_R score from onset to diagnosis), is a good predictor of survival (Arts et al., 
2011b). However, results from two longitudinal studies carried out by different 
research groups using the same MUS protocol, show different results (Arts et al., 
2011a; Lee et al., 2010). In a small cohort of patients (n=10), where few muscles 
examined (3 groups) in few follow-up tests (total 3) were undertaken in a 6-month 
study period, the rate of change of muscle thickness was found to correlate well with 
the ALSFRS_R score, though variation between muscle groups was noted (Lee et 
al., 2010). However, in a larger cohort (n=31), where more muscles were examined 
(6 groups) at more follow-up points (total 5) over a 5-month study period, the pattern 
of MUS muscle changes was found to be highly variable, with no correlation in 
functional measures observed (Arts et al., 2011a). These studies demonstrated the 
discrepancy in results in single and serial follow-up, small and large cohort 
biomarker studies and reveals potential problems caused by sampling bias, cohort 
heterogeneity, and intra- and inter-individual variation in ALS biomarker studies.       
1.6.2.3 Neurochemical biomarkers 
Disease-related proteins may be produced by tissues primarily affected by ALS or 
by other tissues that may become involved during the disease process. These 
disease-related proteins may be released into body fluids or remain confined within 
these tissues; the test biomarker can be sampled to obtain quantitative and 
qualitative analyses which establish the feasibility of using these factors as disease 
biomarkers. For rare and complex diseases like ALS, national and international 
collaborations are essential to undertake effective biomarker studies, enabling 
sharing of sources and throughput of analyses. Developing a consensus over the 
most appropriate annotated clinical information to be collected, as well as 
standardised protocols and standard operating procedures for sample collection and 
processing, are crucial steps for any shared effort in biomarker validation and to 
minimise pre-analytical and analytical variables. This groundwork in biomarker 
research enables collaboration and comparisons across studies (Otto et al., 2012; 
Schrohl et al., 2008).  
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1.6.2.3.1 Choice of samples for biomarker analysis 
Relevant neurochemicals for biomarker analysis can be studied in different bio-fluids 
and tissues from patients as well as in post-mortem tissue samples. Cerebrospinal 
fluid (CSF) and blood are the current leading bio-fluids in ALS biomarker research. 
With the identification of new therapeutic targets and the improvement in stem cell 
technology, fibroblasts from skin biopsies have also become increasingly important. 
Table 1.7 summarises the strengths and the weaknesses of the most common 
biomarker sources (Otto et al., 2012). 
1.6.2.3.2 Biomarker discovery platforms 
Biomarker development is usually a two-step process, i) Screening for non-
hypothesis driven studies, such as Gene Expression Profiling (GEP) and ‘omic’ 
studies, in order to identify targets, ii) Validation of previously identified putative 
disease biomarkers through large-scale analyses from step i). The recent 
development of new analytical techniques, which has improved biomarkers 
discovery in ALS, are discussed in the below sections.  
1.6.2.3.2.1 Proteomics  
Proteomics is the large-scale analysis of the protein content of a selected biological 
sample. The information obtained concerns protein profiles and the analysis is not 
hypothesis-driven, in-so-far that there is no pre-defined molecular target. The main 
methods employed in proteomics include: 
 
i) Two-dimensional fluorescence difference gel electrophoresis (2D-DIGE):   readily 
interfaced with mass spectrometry for protein identification, but under-representation 
of all potentially relevant proteins, low sensitivity and restricted multiplexing 
capabilities are its main limitations;  
 
ii) Surface-enhanced laser desorption/ionization (SELDI) allows the analysis of a 
large number of samples compared to 2D-DIGE, but does not directly reveal the 
identity of the protein peaks detected. Further analytical work is required to 
characterise the initial targets, which could be a considerable challenge for this 
technology.  
 
Generally, proteomics relies on a preliminary identification of protein spots by gel 
electrophoresis. The subsequent quantification and definition of the protein content
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Table 1.7 Advantages and disadvantages of different sample sources used in neurochemical biomarker studies. 
Characteristics CSF Blood Muscle Skin Urine Saliva 
Proximity to CNS pathology +++ ++ + + + + 
Resistance to exogenous drug contamination +++ + ++ ++ + ++ 
Practicality of sampling ++ +++ + + +++ ++ 
Less invasive + ++ + + +++ +++ 
Ease of handling for storage + ++ + + ++ + 
Potential for DNA/RNA analysis + +++ +++ +++ + ++ 
Less molecular complexity + + ++ ++ ++ +++ 
Candidate molecules to date +++ ++ + + + + 
Adapted from Otto et al., 2012. 
+++: highly significant; ++: significant; + low significance.  
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can be achieved using a mass spectrometry-based technology, in combination with 
isotope labelling or label-free assay (Otto et al., 2012). 
 
A proteomic study of CSF from newly diagnosed ALS patients and from mixed 
controls (a combination of healthy controls and neurological disease controls) has 
identified 3 protein candidates that have distinct expression in ALS (Ranganathan et 
al., 2005). These proteins are i) the 3.42 kDa 7B2CT, a carboxy-terminal fragment of 
the neuroendocrine protein 7B2, ii) the 13.38 kDa Cystatin C, and iii) the 6.88 kDa of 
Transthyretin (TTR), a carrier protein for thyroxine and Vitamin A, which is 
predominantly synthesised by the choroid plexus and glial cells (Ranganathan et al., 
2005).  
 
Cystatin C, a cysteine protease inhibitor and a constituent of the Bunina body 
inclusions found in motor neurons of ALS patients (Okamoto et al., 1993; Okamoto 
et al., 2008), has also been identified in another proteomic study carried out in ALS 
patients and control subjects (Pasinetti et al., 2006). Cystatin C was then further 
examined in CSF and in plasma from ALS patients using a quantitative ELISA 
method (Wilson et al., 2010). The levels of Cystatin C in CSF appeared to be 
reduced, whilst it was elevated in plasma samples from the same patients, 
compared to healthy controls; however, these changes could not differentiate ALS 
from other neurological disease controls. Moreover, Cystatin C levels in CSF and its 
change in longitudinal samples were found to correlate with disease progression 
and survival in ALS (Wilson et al., 2010). In addition, TTR CSF levels were found in 
a recent proteomic study to have distinct levels in ALS patients with rapid disease 
progression and in ALS patients with slow disease progression (Brettschneider et al., 
2010).  
 
Proteomic profiling is a promising tool to identify potential biomarker candidates for 
ALS, although this technique requires further work towards the clarification of the 
pathogenetic relevance of the newly identified targets, as well as the screening of 
the same proteins in large populations of patients and controls.      
1.6.2.3.2.2 Metabolomics 
Metabolomics is a technique that aims at identifying and quantifying small molecules 
(60-1000 kDa) retained in biological tissues which are thought to reflect biochemical 
changes linked to the pathological process. This approach can be applied to large 
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platforms of drug screening and biomarker discovery (Quinones and Kaddurah-
Daouk, 2009). Rozen and colleagues used a screening platform of 300 plasma 
metabolites in the attempt to define the metabolic profile of ALS pathology. They 
found that the differential expression of subsets of metabolites could separate ALS 
patients from healthy controls and included i) significantly decreased or elevated 
molecules in ALS patients, ii) metabolites significantly elevated by treatment with 
Riluzole, and iii) a set of metabolites highly represented in patients with a 
predominantly lower motor neuron disease (Rozen et al., 2005). A recent 
metabolomics study using CSF samples also discovered a perturbation of glucose 
metabolism in ALS patients at diagnosis, and observed a distinct metabolomic 
profile in ALS patients with mutations in the SOD1 gene (Blasco et al., 2010; 
Wuolikainen et al., 2012). With a consensus among researchers supporting strict 
pre-analytical handling and the sharing of the same technology for the analysis, the 
use of metabolomics might therefore become a useful approach for ALS biomarker 
discovery (Otto et al., 2012; Wuolikainen et al., 2009)  
1.6.2.3.2.3 Lipidomics 
Lipidomics targets the lipid component of biological tissues. With the development of 
tandem mass spectrometry and of liquid chromatography for the resolution of lipid 
chemistry,  lipidomics has acquired the potential for large-scale lipid profiling and 
facilitated the development of methods for large datasets analysis (Otto et al., 2012; 
Wolf and Quinn, 2008). The rationale for using lipidomic analysis as means of 
biomarker discovery in ALS is based on observation that energy metabolism 
disturbances and dyslipidemia have been reported in ALS, with some reports 
suggesting that the latter may have some prognostic value (Dupuis et al., 2011). 
Whilst lipidomics may be a promising tool for biomarker discovery in ALS, it is 
important to remember that diet may be a major confounding factor interfering with 
the analysis of the lipid profile observed in ALS pathology.    
1.6.2.3.2.4 Gene expression profiling and transcriptomics 
The complementary DNA microarray has been an important tool in the identification 
of dysregulated biological pathways in ALS. By using an oligonucleotide/cDNA 
microarray, RNA samples from a particular cell type or tissue are extracted, 
fluorescently labelled and then hybridized to the microarray to be quantified.  Gene 
expression profiling (GEP) of post-mortem tissue has shown an ALS-specific 
expression profile and has led to the identification of important aspects of ALS 
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pathogenesis (Dangond et al., 2004; Malaspina and de Belleroche, 2004; Malaspina 
et al., 2001). Recent advances in the development of laser capture microdissection 
techniques have allowed the investigation by GEP of single cell types (Cooper-
Knock et al., 2012b). The gene expression profile of peripheral cells, from blood or 
muscles, has opened new experimental opportunities, for example, the possibility of 
monitoring patients during disease progression and the use of the differential 
regulation of defined RNA species as prognostic factors in the disease (Mougeot et 
al., 2011; Pradat et al., 2012; Saris et al., 2009; Shtilbans et al., 2011; Zhang et al., 
2011a).  
 
In ALS, GEP studies have consistently identified gene expression changes reflecting 
the involvement of defined biological pathways, such as the cytoskeleton, 
inflammation, protein turnover and RNA splicing, irrespectively of tissue type (CNS 
or peripheral) or sample types (mixed-cell or single cell) under investigation 
(Cooper-Knock et al., 2012b). The next-generation sequencing of RNA is a new 
technology that allows sequencing of long stretches of DNA or RNA, i.e. every base 
of the whole transcriptome. This technique has improved the detection rate, allowing 
a better definition of novel transcripts compared to hybridization-based microarray 
assays, although relatively larger amount of starting material is required (Cooper-
Knock et al., 2012b). With the capacity to simultaneously screen a vast number of 
biological pathways, GEP might be in a privileged position to become the platform of 
choice for biomarker discovery in ALS.  
 
Recent advances in ALS GEP studies also include the newly developed approach to 
integrate multiple species and tissue-type microarray-based GEP to identify 
biomarkers (Kudo et al., 2010). Using microarray coupled with the laser capture 
microdissection, the transcriptomic changes were identified in pre-symptomatic 
spinal motor neurons and surrounding glial cells in transgenic mouse models of 
fALS and tauopathy, the SOD1G93A and TAUP301L mice, respectively. The pathways 
regulated in these mouse models were then verified with pre-symptomatic peripheral 
blood transcriptome in SOD1G93A mice, using custom-designed microarray. The 
relevance of these genes was next confirmed by high-throughput immunoassays 
using tissue microarrays from post-mortem spinal cord tissues. Despite the 
difference that may exist between the pre-symptomatic transcriptome in animal 
models and the post-mortem human transcriptome, a number of relevant proteins 
and putative blood biomarkers were identified (Kudo et al., 2010). The underlying 
molecular mechanisms of these identified proteins in ALS pathology now require 
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further investigation. Nonetheless, this approach demonstrates how GEP can be 
utilised and further exploited in the search of biomarkers for ALS.    
1.6.2.3.2.5 High throughput techniques 
Apart from the biomarker discovery platforms discussed above, quantification of 
protein candidates in biological samples can also be achieved by using antibody-
based techniques, such as enzyme-linked immunosorbent assay (ELISA), which 
target single or multiple proteins in each assay. Currently, in ALS the preferred 
target tissues are CSF and blood. Table 1.8 summarises a broad range of targets 
that have been investigated in ALS in CSF and peripheral blood using this method 
(Ryberg and Bowser, 2008; Tarasiuk et al., 2012; Turner et al., 2009). Divergent 
results have been found by different groups for some of the target proteins, and a 
common major shortfall in the quality of these studies is the generally small cohort 
size of these studies and single sampling. Table 1.9 summarises the current leading 
candidates of protein-based biomarker in ALS (Bowser et al., 2011).  
 
1.6.3.2.5.1 Neurofilament: one of the best validated candidates 
Neurofilaments (Nfs) are neurofibrils of 10 nm in diameter, classified as type IV 
intermediate filaments, interacting with microtubule (24 nm) and actin microfilament 
(7 nm) to form the cytoskeleton scaffolding in the neurons (Petzold, 2005). Nfs are 
composed by neurofilament light chain (NfL; coded on chromosome 8p21, 61.5 kDa), 
neurofilament medium chain (NfM; coded on chromosome 8p21, 102.5 kDa), 
neurofilament heavy chain (NfH; coded on chromosome 22q12.2112.5 kDa), and α-
internexin (coded on chromosome 10q24, 66 kDa) (Yuan et al., 2006; Perrot et al., 
2008). Post-translational modifications such as phosphorylation and glycosylation of 
NfL, NfM, and NfH are responsible for the higher molecular weights from sodium 
dodecyl sulfate polyacrylamide gel electrophoresis in the earlier literature with 68, 
150, 190-210 kDa, respectively (Petzold, 2005). NfH is a particularly challenging 
protein as non-phosphorylated it is a near neutral polyampholyte (-2e), while fully 
phosphorylated the charge is -82e (Kim et al., 2011). This has implications for the 
qualitative analysis of NfH phosphoforms by electrophoresis from body fluids, 
resulting in a blurred smear which can be abolished by enzymatically 
phosphorylation/dephosphorylation (Petzold et al., 2011b). Each Nf subunit is 
composed of a non-helical amino region (head domain) and a carboxy-terminal 
regions (tail domain), which are linked by a central α-helical rod domain that is 
highly conserved of approximately 310 amino acids (Perrot et al., 2008). The tail 
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Table 1.8 Selected studies of putative CSF and blood-based biomarkers in ALS. 
Evaluated 
biomarkers 
Findings in ALS Findings (Dx, Phe, Pro)
‡
 References 
CSF Blood (S/P)*  
Neuroaxonal degeneration markers 
NfH ↑ ↑(S) Dx: Increased CSF and serum levels in ALS vs. controls 
Phe: High CSF levels of NfH in UMN predominant 
Prg: High CSF NfH levels with faster rate of disease progression and survival 
(Boylan et al., 2009; 
Brettschneider et al., 
2006c; Ganesalingam et 
al., 2011) 
NfL ↑  Dx: Increased CSF levels 
Phe: High CSF levels of NfL in ALS vs. PMA 
Pro: High CSF levels associated with shorter survival; shorter disease duration 
(Rosengren et al., 1996; 
Tortelli et al., 2012; 
Zetterberg et al., 2007) 
Markers of inflammation and immune activation 
MMP-2 ↑/- ↑(S) Dx: Increased serum levels in ALS vs. controls (Lorenzl et al., 2003; 
Niebroj-Dobosz et al., 
2010) 
MMP-9 -/↓ ↑(S) Dx: Increased serum levels in ALS vs. controls (Beuche et al., 2000; 
Niebroj-Dobosz et al., 
2010) 
MCP-1 ↑ ↑/- (S) Dx: Increased levels 
Pro: correlated with ALSFRS_R and disease progression 
(Baron et al., 2005; Kuhle 
et al., 2009; Tanaka et 
al., 2006; Wilms et al., 
2003) 
Interleukin-6 ↑/- ↑/- (S) Dx: CSF levels higher in ALS vs. NDC; serum levels higher in ALS vs.  NDC; both CSF/serum levels 
found no difference with HC in another study 
(Moreau et al., 2005; Ono 
et al., 2001; Sekizawa et 
al., 1998) 
TNF-α  ↑/- (S) Dx: Conflict results from different studies (Moreau et al., 2005; 
Poloni et al., 2000) 
Complement 
C3, C4 
↑  Dx: CSF C3, C4 levels in ALS higher than HC; pNfH/C3 ratio predict the diagnosis of ALS (Ganesalingam et al., 
2011; Goldknopf et al., 
2006) 
Markers of neuroprotective 
VEGF ↓/-/↑ 
 
↑/- (S) 
-(P) 
Dx: Decreased CSF levels in hypoxaemic ALS vs. ND; increased serum levels in end-stage ALS. 
Phe: Increased CSF levels in limb-onset 
(Devos et al., 2004; 
Ilzecka, 2004; Moreau et 
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Prg: Increased CSF levels with long duration; Serum levels inversely correlate with disease duration al., 2006; Nygren et al., 
2002) 
sVEGFR1  ↓ Phe: Decreased levels in Definite ALS vs. Probable ALS (Anand et al., 2012) 
Cystatin C
†
 ↑/↓  Dx: Increased levels in ALS vs. HC; one proteomic study show decreased levels in ALS 
Pro: correlate with disease progression and survival 
(Pasinetti et al., 2006; 
Ranganathan et al., 
2005; Wilson et al., 2010) 
TDP-43 ↑ ↑ (P) Dx: Higher CSF levels in ALS vs. NDC; Higher plasma levels in ALS vs. HC 
Pro: CSF levels correlate with shorter survival time; plasma levels correlate with age 
(Kasai et al., 2009; Noto 
et al., 2011; Verstraete et 
al., 2012a) 
 
Adapted from Tarasiuk et al., 2012; Turner, et al., 2009; Ryberg and Bowser, 2008.  
*Blood (S/P): (Serum/Plasma) 
‡(Dx, Phe, Pro): (Diagnosis. Phenotype, Progression) 
†: contain findings from proteomic studies 
Abbreviation: HC: healthy controls; MCP-1: Monocyte chemoattractant protein-1; MMPs: Matrix metalloproteinases; NDC: neurological 
disease controls; NfH: Neurofilament heavy chain; NfL: Neurofilament light chain; pNfH: phosphorylated NfH; sVEGFR1: soluble vascular 
endothelial growth factor receptor 1; TNF-α: Tumour necrosis factor-α; VEGF: Vascular endothelial growth factor.  
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Table 1.9. Current leading candidates of neurochemical biomarkers in ALS. 
Method used to identify these candidates Reference 
Methods measuring single-protein antibody concentrations 
pNfH in CSF or blood (Boylan et al., 2009; 
Boylan et al., 2012; 
Brettschneider et al., 
2006c; Lu et al., 
2012) 
Ratio of CD14 to S100β in CSF (Sussmuth et al., 
2010) 
Ratio of pNfH to complement C3 in CSF (Ganesalingam et al., 
2011) 
Cystatin C levels as prognostic indicator of disease 
progression 
(Wilson et al., 2010) 
Methods measuring concentrations of multiple antibodies 
Levels of IL-2, IL-6. IL-10, IL-15, and GM-CSF in CSF (Mitchell et al., 2009) 
Levels of MCP-1 and IL-8 in CSF plus IL-8, CCL11, CCL24, 
and CCL26 in blood 
(Kuhle et al., 2009) 
MS-based methods 
Cystatin C, TTR, neuroendocrine protein 7B2 in CSF (Ranganathan et al., 
2005; Ryberg et al., 
2010) 
Α2-glycoprotein in CSF (Brettschneider et al., 
2008) 
C3 and other complement in blood (Goldknopf et al., 
2006) 
Cystatin C and neurosecretory protein VGF in CSF (Pasinetti et al., 2006) 
Fetuin-A and TTR in CSF as disease progression (Brettschneider et al., 
2010) 
Adapted from Bowser et al., 2011 
Abbreviations: CCL, CC-chemokine ligand; C3, complement 3; GM-CSF, 
granulocyte macrophage-colony stimulating factor; MCP-1, monocyte 
chemoattractant protein-1; pNfH, phosphorylated neurofilament heavy chain.  
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domain is the distinctive feature for NfL, NfM and NfL: short in NfL, longer and rich in 
repeats of phosphorylation site Lys-Ser-Pro (KSP) for NfM and NfH (Julien and 
Mushynski, 1982; Julien and Mushynski, 1983). Nfs are heteropolymers, with a 
subunit stoichiometry of 4:2:2:1 (NfL-α-internexin-NfM-NfH) (Yuan et al., 2006). As 
mentioned, Nfs undergo post-translation modifications, such as phosphorylation, 
glycosylation, nitration, oxidation and ubiquitination, in response to physiological 
(such as development, neurite outgrowth, interactions with other proteins) and 
pathological situations including anterograde (Wallerian degeneration) and 
retrograde axonal degenerations as seen in a number of neurodegenerative 
conditions (Perrot et al., 2008).  
 
When growing axons reach their targets, NfL is the first subunit to be expressed, 
together with α-internexin and peripherin, and followed by NfM (Carden et al., 1987; 
Willard and Simon, 1983). At this stage, the expression levels of NfL and NfM is low 
(Carden et al., 1987). The appearance of NfH occurs after the synaptogenesis and 
accompanied by robust up-regulation of NfL and NfM expression (Carden et al., 
1987). These subunits are then assembled in the perikaryon, followed by slow 
axonal transport toward the nerve terminal (Hoffman and Lasek, 1975). It is known 
that about 80% of axonal Nfs are highly phosphorylated and integrated in the 
structure of axons, while the remaining 20% of non- or hypophosphorylated Nfs is 
involved in ante- and retrograde axonal transport (Nixon, 1993; Roy et al., 2000). At 
nerve terminal, Nfs are degraded by calcium-activated proteases, such as calpain, 
and non-specific proteases like lysosomal cathepsin D, trypsin and α-chymotrypsin 
(Chin et al., 1983; Malik et al., 1983; Roots, 1983). Susceptibility of Nfs to proteases 
decreases with increase of phosphorylation (Goldstein et al., 1987; Sternberger and 
Sternberger, 1983; Pant, 1988).    
 
Nfs are not essential for axonogenesis, but have critical roles on axonal diameter. 
Neurofilament numbers and density are correlated with axonal calibre in myelinated 
axons (Griffin and Watson, 1988), which is directly related to nerve conduction 
velocity. Nfs interact with a number of partners that can modulate functions (through 
enzymes, such as kinases and phosphatases) and structure (through molecular 
motors, such as Dynein, Kinesin) of Nf, as well as the dynamic interactions (through 
MAP2, STOP, Hamartin, Fodrin, Synapsin I, etc) with other cytoskeletal proteins 
such as microtubules, tubulin, actin, and orgenelles (Perrot et al., 2008). Genetically 
reduction of Nfs expression in experimental animals causes reduced neurofilament 
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content, axonal caliber, and conduction velocities (Griffin and Watson, 1988; Julien, 
1999).  
 
Due to dysfunction of Nf synthesis, phosphorylation, distribution by axonal transport 
and their degradation, abnormal aggregations of Nfs are a hallmark of a number of 
human neurological disorders, including Alzheimer’s Disease, Parkinson’s Disease, 
Charcot-Marie-Tooth, neuronal intermediate filament inclusion disease, diabetic 
neuropathy, giant axonal neuropathy, multiple sclerosis, glaucoma, as well as 
amyotrophic lateral sclerosis (Hermann and Griffin, 2002; Perrot et al., 2008).   
 
One of the pathological characteristics in ALS is the intraneuronal aggregates of Nfs 
(named spheroids) in affected neurons (Carpenter, 1968; Delisle and Carpenter, 
1984; Hirano et al., 1984; Munoz et al, 1988). Codon deletions or insertions in the 
KSP repeat of NfH have been identified in sporadic ALS (Al-Chalabi et al., 1999; 
Figlewicz, et al., 1994; Tomkins et al., 1998). Expression of a mutant NfL subunit 
(Lee et al., 1994) and the overexpression of NfL (Xu et al., 1993), NfM (Wong et al., 
1995), or human NfH (Cote et al, 1993) induces Nf pathology in experimental 
animals similar to those in observed in ALS patients. The pathology caused by 
excess human NfH can be rescued by co-overexpression of human NfL in a 
dosage-dependent pattern, suggesting the importance of subunit stoichiometry in 
ALS pathogenesis (Meier et al., 1995). Mice expressing mutant SOD1 display Nf 
pathology and a phenotype similar to mice overexpression NfL or human NfH 
(Borchelt et al., 1998; Tu et al., 1996). Depletion of axonal NfH, by preventing NfH 
entering the axons, and hence perikaryal accumulation of NfH is not beneficial for 
SOD1G37R mice; in fact, neither initiation nor progression of pathology is not affected 
in this SOD1G37R mouse model (Eyer et al., 1998). However, depletion of axonal NfL, 
the main subunit for Nf assembly, with subsequently reduced axonal NfM and NfH 
and increased perikaryal NfM and NfH levels, delays onset and slows disease 
progression in SOD1G85R mice (Williamson et al., 1998). Furthermore, 
overexpression of NfL or NfH delays onset and extend lifespan in SOD1G93A mice 
(Kong and Xu, 2000). Similarly, overexpression of human NfH in SOD1G37R mice 
also extends lifespan in these mice (Couillard-Despres et al., 1998). These findings 
suggest that a protective effect of perikaryal accumulation of Nfs is responsible for 
slowing disease in these models.  Possible mechanisms of this protective effect 
include Nfs may act i) as calcium chelators (Roy et al., 1998), ii) to interfere with 
glutamate receptor function and prevent glutamate excitotoxicity (Ehlers et al., 1998), 
75 | P a g e  
 
and iii) as a phosphorylation sink for cyclin-dependent kinase 5 dysregulation 
induced by mutant SOD1, and hence reducing the detrimental hyperphosphorylation 
in neurons (Nguyen et al., 2001).  
 
Nfs therefore play a crucial role in ALS, although the pathology-causing and 
pathology-relieving mechanisms of Nfs in ALS and SOD1 mouse models remain to 
be further clarified. Together with the physiological role in maintaining normal 
neuronal structure and physiological functions as well as their pathological 
involvements in other neurodegenerative disorders, Nfs have become surrogate 
markers for axonal injury, degeneration and loss, which led to quite a number of 
quantification studies, essentially in CSF samples (Petzold, 2005). 
1.7 Aims of this thesis 
The Hypothesis tested in the experiments described in this Thesis is that plasma 
NfH levels may extend on earlier CSF work and be a biomarker of disease 
progression in ALS patients. The specific Aims of this research project are:  
i) To develop and validate a reliable ELISA method for the sensitive and 
accurate detection of NfH in plasma;  
 
ii) To evaluate whether plasma NfH levels could be used to monitor disease 
progression in a mouse model of ALS with a homogeneous and well characterised 
pattern of disease progression; 
 
iii) To examine whether plasma NfH levels can reflect therapeutic effects of 
known and novel disease-modifying agents for ALS; 
 
iv) To examine whether plasma NfH levels can be used to monitor disease 
progression in a large, heterogeneous cohort of ALS patients.  
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Chapter 2 
Development of a sensitive, quantitative immunoassay for the measurement 
of plasma neurofilaments for ALS 
 
2.1 Introduction 
There is an urgent need to develop reliable biomarkers for ALS not only for 
monitoring disease progression, accelerating diagnosis and predicting prognosis, 
but also for improving the efficacy of clinical trials for the development of new 
therapeutic strategies. Neurofilaments (Nfs) are one of the leading candidate 
biomarkers in ALS. However, most of studies undertaken to date were conducted 
using cerebrospinal fluid (CSF) as sample source, which is not an appropriate tissue 
for long-term repetitive sampling in debilitating diseases such as ALS. In the 
experiment discussed in this Chapter, I examined the possibility that plasma Nfs 
may be a useful biomarker of disease progression in ALS. 
2.1.1 Neurofilament heavy chain (NfH) as a biomarker of ALS 
Protein aggregation is a characteristic feature of neurodegenerative disorders 
including ALS. Nfs are components of the protein aggregates found in affected 
tissues from ALS individuals and animal models of ALS (Strong et al., 2005). Nfs are 
a major component of the neuroaxonal cytoskeleton and are important for 
maintaining axonal calibre, and thereby modulation of conduction velocity. Nfs also 
interact with other cytoskeletal proteins to ensure axonal transport of key organelles, 
growth factors, and signalling factors (Perrot et al., 2008). Nfs are assembled into a 
unique heteropolymer structure with a specific stoichiometric composition of at least 
four subunits: neurofilament light chain (NfL, 68 kDa), neurofilament medium chain 
(NfM, 150 kDa), and neurofilament heavy chain (NfH, 190-210 kDa) and alpha-
internexin (Petzold, 2005). The three neurofilament subunits differ mainly in the 
length of the carboxy-terminal tail domain, which results in different states of 
phosphorylation and of susceptibility to proteases (Goldstein et al., 1987). Mutations 
in Nfs have been reported in several neurodegenerative diseases, such as 
Alzheimer’s disease (AD), Parkinson’s disease (PD), Charcot-Marie-Tooth disease, 
giant axonal neuropathy, diabetic neuropathy, progressive supranuclear palsy, 
spinal muscular atrophy, as well as ALS (Perrot et al., 2008). Although only a small 
number of variants in the NfH gene have been identified in approximately 1% of 
sporadic ALS (sALS) patients (Al-Chalabi et al., 1999; Figlewicz et al., 1994), one 
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common pathological finding of both sALS and familial ALS (fALS) is the 
accumulation of phosphorylated Nfs in the perikaryon and in axonal spheroids, 
which are normally only present in distal axons and nerve terminals (Manetto et al., 
1988). Manipulations of the stoichiometry of the three Nfs subunits have been 
shown to facilitate the development of early-onset motor neuron death in transgenic 
mouse models of ALS (Cote et al., 1993; Lee et al., 1994; Xu et al., 1993), thus 
supporting the critical involvement of Nfs in ALS pathology.  
 
Monitoring of tissue-specific components released into biological fluids during 
disease progression can be used to aid diagnosis and as readouts of pathological 
severity (Ganesalingam and Bowser, 2010; Sussmuth et al., 2008). Nfs levels in the 
CSF, the closest body fluid compartment to the central nervous system (CNS), have 
been investigated as potential disease biomarkers in several neurological disorders. 
Recent studies have shown that CSF Nf levels might serve as a prognostic marker 
in multiple sclerosis (Salzer et al., 2010), may assist in the differential diagnosis 
between frontotemporal dementia (FTD) and early onset AD, particularly in 
combination with Aβ42 and phosphorylated-tau proteins (de Jong et al., 2007), and 
may help distinguish Parkinsonian syndromes in combination with CSF tau levels 
(Brettschneider et al., 2006b; Constantinescu et al., 2009). Furthermore, CSF Nf 
levels are much higher in ALS than in other neurodegenerative disorders such as 
AD (Brettschneider et al., 2006c; Ganesalingam et al., 2011; Norgren et al., 2003; 
Rosengren et al., 1996) and correlate inversely with disease duration (Zetterberg et 
al., 2007). Studies have also suggested that the phosphorylation state of Nfs can be 
indicative of neuronal pathology, with high phosphorylated levels present in 
neurodegenerative disorders (Perrot et al., 2008). However, because of its invasive 
nature, serial CSF sampling is not tolerated by all patients and is clearly not an ideal 
source of bio-fluids for repeated bioassays for the purpose of monitoring progression 
in ALS. Thus, a functionally validated Nf-based blood biomarker for the longitudinal 
monitoring of disease development and informative of treatment response would be 
highly desirable.  
2.1.2 Established approaches for the detection of NfH in the peripheral blood 
of ALS 
Boylan and colleagues have previously shown that phosphorylated NfH (pNfH) is 
detectable in the blood from both SOD1 murine models and ALS patients, using an 
in-house ELISA method (Boylan et al., 2009). However, pNfH was only detectable 
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after 74 days of age and reached a peak concentration of only 35 ng/mL at 133 days 
of age (end-stage) in SOD1G93A mice, and was undetectable in wild-type (WT) mice. 
In ALS (n=19) and control subjects (n=19), median pNfH in the plasma was 0.53 
and 0.17 ng/mL, respectively (p<0.001) (Boylan et al., 2009). These levels observed 
in human samples were surprisingly low, considering that the average concentration 
of overall proteins in the blood is 60 ng/mL in humans (Boylan et al., 2009). In 
addition, pNfH in SOD1G93A mice was only detected relatively late in the disease, 
which is surprising as motor neuron degeneration occurs earlier in the disease.  
Furthermore, pNfH was undetectable in WT animals, in contrast to the findings in 
human control subjects. These findings suggested that this existing ELISA method 
may not be ideal in quantifying pNfH in the blood of either mice or humans.    
2.1.3 Limitations of existing methods to quantify NfH levels from blood: lack of 
parallelism 
Several studies have examined Nf levels as a potential biomarker in ALS, significant 
limitations have been subsequently identified which limit the extrapolation of data 
derived from CSF samples to blood samples: Notably, a lack of parallelism. 
 
Precise quantification of NfH levels from biological samples using immunoassays 
can be compromised by at least four factors: (1) the change in solubility and 
polymerisation characteristics of Nfs subunits, leading to the formation of Nfs 
aggregates; (2) differential resistance to proteases, resulting in variable stability; and 
(3) differential interactions with other proteins, such as ubiquitin and (4) presence of 
auto-antibodies. These factors can result in the masking of those NfH epitopes 
relevant to immunoassays, resulting in a different bio-dilution curve compared to that 
observed with the soluble, stable NfH protein standard curve for such 
immunoassays from different bio-fluids.  
 
Typically, in immunoassays using biological samples such as blood, CSF or other 
body fluids, it had been possible to obtain a dilution-optical density curve in a linear 
range, which is parallel to the curve obtained with the purified protein standard. If the 
bio-dilution curve from biological samples diverges from, and is not parallel to that 
obtained with the standard curve, this is referred to as 'lack of parallelism.’ ‘Lack of 
parallelism’ suggests that the protein in the biological sample and that in the protein 
standard presents different bio-properties, and as a consequence the standard 
curve may not be suitable for use in accurate quantification of protein levels from the 
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respective biological fluid (Plikaytis et al., 1994). Consequently the results may be 
inconclusive or mis-leading, since after correcting for the dilution factor, the protein 
concentrations calculated from a 1:1 dilution will be very different to the protein 
concentrations calculated from other sample dilutions.  
 
To illustrate this further, an example of such a lack of parallelism is shown for 
human serum samples assayed for Haemophilus influenza type b (Hib) antibody (Ab) 
in the data presented in Fig. 2.1, taken from Plikaytis et al (1994). The Figure shows 
the results of two typical ELISA for Hib Ab in which the OD readings for serum 
samples are shown alongside the results obtained with the standards. In the results 
shown in Fig. 2.1A, the samples show clear parallelism with the standard curve, 
indicating that the Hib Ab at the concentration presented in the samples has the 
same bio-properties as the Hib Ab in the standard curve. However, in the data 
presented in Fig. 2.1B, the serum samples show a clear lack of parallelism with the 
standard OD readings, so that the calculated Hib Ab concentration will be very 
different in the samples at different dilutions. For example, compare the data 
identified by the large and small arrows in Fig. 2.1B, which represent Hib Ab 
concentrations of 2 and 9.25 µg/mL, respectively, for the same serum sample at two 
different dilutions (Plikaytis et al., 1994). This finding clearly illustrates the 
confounding effects of the lack of parallelism of the bio-sample with the standard 
curve in an immunoassay. 
2.1.4 Hypothesis and Aims 
Hypothesis 
In this Chapter, I examined the probability that accurate measurement of plasma 
NfH levels could be obtained by the development of a highly sensitive, reproducible 
ELISA, that specifically overcome the lack of parallelism from plasma samples, 
which causes a ‘Hook’ shape on the bioassay dilution curve. 
Aims 
The aims of the work described in this Chapter are to develop a new ELISA method 
for the detection of plasma NfH, both hyperphosphorylated and variably 
phosphorylated NfH, from an existing method developed for use in CSF (Petzold et 
al., 2003). Since the SOD1G93A mouse is a well characterised, widely used model of 
ALS, with a reproducible progressive phenotype, plasma from SOD1G93A mice at 
end stage of disease was therefore used as a platform for development of the NfH  
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Figure 2.1  
 
 
 
Figure 2.1. Antibody concentration calculations by using a standard curve 
prepared from a serial dilution of H. influenzae type b standard reference 
serum (FDA 1983) (oval) and two serially diluted serum samples (square) 
plotted on a fully specified logit-log scale. (A) The parallel case; the slopes for 
the standard reference and serum sample 1 (black square) curves are 1.370 and 
1.366, respectively. (B) The nonparallel case; the slopes for the standard reference 
and serum sample 2 (blue square) curves are 1.361 and 0.677, respectively. Serum 
antibody concentrations for points with big arrow head and small arrow head are 
2.00 and 9.25 µg/ml, respectively. Adapted from Pikaytis et al., 1994. 
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assay. In view of the very small volumes of plasma that can be obtained from mice, 
the method developed also has to be suitable for use in very small volumes of 
plasma. 
2.2 Methods and Materials 
2.2.1 Experimental animals 
2.2.1.1 Genotyping of SOD1G93A mice  
Mice expressing the human SOD1G93A mutant protein (TgN[SOD1-G93A]1Gur) were 
maintained by breeding male heterozygous carriers with female (F57BL/6 x SJL) F1 
hybrids within the biological services facility of UCL Institute of Neurology under 
licence from the UK Home Office and following ethical approval from UCL Institute 
of Neurology. The presence of the SOD1G93A mutation was confirmed by PCR 
reaction from ear biopsies of 3-week-old mice. Male SOD1G93A mice were examined 
at 120 days of age, near to end stage in our colony of SOD1G93A mice in which male 
mice live for a mean 123±2 days (Kalmar et al., 2008). WT, age- and sex-matched 
mice were used as controls. Each experimental group consisted of 10 mice from 6 
different litters.   
  
Genotyping of SOD1G93A mice by polymerase chain reaction 
The mice carrying a mutant human SOD1 transgene were identified by polymerase 
chain reaction (PCR) amplification of the transgene from genomic DNA. Ear notches 
were collected soon after the mice were weaned. The tissue sample was then 
digested using rapid digestion buffer. 
 
For PCR, 2.5 µl of each DNA sample was added to a reaction tube, which contained 
17.65 µl sterile water, 2.5 µl PCR buffer, 0.75 µl MgCl2 (50 mM), 0.5 µl dNTP 
solution, 0.25 µl of both forward and reverse primers for the endogenous SOD1 
enzyme and human mutant SOD1 enzyme, and 0.1 µl Taq polymerase, to make the 
final volume of 0.25 µl. In order to differentiate the human transgene from murine 
SOD1, primers with the following sequences were used:  
 
                                   5’ CAT CAG CCC TAA ATC TGA 3’ 
                                   5’ CGC GAC TAA CAA TCA AAG 3’     
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The samples were then temperature cycled, as summarised in Table 2.1. The PCR 
products were subsequently visualised by gel electrophoresis by running 15 µl of 
each PCR product on a 2% gel agarose gel at 85 V for 20 minutes. 
2.2.1.2 Plasma collection 
Blood from 120-day-old SOD1 mice and their age-matched WT littermates was 
collected via cardiac puncture under terminal anaesthesia into an EDTA-coated tube 
(Greiner bio-one; K3EDTA). Each tube was then centrifuged at 14,000 rpm for 8 
minutes. The plasma was collected, protease inhibitor added (Sigma; v/v: 1/100), 
the sample was then aliquoted and stored at -80°C freezer until assayed. 
2.2.2 ELISA 
The in-house sandwich ELISA developed in this Chapter was modified from a 
method originally designed for assessment of NfH levels in CSF samples. Here we 
adhere to a previously proposed nomenclature and indicate that the capture 
antibodies used for NfH phosphoform quantification in superscript NfHSMI35 for 
variably-phosphorylated NfH and NfHSMI34 for hyperphosphorylated NfH (Petzold et 
al., 2003). 
2.2.2.1 Antibodies 
The capture antibodies used in this study were mouse monoclonal anti-NfH 
antibodies, SMI-34R and SMI-35R (Covance, USA) and the detector antibody was 
rabbit polyclonal anti-Neurofilament 200 (N4142; Sigma, UK).  The reporter antibody 
was horseradish peroxidase (HRP)-labelled swine polyclonal anti-rabbit antibody 
(P0217; DAKO, Denmark). 
2.2.2.2 Chemicals and Reagents 
The following reagents were used in this study: Sodium barbitone (No. 27283; BDH, 
USA); Barbitone (B-0375), ethylenediaminetetraacetic disodium salt (EDTA; E4884), 
protease inhibitor cocktail (PI, P8340), NaHCO3, Na2CO3, Tween20 (P1379), urea 
and bovine serum albumin (BSA) (all purchased from Sigma, UK); One step HRP 
substrate, TMB (3, 3’, 5, 5’-tetramethylbenzidine; DAKO, Denmark); Hydrochloric 
acid (HCl; Merck, Germany); Bovine Neurofilament H, 200kD (N2160-15B; 
USBiological, USA).  
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Table 2.1. Summary of the cycles involved in PCR analysis of SOD1G93A samples. 
No. of cycles Temperature Duration of cycle 
1 95°C 3 minutes 
36 95°C 30 seconds 
36 60°C 30 seconds 
36 72°C 45 seconds 
1 72°C 2 minutes 
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2.2.2.3 NfH Standards 
Gel determined bovine NfH (bNfH; USBiology) was reconstituted and aliquots stored 
at -20°C. The standard curve used for the NfH assay was calculated from dilution of 
200 µg bovine NfH in Barb2EDTA buffer (Sodium Barbitone, Barbitone, 6 mM EDTA 
at pH 8.6) containing 0.1% BSA and ranged from 0 to 100 ng/mL. 
2.2.2.4 Plasma samples 
In these experiments, plasma obtained from SOD1G93A mice at end stage of disease 
was used as a biological sample in which NfH levels would be expected to be high 
compared to WT controls. For measurement of NfH levels, plasma was thawed and 
each sample analysed in duplicate on a single plate.  
2.2.2.5 Existing method for detection of NfH 
As a platform to develop a reliable immunoassay for the quantification of plasma 
NfH, using very small amount of samples obtained from mice, I first examined the 
feasibility of using an already established method developed for the detection of NfH 
in CSF in human (Petzold et al., 2003). This existing method was therefore used as 
a starting point from which further steps for optimisation were taken as needed to 
extend this method for the use of plasma samples.  
 
The microtitre plates were coated with 100 µl of capture antibodies, either SMI-34R 
or SMI-35R, in 0.05 M carbonate buffer, pH 9.5 (w/v, 2/10000), at 4ºC overnight. 
The plates were rinsed in Barb2EDTA buffer containing 0.05% Tween 20 and 0.1% 
BSA (wash solution) once and then blocked with 150 µl of Barb2EDTA buffer 
containing 1% BSA at room temperature (RT) for 1 hour. After 2 rinses with wash 
solution, 95 µl of Barb2EDTA buffer containing 0.1% BSA (sample diluent) was 
added into each well. Five microliters of standard, quality control or plasma sample 
were then loaded in duplicate into the plate. The plate was then incubated on a 
shaker for 1 hour (RT). After washing (3x5 minutes), 100 µl of detector antibody (w/v. 
10/10000 in sample diluent) was added into each well and incubated for 1 hour on a 
shaker (RT). The plate was then washed (3x5 minutes) before 100 µl of reporter 
antibody (w/v, 10/10000 in sample diluent) was loaded into each well and incubated 
for 1 hour on a shaker (RT). After washing (6x5 minutes), 100 µl of TMB substrate 
was added into each well and incubated for approximately 20 minutes in the dark on 
a shaker (RT). The reaction was then stopped by adding 50 µl of 1M HCl into each 
well. The absorbance was read immediately at 450 nm, with 750 nm as the 
85 | P a g e  
 
reference wavelength, on an Omega plate reader (Software version: 1.02; BMG 
LABTECH). 
2.2.3 Western blot analysis 
2.2.3.1 Samples  
Western blot (WB) analysis of NfHSMI34 was carried out in plasma from 120-day-old 
SOD1G93A and WT mice and purified bovine NfH protein (USBiological; N2160-15B). 
Each set of samples contained plasma from 3 mice from different litters. All sets of 
samples were firstly filtered twice through the Amicon® Ultra Centrifugal filter 
(Millipore; UFC510024) to remove low molecular weight proteins in the plasma.  
2.2.3.2 Sample preparation  
Plasma samples were incubated at three conditions, all at 1:1 dilution factor: i) 4 M 
urea-Barb2EDTA buffer incubation at 4ºC for 48 hours, ii) 4 M urea-Barb2EDTA 
buffer incubation for 1 hour (RT), and iii) Barb2EDTA  buffer incubation for 1 hour 
(RT). Samples were then mixed with lithium dodecyl sulfate sample buffer and 0.5 M 
dithiothreitol before being denatured at 70ºC in a water bath for 10 minutes. Purified 
bovine NfH protein was incubated using the above conditions ii) and iii). 
2.2.3.3 Blot management  
HiMarkTM Pre-stained HMW protein standard (ranged between 460-30 kDa; 
Invitrogen, LC5699), purified bNfH protein and plasma samples were loaded into 3-
8% NuPAGE® Noves® Tris-Acetate gels (Invitrogen, EA0375BOX). The gel 
electrophoresis was set at 150 volt for 100 minutes, and the proteins were then wet 
blotted to a nitrocellulose membrane as previously described (Petzold et al., 2011b). 
The membrane was then blocked with Barb2EDTA buffer containing 5% skimmed 
milk at room temperature for 1 hour. After washing (4x10 minutes), the membrane 
was incubated in Barb2EDTA buffer containing 0.1% skimmed milk with SMI-34R 
(1:1000) at 4ºC overnight. The membrane was then washed (6x15 minutes), 
followed by 2-hour incubation with HRP-labelled rabbit anti-mouse IgG (Dako, 
P0260, 1:1000, RT) and washed (6x15 minutes). The membrane was then treated 
with the chemiluminescence substrate (SuperSignal West Pico, Thermo Scientific, 
#34078) for 5 minutes. The dried membrane was visualised on an AlphaEase SP 
CCD camera (2 minutes exposure). 
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2.2.3.4 Band specificity validation  
Pre-absorption of the primary antibodies, using high concentration of NfH standard 
proteins, abolished all the bands at high molecular weight. 
2.2.3.5 Densitometry  
The immunoblot bands were quantified using AlphaEase®FC software version 5.0.2. 
Densitometric values of bands from urea-treated conditions were normalised to non-
urea treated conditions. 
2.2.4 Statistical analysis 
Statistical analyses were undertaken using SAS software (V9.1). Non-parametric 
analysis Mann-Whitney U test was used. 
2.3 Results 
2.3.1 Plasma NfH aggregates cause a NfH ‘Hook shaped curve’  
In the first set of experiments, I examined whether an existing published method 
used for the detection of NfH in CSF samples was suitable for reliable measurement 
of NfH in plasma samples. In order to optimise the chance of detecting NfH, plasma 
from end-stage SOD1G93A mice was examined as it was expected that NfH levels 
would be significant at this stage in this model of ALS. As can be seen in the bio-
dilution curve presented in Fig. 2.2, a hook shape curve was observed in the serial 
dilution of plasma samples from 120-day-old SOD1G93A mice. (This phenomenon 
was termed NfH ‘Hook Effect’ in my publication about the work presented in this 
Chapter (Lu et al., 2011)). In addition, it can be seen that the plasma levels of NfH 
from age-matched WT littermates were undetectable (Table 2.2). Figure 2.2 shows 
a clear lack of parallelism between the clinical course of SOD1G93A plasma samples 
and that of the NfH standards. This lack of parallelism introduced an analytical error, 
averaging at 300% for a 1:16 dilution (comparison of the 4th dilution and the 1st 
dilution) (Fig. 2.2B). 
 
Subsequent immunoblotting showed that this lack of parallelism was likely to be due 
to a combination of NfH aggregate formation (see 238-460 kDa bands in Fig. 2.3A, 
lanes 4&7) and endogenous binding of NfH cleavage products (Fig. 2.3A, 5 bands 
below the expected ~205 kDa on a SDS gel, lanes 4-9). Addition of 4 M Urea partly 
dissolved the aggregates after one hour (Fig. 2.3A, lanes 5&8, solid arrows). The 
NfH aggregates were completely broken up by a longer incubation for 48 hours (Fig.  
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Figure 2.2 
 
 
Figure 2.2. Lack of parallelism from plasma samples impresses with a typical 
‘hook shaped curve’ for NfH. (A) Normalised optical density (NOD) in doubling 
dilution of plasma samples from 120-day SOD1G93A mice showed a hook shape at 
the start of the dilution curve (arrow), i.e. an increase in NOD, while the NOD of the 
NfH standard attenuated. (B) Averaged concentration of an undiluted sample was 
approximately a third of the levels at a dilution 1:16. Error bars: ±SEM. 
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Table 2.2. A summary of initial plasma NfHSMI34 levels obtained from 120-day-old 
WT and SOD1G93A mice, using the ELISA method originally designed for CSF 
samples in Human. 
Group Sample Dilution NfHSMI34 levels 
(ng/mL) 
WT 
 
Mouse 1 1:2 
1:4 
1:8 
1:16 
All undetectable 
Mouse 2 1:2 
1:4 
1:8 
1:16 
All undetectable 
Mouse 3 1:2 
1:4 
1:8 
1:16 
All undetectable 
SOD1 
 
Mouse 1 
 
1:2 
1:4 
1:8 
1:16 
154.42 
396.71 
500.82 
655.68 
Mouse 2 1:2 
1:4 
1:8 
1:16 
169.83 
230.17 
314.04 
375.96 
Mouse 3 1:2 
1:4 
1:8 
1:16 
313.37 
518.17 
715.21 
790.01 
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Figure 2.3 
 
 
Figure 2.3: Disruption of NfH aggregates. (A) The western blot shows the effect 
of urea in disrupting NfH aggregates in plasma of SOD1G93A mice. Lane 1: the 
molecular weight (MW) standards; Lanes 2 and 3: Purified bovine NfH; Lanes 4-6: 
SOD1G93A plasma sample Set A; Lanes 7-9: SOD1G93A plasma sample Set B; Lanes 
2, 4, and 7: 1 hour incubation in Barb2EDTA buffer at RT; Lanes 3, 5, and 8:  1 hour 
incubation in Barb2EDTA buffer with 4 M urea at RT; Lanes 6 and 9: 48 hours 
incubation in Barb2EDTA buffer with 4 M urea at 4°C. (B) Densitometry of bands i) 
between 268-460 kDa, ii) around 238 and 268 kDa, iii) around 171 kDa, iv) around 
117 kDa, and v) around 71 kDa. All densitometric values for bands with urea 
incubation were normalised to corresponding non-urea incubation condition. Error 
bars represent the SEM of Densitometric values normalized to non-urea condition of 
corresponding bands in three repeats of samples. Error bars: ±SEM. 
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2.3A, lanes 6&9, solid arrows; Fig. 2.3B). As aggregates were broken up the lower 
molecular weight bands became stronger (Fig. 2.3A, lanes 5&6). However, in 
contrast to the consistent break up of aggregates, the appearance of cleavage 
products (dashed arrows) was less consistent (Fig. 2.3A, lanes 5, 6, 8, 9; Fig. 2.3B). 
2.3.2 Disruption of NfH aggregates in plasma 
In view of the finding that NfH aggregates in plasma might contribute to the ‘hook 
shaped curve’ shown in Fig. 2.2, I next developed a method to overcome this effect. 
Using plasma samples from 120-day-old SOD1G93A mice and age-matched WT 
controls, a number of established methods for the gentle disruption of NfH 
aggregates were therefore tested, including addition of a calcium chelator, such as 
EGTA or EDTA (Yabe et al., 2001a; Yabe et al., 2001b) or the pre-thawing of 
samples at 4°C (Petzold et al., 2003). As the results presented in Fig. 2.4 show, 
both of these methods improved the quantification of NfH levels during serial dilution. 
However, the error remained high, averaging 36% for pre-thawing (Fig. 2.4A), 63% 
for EDTA and 33% for EGTA (Fig. 2.4B). The effects of calcium chelators and/or 
prethawing were therefore not consistent enough to achieve parallelism. 
 
As shown in Fig. 2.5, the most effective method for the disruption of NfH aggregates 
was found to be incubation in urea (Fig. 2.5). Urea incubation had a dose-dependent 
effect (0.5 M - 4 M) with the highest NfHSMI34 and NfHSMI35 levels detected following 
incubation of the sample diluent in 0.5 M urea at RT, 1 hour prior to incubation in the 
ELISA. Longer incubation periods (up to 24 hours at 4ºC) reduced the levels of NfH 
phosphoforms detected, with a decrease of up to 75% for NfHSMI34 and a 60% 
decrease for NfHSMI35 (Fig. 2.6). 
 
Incubation of the plasma samples in 0.5 M urea-Barb2EDTA buffer at a 1:8 dilution 
for 1 hour at RT before adding to the ELISA abolished the hook shaped dilution 
curve and substantially improved parallelism (Fig. 2.7A & 2.7B). 
 
A summary of the final optimised method for the detection of NfH phosphoforms in 
plasma is shown in Table 2.3. The Table details the protocol which overcomes the 
lack of parallelism and is therefore suitable for detection of NfH phosphoforms in i) 
plasma, and ii) small sample volumes.  
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Figure 2.4 
 
 
Figure 2.4. The effect of pre-thawing and calcium chelators on disruption of 
NfH aggregates. Both pre-thawing plasma samples (A) and addition of calcium 
chelators (B) reduced the NfH “Hook Effect” observed during doubling dilutions, 
resulting in an averaged elevation of NfH levels during serial dilution of 36%, 63% 
and 33% for pre-thawing, EDTA and EGTA, respectively. Error bars: ±SEM. 
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Figure 2.5 
 
 
 
Figure 2.5. The effects of urea at different concentration on NfH levels in 
plasma of SOD1G93A mice. Plasma levels of both NfHSMI34 and NfHSMI35 largely 
increased after 1 hour urea-Barb2EDTA buffer incubation at room temperature, up to 
47% at 0.5 M urea. Error bars: ±SEM. 
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Figure 2.6 
 
 
 
 
Figure 2.6. The effects of incubation period in Barb2EDTA buffer with urea at 
various concentration on NfH levels in plasma of SOD1G93A mice. Levels of 
NfHSMI34 and NfHSMI35 largely attenuated after 24-hour incubation at 4°C up to 75% 
and 60%, respectively. 
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Figure 2.7 
 
 
Figure 2.7. The effects of 1 hour incubation of 0.5 M Urea-Barb2EDTA buffer at 
room temperature on plasma NfH levels in SOD1G93A mice. (A) Using serial 
dilution of samples, more consistent NfH levels were detected at the 2nd (16%) and 
3rd (11%) dilution. (B) In addition, the NfH ‘Hook Effect’ disappeared and parallelism 
was improved using the new urea-timed method (Incubation in 0.5 M Urea-
Barb2EDTA buffer at room temperature for 1 hour). Error bars: ±S.E.M. 
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Table 2.3 The optimised protocol for an ELISA detecting NfH in the plasma. 
Capture antibody Load 100 µl of Capture antibody (Covance SMI-34R or 
SMI-35R in carbonate buffer1; v/w, 2/10000) into a 96-well 
microtitre plate*. 
Incubate the plate at 4°C overnight. 
Block the plate Decant the Capture antibody. 
Rinse the plate twice with 150 µl wash solution3. 
Block the plate with 100 µl blocking solution4 at RT for 1 
hour on the shaker. 
Sample preparation Add 5 µl of original plasma into 35 µl of Barb2EDTA buffer2 
containing 0.5 M urea.  
Well-mixed and incubate at RT for 1 hour----diluted plasma. 
Load the samples Decant the blocking solution. 
Rinse the plate twice with 150ul wash solution. 
Load 95 µl of sample diluent5 into each well of the plate. 
Apply 5 µl of NfH standard (ranging from 0-100 ng/mL), the 
diluted and pre-incubated plasma, and the quality control 
sample in duplicates. 
Incubate at RT for 1 hour on the shaker. 
Detector antibody Decant the samples. 
Wash the plate 3 times with 150 µl wash solution for 5 
minutes on the shaker. 
Load 100 µl of detector antibody (Sigma Rabbit anti-
neurofilament 200 in sample diluent; v/w, 10/10000) into the 
plate. 
Incubate at RT for 1 hour on the shaker. 
Reporter antibody Decant the detector antibody. 
Wash the plate 3 times with 150 µl wash solution for 5 
minutes on the shaker. 
Load 100 µl of reporter antibody (DAKO Swine anti-rabbit 
HRP-linked antibody in sample diluent; v/w, 10/10000) into 
the plate. 
Incubate at RT for 1 hour on the shaker. 
Chemiluminescence 
readout 
Decant the reporter antibody. 
Wash the plate 6 times with wash solution for 5 minutes on 
the shaker. 
Load 100 µl of TMB into the plate.  
Incubate at RT for 20 minutes on the shaker in the dark. 
Stop the reaction with 50 µl of 1M HCL. 
Read the plate at 450 nm, with 750 nm as the reference 
wavelength. 
*All loading volume refers to volume adding into each well of the microtire plate. 
1
Carbonate Buffer (pH 9.6): 13.85g anhydrose sodium carbonate and 26.10g sodium hydrogen 
carbonate in per litre distilled water 
 2
Barb2EDTA buffer (pH 8.6): 13.1g sodium barbitone, 2.1g barbitone, and 0.25g EDTA in per litre  
 distilled water 
 
3
Wash solution: 0.1% bovine serum albumin (BSA) and 0.05% Tween 20 in Barb2EDTA buffer  
 4
Blocking solution: 1% BSA in Barb2EDTA buffer  
 
5
Sample diluent: 0.1% BSA in Barb2EDTA buffer 
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2.3.3 A comparison of plasma NfH levels in end-stage SOD1G93A mice with age-
matched WT littermates, using the modified in-house ELISA 
Using the modified, optimal ELISA described above and detailed in Table 2.3, 
plasma NfH levels in WT and 120-day-old SOD1G93A mice were next compared. 
Plasma NfHSMI34 levels from SOD1G93A mice (n=10) were significantly higher (median:  
304.19.1 ng/mL) than in plasma from age-matched WT littermates (median: 28.33 
ng/mL, n=11, p=0.001, Mann-Whitney U test; Fig. 2.8A). A similar pattern was 
observed for NfHSMI35 and in plasma of SOD1G93A mice (n=10) NfHSMI35 levels were 
significantly higher (median: 77.61 ng/mL) than WT levels (median: 13.53 ng/mL, 
n=10, p=0.019, Mann-Whitney U test; Fig. 2.8B). Examination of WT mouse plasma 
therefore revealed that this optimised ELISA developed in the experiments 
developed in this Chapter was also sensitive enough to detect normal levels of 
plasma NfH in WT mice. 
2.4 Discussion 
In this Chapter, I examined whether an existing ELISA method, developed for 
measurement of NfH phosphoforms in CSF was suitable for use in plasma samples. 
Having confirmed that a clear ‘hook shaped curve’ prevented accurate 
measurement of plasma NfH, using end-stage SOD1G93A mouse plasma, I next 
developed a sensitive in-house ELISA that overcame the NfH ‘Hook Effect.’ Using 
this assay, I then established that levels of plasma NfHSMI34 and NfHSMI35 were 
elevated in plasma of 120-day-old SOD1G93A mice that model ALS compared to age-
matched WT mice and revealed that even WT plasma contains NfH, albeit at low 
levels. 
2.4.1 From CNS to Peripheral circulation  
Although the blood-brain barrier and the blood-spinal cord barrier both have a robust 
effect in limiting CNS-to-blood transfer, molecules expressed in the CNS still may 
enter the blood under both physiological conditions and also during pathological 
disruptions of the CNS. One of the commonest pathological hallmarks in ALS is the 
accumulation of phosphorylated Nf in perikaryon and axonal spheroids (Manetto et 
al., 1988), as the consequence of a failed protein quality control machinery. 
Detection of neuron-specific and glia-specific proteins in CSF has been observed in 
a number of neurodegenerative disorders such as AD, MS and ALS (Brettschneider 
et al., 2006c; de Jong et al., 2007; Salzer et al., 2010). Therefore it is not surprising 
that Nfs can enter the circulation system in a mouse model of ALS. 
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Figure 2.8 
 
 
 
Figure 2.8. NfH levels in plasma of 120 days old SOD1G93A mice compared to 
WT littermates. (A) NfHSMI34 and (B) NfHSMI35 levels were both significantly elevated 
in the plasma of SOD1G93A (filled circles) mice at 120 days, compared to levels in 
WT (open squares) littermates. *: p<0.05, **: p<0.01, ***: p<0.0001, N.S.: p>0.05. 
Mann-Whitney U test. Red dash lines: median values of each group. 
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Previous studies have reported significantly higher CSF levels of phosphorylated 
Nfs in ALS patients compared to both healthy controls and to other 
neurodegenerative disorders such as Alzheimer’s disease (Brettschneider et al., 
2006c; Norgren et al., 2003; Rosengren et al., 1996). It is therefore reasonable to 
hypothesise that similar patterns of Nf levels may be found in the plasma of such 
patients. In view of the far greater accessibility to plasma and the problems 
associated with repeated CSF sampling, particularly in patients with severe 
diseases like ALS, it seems appropriate to develop a sensitive and reliable 
immunoassay for the quantification of plasma Nf levels. Plasma is clearly a readily 
accessible body fluid compartment, from where sampling can easily continue during 
longitudinal follow-up of the disease, causing minimal impact on the quality of like of 
patients.  
2.4.2 A breakthrough for NfH immunoassay  
Here I describe a new method for the accurate quantification of NfH levels which 
overcomes a crucial analytical problem. Researchers have previously experienced 
significant analytical difficulties with reliable and reproducible quantification of NfH 
levels in blood samples of mutant SOD1 mice and patients suffering from ALS. A 
typical example of this problem is illustrated in the results of measurement of NfH 
levels in serial dilutions of blood shown in Figure 2.2. These data are resembled to 
the so called ‘Hook Effect’ when high concentrations of protein (e.g. undiluted 
samples) produce a decline in the dose response curve, resembling the shape of a 
hook, and leads to a lack of parallelism between plasma samples and standards 
(Fig. 2.1 and Fig. 2.2A). This NfH ‘hook shaped curve’ was not previously observed 
when measuring NfH levels in CSF samples (Petzold et al., 2003), but has been 
reported with serial dilutions of homogenate from brain/spinal cord tissue (Petzold, 
unpublished observations). Because of the ‘hook shaped curve’ observed in Fig. 2.2, 
we previously termed the lack of parallelism for NfH from blood samples the NfH 
‘Hook effect’ (Lu et al., 2011). Subsequently, the work presented in this Chapter has 
since been reproduced independently by pioneering and leading experts in the field 
on neurofilament proteins and experimental models for ALS (Swarup et al., 2011). 
Following our protocol, these researchers found a concentration of 0.3 M urea to be 
optimal for their own in-house ELISA for the use of spinal cord homogenate samples, 
which is very close the 0.5 M concentration originally described by us.   
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2.4.2.1 The ‘Hook Effect’ in Oncology and Endocrinology 
The ‘Hook Effect’, otherwise known as the ‘high dose Hook Effect’, was first 
described in the 1970s in a two-site immunoradiometric assay for ferritin (Miles et al., 
1974). This effect resulted in low values from undiluted samples with extremely high 
concentrations of the analytes that saturated both the capture and detector 
antibodies concurrently, which consequently failed to form the so-called sandwich 
complex for the final readout. The phenomenon was later widely observed in clinical 
immunoassays examining hormones and tumour markers, such as prolactin in 
macroprolactinoma (Frieze et al., 2002; St-Jean et al., 1996), prostate specific 
antigen (Charrie et al., 1995; Furuya et al., 2001), alpha-fetoprotein in 
hepatoblastoma (Jassam et al., 2006), and calcitonin in metastatic medullary thyroid 
carcinoma (Leboeuf et al., 2006). This effect can be overcome by serial sample 
dilutions to keep the analytes in each well within the detection threshold of 
immunoassays.  
2.4.2.2 Overcoming the NfH ‘Hook Effect’ 
In the first set of experiments in this Chapter, I examined the suitability of the 
existing method for detection of plasma NfH in SOD1G93A mice that has been used 
for measuring CSF NfH (Petzold et al., 2003). As can be seen in Table 2.2 for NfH, 
the assayed values for serial sample dilution increased as the dilution factor 
increased. However, we found that serial sample dilution itself within detectable 
limits still failed to give constant analytical results for each sample from SOD1G93A 
mice as shown in Fig. 2.2B. Furthermore, for NfH there was no antigen excess as in 
the case of most of the hormone/tumour marker immunoassay. The NfH ‘Hook 
Effect’ was therefore considered to be due to endogenous binding. Further 
immunoblotting confirmed that plasma samples of SOD1G93A mice contain NfH 
aggregates in the higher molecular range (238-460 kDa) (Fig. 2.3A). 
 
The use of urea to manipulate protein folding and unfolding properties (Saha and 
Das, 2007; Zangi et al., 2009), as well as protein dynamics and conformational 
changes such as Nf assembly (Cohlberg et al., 1995; Hisanaga and Hirokawa, 1990; 
Shea, 1994; Tokutake, 1990) is well established. Not surprisingly, in the experiment 
described in this Chapter, pre-incubation with urea solubilised the NfH aggregates at 
a concentration of 4 M (Fig. 2.3A). Since pre-absorption of the primary antibody 
abolished all the bands in the immunoblot, it is likely that bands below 205 kDa on 
the blot (Fig. 2.3) represent fragments of NfH rather than unspecific binding. In 
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addition, previous studies of immunoblotting using SMI-34R and SMI-35R (NfH 
specific antibodies), have shown no cross-reaction with NfM and NfL (Petzold et al., 
2011a), since SMI-34R and SMI-35R are specific for the epitopes in the tail region of 
neurofilament heavy chain. The densities of these lower molecular bands changed 
after timed-urea incubation, also suggesting that smaller fragments of NfH were 
produced during the incubation with urea. Bands at 117 kDa were found coincidently 
at a similar range to bands detected in brain tissue in patients of traumatic brain 
injury; these 117 kDa bands were considered as a cleavage product by 
enterokinase in CNS (Petzold et al., 2011a). Therefore, it is very likely that pre-
cleavage of NfH in the CNS occurred prior to the release of NfH into the peripheral 
blood and was dissembled from the high MW aggregates of NfH after urea 
incubation.    
 
Nonetheless, 4 M urea was not compatible with the NfH ELISA. By titrating the 
molar concentration of urea, we found that aggregates could be sufficiently broken 
up to achieve analytical parallelism at 0.5 M urea. Consistent with the data from 
previous studies (Kushkuley et al., 2010; Yabe et al., 2001a; Yabe et al., 2001b), the 
addition of EDTA and EGTA partly disrupted NfH aggregates following 24-hour 
incubation. Although I did not test longer incubation periods as these make the 
protocol less practical, but I note that Kushkuley et al., 2009 observed a peak effect 
of EGTA incubation after 7 days of incubation (Kushkuley et al., 2009). For routine 
laboratory purposes, shorter (1 hour) incubation periods with 0.5 M urea are 
preferable to longer (7 days) incubation periods with EGTA. 
 
A similar approach to that used in these experiments, using low dose urea pre-
incubation, to overcome NfH ‘Hook Effect’ in ELISA testing the spinal cord 
homogenates has also been tested and developed by another group (Swarup et al., 
2011).  
2.4.3 Plasma NfH levels significantly increase in end-stage SOD1G93A mice that 
model ALS 
Exploiting the ability of urea to release NfH from aggregates, I proceeded to 
investigate the levels of NfHSMI34 and NfHSMI35 in an established mouse model of a 
neurodegenerative disease, the SOD1G93A mouse model of ALS. Plasma was 
collected near to disease end-stage, at 120 days of age, and NfH levels were 
compared to levels in control, age- and sex-matched WT mice. The first conclusion 
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that can be drawn from these experiments is that the assay was sensitive enough 
even to detect very low levels of NfH in WT mice, both hyperphosphorylated and 
variably-phosphorylated NfH (Fig. 2.8). This is an important methodological 
improvement compared to previous studies (Boylan et al., 2009; Petzold et al., 2003) 
where plasma NfH levels in WT mice were undetectable using conventional NfH 
ELISA. The method developed in this Chapter also disrupts NfH aggregates and 
overcomes the problem of endogenous binding, thereby abolishing the ‘Hook Effect’ 
and improving analytical sensitivity, reliability and reproducibility. This finding 
suggests firstly that plasma is a compartmentalised bio-fluid where neurofilaments 
ultimately appear following intracellular clearance from the CNS, not only under 
pathological conditions but also under normal physiological conditions. Secondly, 
the existence of hyperphosphorylated NfH in plasma itself is not a pathological 
indicator since it is present even in WT undiseased mice, although it has long been 
thought to be abundant in pathological conditions (Perrot et al., 2008). In view of this 
finding, it is clear that the detection of NfH in plasma is not disease specific and 
therefore not of diagnostic value for ALS or any other neurodegenerative disease. 
 
In 120-day-old SOD1G93A mice, the median plasma NfHSMI34 (hyperphosphorylated) 
and NfHSMI35 (variably-phosphorylated) forms of NfH levels were 10.7-fold and 5.7-
fold higher in SOD1G93A mice compared to WT controls, respectively. This elevation 
in NfH levels is consistent with the known motor neuron and motor axon 
degeneration which is a feature of the SOD1G93A mouse model of ALS, resulting in 
the release of Nf into the blood. Previous studies have shown that by 120 days of 
age in male SOD1G93A mice, approximately 70% of motor neurons have died 
(Kalmar et al., 2008). In addition, the differential alteration of the two forms of NfH 
observed in this study is consistent with immunohistochemical evidence showing a 
pathological increase in perikaryal accumulation of phosphorylated Nf in ALS 
(Manetto et al., 1988; Wong et al., 2000). The chemical properties of Nf aggregate 
formation and dissociation have been intensively investigated and phosphorylation 
of NfH has been found to be a key feature facilitating Nf formation (Kushkuley et al., 
2009; Kushkuley et al., 2010). This finding is in line with my data showing that the 
increase in hyperphosphorylated NfH (NfHSMI34) from NfH aggregates was much 
more than that of the less phosphorylated NfH (NfHSMI35). 
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2.4.4 Conclusions  
The results presented in this Chapter describe the development of an in-house 
ELISA for the detection of two phosphoforms of NfH in plasma. This method is a 
substantial improvement on existing immunoassays for the detection of NfH 
phosphoforms since it: i) overcomes the ‘Hook Effect’; ii) is highly sensitive; iii) is 
reproducible, and iv) is suitable for detection of NfH in plasma.  
 
 Some of the results described in this Chapter have been published. 
Ching-Hua Lu, Bernadett Kalmar, Andrea Malaspina, Linda Greensmith, 
Axel Petzold. (2011). A method to solubilise protein aggregates for 
immunoassay quantification which overcomes the neurofilament “hook” 
effect. Journal of Neuroscience Methods, 195, 143-150. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
103 | P a g e  
 
Chapter 3 
Plasma neurofilament heavy chain levels correlate with disease progression 
and are biomarkers of treatment response in SOD1G93A mouse model of ALS 
 
3.1 Introduction 
In Chapter 2, I described the development of a quantitative, sensitive immuoassay 
that can reliably detect NfH phosphoforms in plasma from SOD1G93A mice. In this 
Chapter, using this mouse model of ALS as a test-bed, I examined whether plasma 
NfH levels could be used to monitor disease progression and the effects of disease 
modifying treatments in SOD1G93A mice.  
3.1.1 The need for biomarkers in ALS 
Riluzole remains the only FDA-approved treatment for ALS, which prolongs median 
survival by only 2-3 months in patients treated for at least 18 months (Miller et al., 
2007). Importantly, the greatest benefit of Riluzole is observed when treatment is 
initiated early in the course of disease (Zoing et al., 2006). In the absence of reliable 
diagnostic biomarkers, the recognition of ALS relies largely on clinical assessment 
and electrophysiological findings, which provide evidence of upper and lower motor 
neuron involvement (Carvalho and Swash, 2009). The lack of more specific 
investigative tools and of easily measurable biomarkers typically results in a 9-14-
month delay between symptom onset to diagnosis, for both sporadic (sALS) and 
familial ALS (fALS) (Cellura et al., 2012; Iwasaki et al., 2002). This delay not only 
prevents patients from receiving early administration of Riluzole, reducing the 
benefit of the only available therapy, but also impedes their early recruitment to 
clinical trials, thereby reducing the likelihood of success of potential disease-
modifying agents. Therefore, there is a critical need to develop biomarkers for ALS, 
to both speed up diagnosis and to monitor disease progression. This is particularly 
true for clinical trials, where such a biomarker would be invaluable for statistical 
power and as an indicator of both positive and negative responses to treatment.  
3.1.2 Neurofilament Heavy Chain (NfH) as a candidate biomarker for ALS 
Although the precise underlying pathology of ALS is not yet fully understood, a 
number of molecular mechanisms have been identified that play a part in ALS both 
in humans and in mouse models of the disease (see Chapter 1 Section 3). 
Transgenic mice carrying the mutant human superoxide dismutase 1 (SOD1) gene 
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which is responsible for approximately 10-20% of familial ALS cases (Rosen et al., 
1993), have a disease phenotype that resembles that of ALS patients, including 
progressive motor neuron degeneration accompanied by gradual muscle paralysis 
and premature death (Gurney et al., 1994). These mice have been invaluable in 
research efforts to evaluate several pathological changes that contribute to ALS.  
ALS is now known to be a multifactorial disorder, and protein aggregation plays an 
important role in its pathophysiology (Bento-Abreu et al., 2010). Several proteins 
have been shown to aggregate in tissues of ALS patients and animal models of ALS, 
including structural proteins of the axonal cytoskeleton such as neurofilaments 
(Strong et al., 2005). A common pathological finding in both sALS and fALS is the 
accumulation of phosphorylated Nfs in the perikaryon and in axonal spheroids, 
which are normally only present in distal axons and nerve terminals (Manetto et al., 
1988). NfH has been implicated in the pathogenesis of ALS also based on genetic 
investigations. A small number of allelic variants of the NEFH gene have been 
identified in approximately 1% sALS patients (Al-Chalabi et al., 1999; Figlewicz et al., 
1994), Manipulations of the stoichiometry of the three Nf subunits has been shown 
to facilitate the development of early-onset motor neuron death in transgenic mouse 
models of ALS (Cote et al., 1993; Lee et al., 1994; Xu et al., 1993), thus supporting 
the critical involvement of Nfs in ALS pathology.  
 
The measurement of specific components of the affected tissue which are released 
into biological fluids during disease progression can be used to aid diagnosis and 
evaluate/predict disease severity in ALS (Ganesalingam and Bowser, 2010; Otto et 
al., 2012; Sussmuth et al., 2008). It has also been suggested that the 
phosphorylation state of Nfs can be indicative of neuronal pathology and high levels 
of phosphorylated NfH have been detected in neurodegenerative disorders (Perrot 
et al., 2008). Nfs levels in the CSF have been investigated as potential disease 
biomarkers in several neurological disorders (Brettschneider et al., 2006a; 
Brettschneider et al., 2006b; Constantinescu et al., 2009; de Jong et al., 2007; 
Ganesalingam et al., 2011; Norgren et al., 2003; Rosengren et al., 1996; Salzer et 
al., 2010; Zetterberg et al., 2007). However, because of its invasive nature, serial 
CSF sampling is not tolerated by all patients and CSF is clearly not the ideal bio-
fluid for repeated sampling in order to monitor progression and evaluate treatment 
response in frail and advanced ALS patients. Thus, a functionally validated Nf-based 
blood biomarker for the longitudinal monitoring of disease development and 
informative of treatment response would be highly desirable.  
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3.1.3 Current and potential therapeutics tested in SOD1G93A mice 
It would be highly valuable if a biomarker can reflect the beneficial or detrimental 
effect of a testing drug so that it can be used as a surrogate outcome measure in the 
clinical trial. In this Chapter, whether the expression levels of plasma NfH reflect the 
effects of known and novel therapeutics was examined in SOD1G93A mice. 
3.1.3.1 Riluzole 
Riluzole is the only FDA approved drug for ALS and has a modest effect on the 
progression of ALS. However, there is limited information about the effect of this 
drug in animal models of ALS. Its mechanism of action is not fully understood, 
although it is generally believed to inhibit glutamate release and reduce 
excitotoxicity (Nirmalananthan and Greensmith, 2005). A number of studies have 
suggested that Riluzole may also has an effect in up-regulating the HSR in the cells, 
and has been shown to increase the active form of HSF1 under physiological 
conditions in Hela cells (Yang et al., 2008). A more recent study has suggested that 
Riluzole can increase amount of HSF1 by slowing down the turnover rate of HSF1 
and concurrently, via HSF1, may also increase the activity of the Glial Glutamate 
Transporter 1 (GLT1) promoter, which contains multiple Heat Shock Elements 
(HSE), leading to increased expression of GLT1 protein, Hsp70 and Hsp90 (Liu et 
al., 2011). Overall, these experiments have demonstrated a potentially synergistic 
effect of the various routes through which Riluzole can promote neuronal survival 
under stress (Liu et al., 2011). 
3.1.3.2 Arimoclomol 
Arimoclomol is a hydroximic acid derivative which acts as an amplifier of Hsp 
expression by stabilisation of the active phosphorylated trimer of HSF1 and 
prolongation of the binding of HSF1 to HSE, which encodes a number of major Hsps 
in response to cell stresses (Crul et al., 2013). Importantly, compounds in the 
Arimoclomol family act as a ‘smart drugs’ to co-induce the HSR, but only in cells 
already under stress (Hargitai et al., 2003; Kalmar and Greensmith, 2009), which is 
an important characteristic when considering their use as therapeutic agents in 
humans.   
 
In the SOD1G93A mouse model of ALS, daily intraperitoneal administration of 
Arimoclomol prolonged survival by 22% and 18%, when the treatment started from 
pre-symptomatic stage and at disease onset, respectively (Kieran et al., 2004).  
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Arimoclomol-treated SOD1G93A mice treated pre-symptomatically also presented 
with a displayed a delay of disease onset, showed improved hindlimb 
neuromuscular functions and spinal motor neuron survival at end-stage. Whether 
given at symptom onset (75 days of age), when the loss of body weight is the only 
disease manifestations (Kieran et al., 2004) or later, at 90 days of age when SOD1 
mice have lost 40% of their sciatic motor neurons (Hegedus et al., 2007; Sharp et al., 
2005), Arimoclomol-treated SOD1G93A mice had significantly improved hindlimb 
muscle strength and an increased number of motor units and spinal motor neurons 
compared to untreated animals (Kalmar et al., 2008).   
 
It has become clear that non-neuronal cells that interact with motor neurons, 
particularly glial cells within the CNS, play a critical role in disease progression in 
ALS (Appel et al., 2011; Clement et al., 2003; Phatnani et al., 2013).  Astrocytes are 
known to have a robust HSR and up-regulate Hsps in response to stress (Batulan et 
al., 2003; Choi et al., 2011; Imuta et al., 1998). This effect can be further augmented 
by Arimoclomol following peripheral nerve injury (Kalmar et al., 2002). It is therefore 
possible that the increased expression of Hsps within astrocytes observed following 
treatment with Arimoclomol, results in an improved function of the astrocytes 
themselves, which in turn acts to support and protect vulnerable motor neurons.  
 
In addition to their interaction with non-neuronal cells within the CNS, motor neurons 
also interact with their target muscle fibres in the periphery. The very first physical 
manifestation of disease in ALS occurs at the neuromuscular junction (NMJ), much 
earlier than the degeneration of motor neuron in both ALS mouse models and in 
ALS patients (Fischer et al., 2004; Frey et al., 2000; Kalmar et al., 2012b). It has 
been shown that the first signs of the disease-modifying effects of Arimoclomol in 
SOD1G93A mice manifest in the muscle, at an early pre-symptomatic stage, rather 
than the spinal cord, where Arimoclomol-induced up-regulation of Hsps only occurs 
later in the disease (Kalmar et al., 2012b). Treatment with Arimoclomol improves 
muscle innervation as well as markers of neuromuscular transmission in SOD1G93A 
mice, prior to any central effect on the HSR within the spinal cord, indicating an early 
peripheral effect of this Hsp-based therapy in ALS (Kalmar et al., 2012b). Similar 
beneficial effects of systemic treatment with a single Hsp have also been reported in 
SOD1G93A mice, following intraperitoneal injection with recombinant Hsp70 protein 
(Gifondorwa et al., 2012).  
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The broad-based effect of Arimoclomol may be an effective approach in the 
development of a disease-modifying therapy for ALS. Arimoclomol has also been 
tested in humans. Seven Phase I studies in healthy volunteers have established that 
Arimoclomol has no significant effect of food or fasting on the pharmacokinetics or 
tolerability (Lanka et al., 2009). The Phase IIa clinical trial showed oral 
administration of Arimoclomol is safe and well-tolerated up to 300mg/day, with a 
good level of CSF penetration (Cudkowicz et al., 2008). A Phase II/III trial is 
currently undergoing in patients with SOD1-related fALS (NCT00706147). 
3.1.3.3 Cogane 
Cogane (Phytopharm plc) is an orally bioavailable neurotrophic factor inducer that 
readily crosses the blood brain barrier. Cogane has been shown to be 
neuroprotective in a model of Parkinson’s disease, where it induces the expression 
of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic 
factor (GDNF) (Visanji et al., 2008). In ALS, treatment with Cogane from the onset of 
symptoms around 70 days of age has shown beneficial effects in improving hindlimb 
muscle functions and motor neuron survival in SOD1G93A mice (Kalmar et al., 2012a). 
3.1.4 Hypotheses and Aims 
In this Chapter, I tested the hypothesis that plasma NfH levels may be a biomarker 
of disease progression in ALS and may be used to monitor the effects of disease 
modifying agents in SOD1G93A mice. For this purpose, I undertook a series of 
experiments with the following Aims: 
i) To establish whether plasma NfH levels increase with disease progression in the 
SOD1G93A mouse model of ALS; 
 
ii) To investigate whether increased plasma NfH levels correlate with physiological 
and morphological changes linked to disease progression in SOD1G93A mice; 
 
iii) To test whether the NfH ELISA developed in the experiment phase of this project 
and presented in Chapter 2, was sensitive enough to detect the effects of an 
established and potential disease-modifying therapies in SOD1G93A mice;  
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iv) To assess whether the method was suitable for use in monitoring disease 
progression in less aggressive form of ALS, using an alternative mouse model of 
ALS.  
3.2 Methods and Materials 
3.2.1 Experimental animals 
All animals were bred and maintained by Biological Services in the UCL Institute of 
Neurology. The experiments described in this study were carried out under licence 
from the UK Home Office and following approval from the UCL Institute of 
Neurology’s Ethical Review Panel. In these experiments, I examined plasma NfH 
levels in the most widely used SOD1 mouse model of ALS, the high copy SOD1G93A 
strain. In addition, in some experiments, plasma NfH levels were also examined in a 
more slowly progressing SOD1 model, the SOD1G93Adl strain. 
3.2.1.1 Breeding of SOD1G93A mice 
Transgenic mice expressing human SOD1G93A mutant protein (TgN[SOD1-
G93A]1Gur; Jackson Laboratories, Bar Harbour) were maintained by breeding male 
heterozygous carriers with female (C57BL/6 x SJL) F1 hybrids. The presence of the 
SOD1G93A mutation was confirmed by PCR reaction from ear biopsies in all mice, at 
the age of 3 weeks (see Chapter 2, Section 2.1.1).  
 
The high copy strain SOD1G93A mice have approximately 25 copies of the mutant 
transgene. Most of the experiments discussed in this Chapter were undertaken 
using this strain of SOD1 mice. However, this strain has a very aggressive disease 
and progresses very rapidly after symptom onset. Therefore, in addition to 
measuring plasma NfH levels in the high copy strain of SOD1 mice, in one set of 
experiments I also examined plasma NfH in SOD1G93Adl B6 (SOD1G93Adl) mice 
3.2.1.2 SOD1G93Adl mice 
The SOD1G93Adl mice have a number of transgene copies of 8-10 and display a 
slower course of disease than the high copy strain, so that end-stage is reached by 
37.8 weeks. These mice have been comprehensively characterised (Acevedo-
Arozena et al., 2011). In this study, plasma NfH levels in SOD1G93Adl mice were 
examined before they met their study end-point, at 38 weeks of age. 
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3.2.2 Drug treatment 
In this Chapter, I examined the possibility that changes in plasma NfH levels are 
significant enough to reflect the effects of agents that modify disease progression in 
SOD1G93A mice. In the first test, I examined NfH levels in SOD1G93A mice that were 
treated with Arimoclomol, a pharmaceutical compound with proven efficacy in 
SOD1G93A mice (Kalmar et al., 2008; Kieran et al., 2004). In a separate preclinical 
trial of a novel compound with unknown efficacy in SOD1 mice, I examined the utility 
of plasma NfH levels as a biomarker of drug efficacy to establish whether changes 
in plasma NfH levels could reflect the positive or negative effects of a new test 
compound. In this trial a novel compound called Cogane was under treatment and 
as part of this preclinical trial some mice were also treated with Riluzole, the 
standard ALS treatment, either alone or in combination with Cogane. Therefore, in 
different experiments in this Chapter, mice were treated with the following 
compounds:  
i) Arimoclomol (a kind gift of Biorex R&D Co., Hungary) was dissolved in sterile 
saline (2mg/mL) and the solution stored at 4°C for a maximum of 1 week; mice 
were treated with a dose of 10mg/Kg/day via intra-peritoneal (i.p.)  injection; 
ii) Cogane (Provided from Phytopharm plc) was dissolved into food pellets for mice, 
achieving an oral dose of 30mg/Kg/day; 
iii) Riluzole hydrochloride (from TOCRIS) was dissolved into drinking water, 
achieving an oral dose of 30mg/Kg/day;  
iv) Vehicle: a) sterile saline, i.p. for Arimoclomol trial;  
 b) normal chow or drinking water for Cogane trial. 
3.2.3 Arimoclomol trial 
In the first treatment trial the effect of Arimoclomol on NfH levels in SOD1G93A mice 
was examined. In order to obtain the maximum blood sample volume from mice 
aged between 65-120 days whilst still complying with  the UK Home Office 
Regulations (less than 15% of the blood volume should be removed in any 30-day 
period, i.e. 10.5 ml/kg) (Wolfensohn, 2003), only male mice were examined in this 
part of study. 
3.2.3.1 Experimental groups in Arimoclomol trial 
Depending on genotype, the mice were randomly assigned to one of 3 treatment 
groups:  
110 | P a g e  
 
i) Transgenic mice carrying human SOD1G93A mutant gene treated daily with 
Arimoclomol (10mg/Kg; i.p.) from 35 days of age (SOD1+A mice); 
ii) Transgenic mice carrying human SOD1G93A mutant gene treated daily with vehicle 
(i.p.) from 35 days of age (SOD1 mice);  
iii) Untreated, age-matched WT littermates (WT mice). 
3.2.3.2 Longitudinal plasma sampling in Arimoclomol treated SOD1G93A mice 
The effect of Arimoclomol on plasma NfH levels was longitudinally examined in,   
i) Arimoclomol treated SOD1G93A mice (SOD1+A; n=19); 
ii) Vehicle treated SOD1G93A mice (SOD1; n=19); 
iii) Untreated wild-type (WT; n=13). 
The mice were repeatedly examined at various stages of disease progression 
ranging from pre-symptomatic to end-stage disease, i.e. 65 days; 90 days; 105 days; 
120 days.  
3.2.4 Cogane Trial 
Cogane (5β,20α,25R-spirostan-3β-ol) is a novel small molecule, orally bioavailable 
neurotrophic factor inducer, which has shown beneficial effects in a mouse model of 
Parkinson’s disease (Visanji et al., 2008) and ALS (Kalmar et al., 2012a). In this 
study, the effect of a novel agent, Cogane, on plasma NfH levels was examined in 
test experiments, using Riluzole as the standard treatment arm. 
3.2.4.1 Experimental groups in Cogane trial 
All treatment was given to female SOD1G93A mice from 70 days of age, at the time 
of symptom onset.  
 
i) Group COG: Mice treated with Cogane, 30mg/kg/day (in food);  
ii) Group COG+RIL: Mice treated with Cogane, 30mg/kg/day (in food) in addition to 
Riluzole, 30mg/kg/day (in drinking water); 
iii) Group RIL: Mice treated with Riluzole, 30 mg/kg/day (in drinking water);  
iv) Group VEH: Vehicle treatment of normal chow for Cogane or normal drinking 
water for Riluzole.    
3.2.4.2 Longitudinal plasma sampling in Cogane trial 
The effect of Cogane on plasma NfH levels was longitudinally examined in,   
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i) Cogane treated SOD1G93A mice (COG; n=16);  
ii) Cogane plus Riluzole treated SOD1G93A mice (COG+RIL; n=17);  
iii) Riluzole treated SOD1G93A mice (RIL; n=15);  
iv) Vehicle treated SOD1G93A mice (VEH; n=12). 
 
The mice were repeatedly examined at two stages of disease progression after 
symptom onset, i.e. 105 days; 120 days.  
3.2.5 Plasma Collection 
Blood sampling was carried out in mice from each experimental group at various 
stages of disease, ranging from pre-symptomatic, early-symptomatic, late-
symptomatic and end stage disease. At each sampling time point before mice 
reached their end stage, the mice were placed in a recovery chamber (Peco Service; 
V1200), set at 38.5°C, for 15 minutes and then transferred into a plastic tube with 
the tail exposed. Blood was collected from the tail veins into an EDTA-coated tube 
(BD Microtainer®, K2E). In mice at end stage (87.5% at 120 days [range between 
111-121 days] for SOD1G93A mice and 36±2 weeks for SOD1G93Adl mice), blood was 
collected by a cardiac puncture, under terminal anaesthesia using pentobarbital. 
Each tube was then centrifuged at 14,000 rpm for 8 min. The plasma was collected 
and protease inhibitor added (Sigma; v/v: 1/100). Each sample was then aliquoted 
and stored at -80°C until further analysis.  
3.2.5.1 Plasma collection in Arimoclomol Trial 
All experimental animals received blood sampling at age 65, 90, 105 and 120 days. 
3.2.5.2 Plasma collection in Cogane Trial 
All experimental animals received blood sampling at age 105 and 120 days. 
3.2.5.3 Plasma collection in SOD1G93Adl  
Blood samples were taken every month between 22 weeks of age and their end-
stage (36±2 weeks) where possible. Although samples were collected from 15 mice, 
not all of them were available for serial samplings of plasma at all stages of disease 
progression. Although it would have been very desirable to also have samples from 
the WT littermates of these SOD1G93Adl mice, they were not available at the time of 
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collection as that original study was not set-up for biomarker study and I only started 
to collect samples from quite late stage of that original study.   
3.2.6 Functional assessments of neuromuscular functions 
In this Chapter, levels of plasma NfH levels were correlated with established 
markers of disease progression in SOD1G93A mice, using behavioural, physiological 
and morphological readouts of disease progression.  
3.2.6.1 Longitudinal assessment of Grip Strength 
In the same mice selected for plasma collection, grip strength was determined 
longitudinally at the same ages, immediately prior to blood collection, according to 
the manufacturer’s instruction (Bioseb, BIO-GS3). Mice were placed on a horizontal 
grid and pulled by the tail against the direction of the force gauge until the animal 
released the grid. An average of four readings for each mouse was obtained at each 
occasion. 
3.2.6.2 Acute in vivo physiological assessment of muscle force   
In a separate set of mice, physiological analysis of hindlimb muscle function was 
undertaken at 105 days of age, corresponding to a late symptomatic stage of 
disease. WT (muscle n=10), SOD1 (muscle n=12) and SOD1+A (muscle n=16) mice 
were deeply anesthetised (4.5% chloral hydrate; 1 ml/100g of body weight, i.p.) and 
prepared for in vivo analysis of isometric muscle force (as described in Kalmar et al., 
2008).  The distal tendons of the Tibialis Anterior (TA) and Extensor Digitorum 
Longus (EDL) muscles in both hindlimbs were dissected free and attached by silk 
thread to isometric force transducers (Dynamometer UFI Devices, Welwyn Garden 
City, UK). The sciatic nerve was exposed and sectioned. The length of the muscles 
was adjusted for maximum twitch tension. The muscles and nerve were kept moist 
with saline throughout the recordings and all experiments were carried out at room 
temperature. Isometric contractions were elicited by stimulating the nerve to TA and 
EDL using square-wave pulses of 0.02 ms duration at supra-maximal intensity, via 
silver wire electrodes. Contractions were elicited by trains of stimuli at frequencies of 
40, 80 and 100 Hz. The maximum twitch and tetanic tension was measured using a 
computer and appropriate software (PicoScope).  
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3.2.6.3 Acute in vivo physiological assessment of motor unit survival   
The number of motor units innervating the EDL muscles was also determined by 
stimulating the motor nerve with stimuli of increasing intensity, resulting in stepwise 
increments in twitch tension due to successive recruitment of motor axons with 
increasing stimulus thresholds. The number of stepwise increments was counted to 
give an estimate of the number of functional motor units (MUNE) present in each 
muscle. 
3.2.7 Morphological assessment of motor neuron survival 
Following physiological assessment of muscle function, the mice (n=5 per group) 
were terminally anaesthetised and perfused transcardially with saline followed by 
fixative containing 4% paraformaldehyde (PFA). The spinal cords were then 
removed and post-fixed in 4% PFA and cryopreserved in 30% sucrose overnight at 
4°C.  Transverse sections (20 µm) of the fixed lumbar spinal cords (L3-L6) were cut 
on a freezing cryostat and collected serially onto glass slides and subsequently 
stained for Nissl (gallocyanin). Large polygonal neurons, with a minimum diameter 
of 20 µm, within the sciatic motor pool, which had a clear nucleolus and a distinct 
Nissl-dense cytoplasm were counted in every 3rd section, in order to prevent 
counting the same neuron twice in consecutive sections (McHanwell and Biscoe, 
1981). 
3.2.8 NfH ELISA 
For a full description of the 4-layer sandwich ELISA and the reagents used in these 
experiments see the detailed method outlined in Table 2.3, Chapter2.  
3.2.9 ELISA Data analysis 
Hyperphosphorylated NfH was detected with the SMI-34R capture antibody labelled 
as NfHSMI34 (averaged intra-assay coefficient of variation (CV): 3.53%, averaged 
inter-assay CV: 3.01% at 12.5 ng/mL), while variably phosphorylated NfH was 
detected with the SMI-35R capture antibody, labelled as NfHSMI35 (averaged intra-
assay CV: 3.03%, averaged inter-assay CV: 5.87% at 12.5 ng/mL). The sensitivity 
(blank + 3SD) of the assay calculates to 0.74 ng/mL, with a detection limit of 1.56 
ng/mL. Measurements with a CV value higher than 10% (Petzold et al., 2003) were 
repeated. Quality control samples were used throughout and absorbance readouts 
from different microtitre plates were adjusted to the quality control readout to allow 
comparison of results across different plates. 
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3.2.10 Statistical analysis 
3.2.10.1 Longitudinal Biomarker and Arimoclomol treatment study 
The results from the study in which NfH phosphoforms levels were determined at 
different ages in SOD1G93A mice in vehicle-treated and arimoclomol-treated mice 
were statistically analysed using SPSS software (V17). The normality of data was 
checked, using a Kolmogorov-Smirnov test, to determine the approach of parametric 
or nonparametric analysis. The repeated Friedman test was used for analysis of NfH 
levels within groups in the longitudinal biomarker study. The Mann-Whitney test or t-
test, according to the normality of data, was used for analysis of NfH levels between 
groups at each time point (WT vs. SOD1; SOD1 vs. SOD1+A), and for analysis of 
the levels of the two NfH phosphoforms in each group, at different time points 
(NfHSMI34 vs. NfHSMI35). Bivariate correlation analysis, using Spearman’s correlation 
coefficient, was examined for plasma NfH levels and grip strength. A minor, 
moderate and strong correlation is considered if Spearman’s rho (R) is <0.3, 0.3-0.5, 
>0.5, respectively. Statistical significance was set at p<0.05. Exponential analysis 
was used to determine the correlation of plasma NfH levels and functional readouts 
in SOD1 mice at various disease stages. A strong correlation was considered when 
the coefficient of determination (R2) obtained from the exponential analysis was 
greater than 0.8. 
3.2.10.2 SOD1G93Adl study and SOD1G93A Cogane drug trial 
For a comparison of the data obtained in the Cogane drug trial and that obtained in 
the study examining NfH phosphoforms levels in an alternative mouse model of ALS, 
the SOD1G93Adl mice, the data were statistically analysed using the Mann-Whitney U 
test for group comparison using SPSS (v20). A p value <0.05 is considered as 
significant. 
3.3 Results 
In this Chapter, the Results of 4 studies are presented:  
 
i) A longitudinal assessment of plasma NfH levels during disease progression in 
SOD1G93A mice to establish whether plasma NfH levels correlate with markers of 
decline in neuromuscular function;  
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ii) An examination of whether the beneficial effect of an established disease-
modifying therapy, Arimoclomol, is reflected in changes in plasma NfH levels in 
SOD1G93A mice;  
 
iii) An investigation of plasma NfH levels in a trial of a new therapeutic agent in 
SOD1G93A mice to establish whether plasma NfH levels predict efficacy of new 
agents;  
 
iv) Examination of plasma NfH levels in an alternative mouse model of ALS to 
determine whether the ELISA assay developed in Chapter 2 was of use in models 
other than SOD1G93A in which it was developed.  
3.3.1 Plasma NfH levels in SOD1G93A mice increase significantly from a late 
symptomatic stage 
In the first set of experiments, I examined longitudinal changes in plasma NfH levels 
at various stages of disease progression in SOD1G93A mice, using the ELISA 
developed in Chapter 2. 
 
Hyperphosphorylated (NfHSMI34) and variably-phosphorylated (NfHSMI35) NfH levels in 
plasma from mice in each experimental group were determined at various stages of 
disease. Figure 3.1A shows the level of plasma NfHSMI34 in individual WT (black 
squares) and SOD1 (green circles) mice at 65, 90, 105, and 120 days of age, and 
Fig. 3.1B shows the mean plasma NfHSMI34 levels in WT and SOD1 mice at each 
age. As can be seen in Fig. 3.1, hyperphosphorylated NfHSMI34  was detected in 
plasma of WT mice, but the levels remained unchanged during the duration of the 
study, up to 120 days of age (Friedman test, p=0.518). In contrast, in SOD1 mice, 
there was a significant increase in NfHSMI34 levels during disease progression 
(Friedman test, p<0.0001). Plasma NfHSMI34 levels were higher in SOD1 mice than in 
WT littermates at all ages examined, although this difference only reached statistical 
significance from 105 days of age onwards (65 days: SOD1 46.2±13.1 ng/mL, WT 
40.6±8.9 ng/mL; 90 days: SOD1 81.8±15.8 ng/mL, WT 52.7±12.2 ng/mL; 105 days: 
SOD1 155.4±19.3 ng/mL, WT 26.7±6.8 ng/mL, p<0.0001; 120 days: SOD1 
328.4±40.3 ng/mL, WT 43.5±17.3 ng/mL, p<0.0001; mean±S.E.M ng/mL; Mann-
Whitney test; Fig. 3.1). 
 
Levels of the variably-phosphorylated NfHSMI35 were also examined. Figure 3.2A 
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Figure 3.1 
 
 
Figure 3.1. Longitudinal assessment of plasma NfHSMI34 levels in WT and SOD1 
mice. The graphs show the plasma level (ng/mL) of NfHSMI34 in (A) individual mice 
and in (B) the mean values in SOD1 (green circles; n=19) and WT (black squares; 
n=13) mice at 65 (pre-symptomatic), 90 (early symptomatic), 105 (late symptomatic), 
and 120 (end stage) days of age. Red lines depict the median values of plasma 
NfHSMI34 levels in each group. Error bars: ±S.E.M. Friedman test was used for 
analysis of the pattern of plasma NfH levels during disease progression, and Mann-
Whitney U test was then used for group comparison at each time point. *** p < 
0.0001. 
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Figure 3.2 
 
 
 
Figure 3.2. Longitudinal assessment of plasma NfHSMI35 levels in WT and SOD1 
mice. The graphs show plasma levels (ng/mL) of NfHSMI35 in (A) individual mice and 
(B) the mean values in SOD1 (green circles; n=19) and WT (black squares; n=13) 
mice at 65 (pre-symptomatic), 90 (early symptomatic), 105 (late symptomatic), and 
120 (end stage) days of age. Red lines depict the median values of plasma NfHSMI35 
levels in each group. Error bars: ±S.E.M. Friedman test was used for analysis of the 
pattern of plasma NfH levels during disease progression, and Mann-Whitney U test 
was then used for group comparison at each time point. ** p =0.002, *** p < 0.0001. 
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shows the plasma NfHSMI35 levels in individual WT (black square) and SOD1 (green 
circles) mice at 65, 90, 105, and 120 days of age, and Fig. 3.2B shows the mean 
plasma NfHSMI35 levels in WT and SOD1 mice at each age. Plasma NfHSMI35 (Fig. 
3.2), considered to be the less pathological form of NfH, was detected in plasma of 
WT mice, but levels remained stable throughout the study period (Friedman test, 
p=0.405). In contrast, in SOD1 mice, plasma NfHSMI35 levels increased significantly 
throughout disease progression (Friedman test, p<0.0001), although not as 
dramatically as NfHSMI34, the more pathological phosphoform. Levels of NfHSMI35 in  
SOD1 mice became significantly higher than WT from 105 days of age onwards (65 
days: SOD1 74.0±20.8 ng/mL, WT 58.0±16.0 ng/mL; 90 days: SOD1 68.8±14.8 
ng/mL, WT 46.2±14.2 ng/mL; 105 days, SOD1 104.8±17.0 ng/mL, WT 34.7±11.6 
ng/mL, p=0.002; 120 days, SOD1 161.0±21.5 ng/mL, WT 21.6±9.9 ng/mL, p<0.0001; 
mean±S.E.M; Mann-Whitney U test; Fig 3.2). 
 
In addition, in WT mice, a comparison of NfHSMI35 and NfHSMI34 levels showed that 
plasma levels of NfH were not only low, but that there was also no difference in the 
relative levels of the two NfH phosphoforms at any age examined (Mann-Whitney 
test, p=0.479, 0.353, 0.817, 0.565 at 65, 90, 105, and 120 days, respectively; data 
not shown). In contrast, in SOD1 mice, a comparison of the relative levels of the two 
NfH phosphoforms revealed that levels of NfHSMI34 compared to NfHSMI35 increased 
as disease advanced (comparison NfHSMI34: NfHSMI35 at 65days: p=0.507; 90days: 
p=0.546; 105 days: p=0.068; 120days: p=0.004; Mann-Whitney U Test). Thus, in 
SOD1 mice plasma levels of the more pathological NfHSMI34 phosphoform increased 
to a greater extent than the less pathological NfHSMI35 phosphoform. 
3.3.2 Correlations between plasma NfH levels and functional measures of 
disease progression in SOD1G93A mice 
In the next set of experiments, I examined whether the increase in plasma NfH 
phosphoforms correlated with disease progression. A number of markers of disease 
progression were examined: both functional and morphological parameters as well 
as longitudinal and acute parameters. Thus longitudinal assessment of body weight 
and grip strength was under taken, as well as functional analysis of in vivo muscle 
force and motor unit survival, and morphological assessment of motor neuron 
survival. For each of these outcome measures, a correlation analysis with NfH levels 
at each age was carried out. 
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3.3.2.1 Increased plasma NfH levels inversely correlate with grip strength in 
SOD1G93A mice  
Body weight (BW) and grip strength (GS) were measured twice a week in both WT 
and SOD1 mice from 65 days of age until 120 days of age. These mice were the 
same experimental animals in which blood was samples for assessment of plasma 
NfH levels. The longitudinal change in mean GS of WT (black squares) and SOD1 
(green circles) mice during disease progression is shown in Fig. 3.3A. It can be seen 
that SOD1 mice have lower GS than WT mice even at the start of the study, at 65 
days. The Figure also illustrates the gradual decline in GS in SOD1 mice, which 
becomes apparent from approximate 93 days and becomes significant from the 
baseline strength from 105 days onwards. The longitudinal pattern of BW in WT and 
SOD1 mice is summarised in Fig. 3.3B, which shows the graduate decrease in BW 
in SOD1 mice. It can be seen that a reduction in BW in SOD1 mice only manifests 
relatively late in the disease, after their BW reaches maximum at around 90 days. In 
Fig 3.3C, the ratio of GS/BW is shown in order to account for the effect of changes 
in BW on GS. It can be seen that even when the decrease in BW is accounted for, 
there is a clear decrease in grip strength in SOD1 mice from approximately 93 days 
onward, in contrast to WT mice, where the ratio of GS/BW remains constant 
throughout the study.   
 
In order to establish the relationship between the changes in plasma NfH levels 
detected in SOD1 mice and the decline in neuromuscular function that occurs as 
disease progresses in these mice a correlation analysis between plasma NfH levels 
and the corresponding mean grip strength was undertaken and the results are 
summarised in Fig. 3.4. No such correlation in plasma NfH levels and grip strength 
was observed in WT mice at any age examined (Fig. 3.4A & 3.4B, left panel). The 
results show that in SOD1 mice, there was a moderate- to-strong inverse correlation 
between plasma NfH levels and grip strength at all the time points examined, 65, 90, 
105 and 120 days (Spearman’s rho (R) : NfHSMI34 vs. GS: -0.583, p<0.0001; NfHSMI35 
vs. GS: -0.335, p<0.0001; Fig. 3.4A & 3.4B, right panel).  
3.3.2.2 Increased plasma NfH levels correlate with the decline in isometric 
muscle force in hindlimb muscles of SOD1G93A mice  
In order to obtain a more detailed assessment of the relationship between plasma 
NfH levels and quantitative functional markers of disease progression, an in vivo 
physiological assessment of isometric muscle force in the hindlimb muscles of  
120 | P a g e  
 
Figure 3.3 
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Figure 3.3. Longitudinal assessment of grip strength and body weight in WT 
and SOD1 mice during disease progression. (A) Mean grip strength (GS) was 
determined weekly in mice of each group from 65-120 days of age. SOD1 mice 
appeared to be significantly weaker than their WT littermates from the beginning of 
the assessment period, at 65 days of age (p<0.05, one-way within subject ANOVA, 
with Bonferroni correction). In SOD1 mice, GS began to decrease significantly from 
105 days (p<0.05, t-test with the baseline). (B) Body weight (BW) was determined 
weekly from 65-120 days in mice of each group. WT mice weighed more than SOD1 
mice at the start of the study and continued to increase weight throughout the study 
(p<0.05, one-way within subject ANOVA, with Bonferroni correction). In SOD1 mice, 
BW began to decline steadily from a maximum at 90 days. (C) Mean grip strength 
was expressed relative to body weight (GS/BW) for WT and SOD1 mice during 
disease progression. In WT mice, GS/BW remained constant throughout the study. 
In contrast, in SOD1 mice, there was a steady decrease in the GS/BW ratio as 
disease progressed. Error bars: ±S.E.M. Black diamonds, WT mice; green circles, 
SOD1 mice. 
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Figure 3.4 
 
 
 
Figure 3.4. The correlation between grip strength and plasma NfH levels in WT 
and SOD1 mice between 65 and 120 days of age. The graphs show the 
relationship between mean grip strength (g) and plasma NfH phosphoform levels 
(ng/mL) in individual WT and SOD1 mice (n=16) at 65, 90, 105, and 120 days of age. 
(A) There is no correlation in WT mice (black squares), while a strong inverse 
correlation between plasma NfHSMI34 levels and grip strength is observed in SOD1 
mice (dark green circles; Spearman’s rho=-0.583, p<0.0001). The best-fit line 
(dashed line) is shown. (B) There is no correlation in WT mice (grey squares), whilst 
a moderate inverse correlation between plasma NfHSMI35 and grip strength is 
observed in SOD1 mice (light green circles; Spearman’s rho=-0.335, p<0.0001). The 
best-fit line (dashed line) is shown. 
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SOD1G93A mice were undertaken. This physiological assessment of isometric muscle 
force of specific muscles provides a more sensitive and quantitative assessment of 
functional decline than grip strength analysis, which can only detect general motor 
deficits in SOD1G93A mice relatively late in the disease process, when many motor 
neurons have already died. We have previously generated similar physiological data 
in our lab in SOD1G93A mice at various stages of disease ranging from early 
symptomatic (90 days) to end-stage disease (130 days) (Kalmar et al., 2008; Kieran 
et al., 2004; Sharp et al., 2005). Using these measures of the decrease in muscle 
force I examined whether plasma NfH levels correlated with this profile of functional 
decline in SOD1G93A mice. 
 
Typical examples of tetanic and twitch force traces from the TA muscles of 105-day-
old WT and SOD1 mice are shown in Fig. 3.5A. The mean maximum twitch and 
tetanic force of the Tibialis Anterior (TA) and Extensor Digitorum Longus (EDL) 
muscles of WT and SOD1 at various stages of disease is summarised in Fig. 3.5B  
(Twitch) and Fig. 3.5C (Tetanus). These results show the well-established, 
progressive decrease in muscle force in both TA and EDL muscles that occurs in 
SOD1 mice as they age (Sharp et al., 2005). The results also show that in SOD1 
mice, TA muscles were affected earlier in disease and to a greater extent than EDL 
muscles.  Thus, the maximum tetanic force (Fig. 3.5C; mean±S.E.M.) in SOD1 TA 
(dark green bars) was 56.7±5 g (n=13) at 90 days, 21.1±3 g (n=16) at 105 days and 
19.5± 3.5 g (n=12) at 120 days. When expressed as a percentage of WT TA (black 
bars) muscle force in age-matched WT mice, the force produced by SOD1 TA was 
41.7% at 90 days, 15.3% at 105 days and 12% at 120 days (p<0.0001 at each time 
point; Mann-Whitney U test). The decline in force in SOD1 EDL (light green bars) 
muscles occurred at a steadier, slower pace. Thus, in SOD1 EDL muscles the force 
produced was 24.7±1.5 g (n=15) at 90 days, 15.7±1.6 g (n=19) at 105 days and 
13.7±1.0 g (n=11) at 120 days, which was 68.6%, 43.9% and 33.3% of the force 
produced in WT EDL (grey bars) muscles at the respective ages (p< 0.01; <0.0001; 
<0.0001, respectively; Mann-Whitney U test). A similar pattern of decline was also 
found in the twitch tension of TA and EDL muscles of SOD1 mice (Fig. 3.5B).  
 
As shown in Fig. 3.5D, an exponential regression analysis of the decline in 
maximum TA muscle force at 90, 105 and 120 days of age (indicated by the 
respective arrows) and their corresponding plasma NfHSMI34 (dark green squares) or 
NfHSMI35 (light green triangles) levels in SOD1 mice was undertaken. It can be seen  
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Figure 3.5 
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Figure 3.5. The correlation between plasma NfH phosphoform levels and 
hindlimb muscle force in SOD1 mice during disease progression. (A) Examples 
of recordings of maximum tetanic (arrow) and twitch (arrow head) tension in TA 
muscles of WT and vehicle treated SOD1 mice at 105 days of age. (B) The bar 
chart shows the mean maximum twitch tension (g) of TA (WT: black bars; SOD1: 
dark green bars) and EDL (WT: grey bars; SOD1: light green bars) muscles. (C) The 
bar chart shows the mean maximum tetanic tension (g) of TA (WT: black bars; 
SOD1: dark green bars) and EDL (WT: grey bars; SOD1: light green bars) muscles. 
(D)The graph shows the percentage loss of TA maximum tetanic tension, relative to 
WT, and the corresponding plasma NfHSMI34 (dark green squares) and NfHSMI35 (light 
green triangles) levels in vehicle treated SOD1 mice at each stage of disease 
(indicated by arrows). Exponential regression lines are shown for NfHSMI34 (dark 
green line) and NfHSMI35 (light green line). Error bars: ±S.E.M. Mann-Whitney U test: 
** p < 0.01; *** p < 0.0001. 
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that there is a moderate-strong correlation between muscle force and plasma NfH 
levels in SOD1 mice (R2=0.79 and 0.82 for NfHSMI34 and NfHSMI35 respectively).  
3.3.2.3 Increased plasma NfH levels correlate with motor unit loss in SOD1G93A 
mice  
Next, the number of functional motor units innervating the EDL muscle of WT and 
SOD1 mice was determined. Examples of typical motor unit traces from the EDL 
muscle of 105-day-old SOD1 and WT mice are shown in Fig. 3.6A. The number of 
functional motor units that survived in EDL muscles was also determined in SOD1 
mice at 90, 105 and 120 days of age and the results are summarised in Fig. 3.6B. In 
WT mice, the number of motor units innervating EDL muscles remained constant 
over the course of the study, and the number of motor units innervating EDL 
(mean±S.E.M.) was found to be 26.6±0.4 (n=14) at 90 days, 30.8±0.4 (n=10) at 105 
days and 25.7±0.5 (n=6) at 120 days. In contrast, in SOD1 mice, a significant 
number of motor units had already died by 90 days, with 22.7±1.2 (n=17) motor 
units innervating EDL, a 15% decline compared to WT (p<0.05). Between 90-105 
days, there was a 60% decrease in the number of motor units innervating EDL units 
innervating EDL, a 15% decline compared to WT (p<0.05). Between 90-105 days, 
there was a 60% decrease in the number of motor units innervating EDL muscles of 
SOD1 mice and by 105 days only 12.6±0.5 (n=15) motor units innervated EDL  
(p<0.01). This decline in motor unit survival in SOD1 mice plateaued at this level, so 
that by 120 days, 10.7±1.0 (n=11; p<0.01) motor units innervated EDL. 
 
Fig. 3.6C shows the results of an exponential regression analysis of the decline in 
motor unit survival in EDL muscles at 90, 105 and 120 days (indicated by the 
respective arrows) and the corresponding plasma NfHSMI34 (dark green squares) or 
NfHSMI35 (light green triangles) levels in SOD1 mice. Motor unit loss, expressed as a 
percentage of motor unit survival in age-matched WT mice, can be fitted into an 
exponential regression with R2=0.70 for NfHSMI34 and R2=0.73 for NfHSMI35, indicating 
a modest correlation between the extent of EDL motor unit loss and plasma NfH 
levels in SOD1 mice. 
3.3.2.4 Increased plasma NfH levels directly correlate with the extent of motor 
neuron death in the spinal cord of SOD1G93A mice  
The defining disease characteristic in both ALS patients and in the SOD1G93A mouse 
model of ALS is motor neuron degeneration. Therefore, in order to determine if  
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Figure 3.6 
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Figure 3.6. The correlation between plasma NfH phosphoform levels and 
motor unit survival in EDL muscles in SOD1 mice during disease progression. 
(A) Typical examples of motor unit traces in the EDL muscle of a WT and a vehicle 
treated SOD1 mouse at 105 days of age. Blue lines indicate traces that have not 
been replicated, and red lines indicate traces that have been replicated. (B) The bar 
chart shows the mean motor unit survival (numbers) in EDL muscles of WT (open 
bars) and vehicle treated SOD1 (green bars) mice. (C) The percentage loss of EDL 
motor units, relative to WT, and plasma NfHSMI34 (dark green squares) and NfHSMI35 
(light green triangles) levels in SOD1 mice at each stage of disease (indicated by 
arrows). Exponential regression lines are shown for NfHSMI34 (thick dark green line) 
and NfHSMI35 (thin light green line). Error bars:  ±S.E.M. Mann-Whitney Test: * p < 
0.05; ** p < 0.01. 
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changes in plasma NfH levels in SOD1G93A mice were a good reflection of the extent 
of motor neuron degeneration, we next established the extent of motor neuron 
survival in the lumbar spinal cord of WT and SOD1 mice at various stages of 
disease. Examples of Nissl-stained spinal cord sections, showing the lumbar ventral 
horn of 105-day-old WT and SOD1 mice are shown in Fig. 3.7A. The results are 
summarised in Fig. 3.7B, which shows the mean motor neuron survival in 90, 105 
and 120 day old SOD1 mice expressed as a percentage of WT. It can be seen that 
by 90 days, a significant number of motor neurons have already died in SOD1 mice 
and only 60.8±1.4% of motor neurons survive compared with WT littermates 
(p<0.01). Motor neurons continue to die in SOD1 mice as disease progresses, so 
that by 105 days, 44.8±1.2% of motor neurons survive (p<0.01) and by 120 days 
this is further reduced and only 29.0±1.3% of motor neurons survive (p<0.01; Mann-
Whitney U test). 
 
In order to establish whether the changes detected in plasma NfH levels correlate 
with the extent of motor neuron degeneration in SOD1 mice, an exponential 
regression analysis of motor neuron survival and plasma NfH levels was undertaken.  
Figure 3.7C summarises the results and shows the decline in motor neuron survival 
in SOD1 mice at 90, 105 and 120 days of age (indicated by the respective arrows) 
and corresponding plasma NfHSMI34 (dark green squares) or NfHSMI35 (light green 
triangles)  levels. It can be seen that the decline in motor neuron survival observed 
in SOD1 mice during disease progression fits into an exponential regression with 
R2=0.99 for both NfHSMI34 and NfHSMI35 (p-value of coefficient: 0.03 and 0.006, 
respectively). This analysis shows that there is a very strong correlation between the 
extent of motor neuron death and plasma levels of both NfHSMI34 and NfHSMI35 in 
SOD1 mice.  
3.3.3 Plasma NfH levels reflect the disease-modifying effects of arimoclomol in 
SOD1 mice 
Since plasma NfH levels correlate with the decline in neuromuscular function in 
SOD1G93A mice, I next examined whether changes in plasma NfH levels could detect 
the effects of agents that modify disease progression, i.e. whether they could be a 
biomarker in the setting of a clinical trial. Therefore in the next set of experiments, I 
investigated whether the beneficial effects of Arimoclomol, an established disease-
modifying therapy in SOD1G93A mice (Kalmar et al., 2008; Kieran et al., 2004), were 
reflected in changes in plasma NfH levels. Therefore, in this study a separate group  
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Figure 3.7. The correlation between plasma NfH phosphoform levels and 
motor neuron survival in SOD1 mice during disease progression. (A) The 
photomicrographs show cross-sections of the lumbar region at L5 level of spinal 
cords from a WT and a vehicle treated SOD1 mouse at 105 days of age stained for 
Nissl. The location of the sciatic motor pool is indicated within the broken circle. 
Magnificent: 5X. Scale bar = 250µm. (B) The bar chart shows the mean motor 
neuron survival in SOD1 mice expressed as a percentage of that in age-matched 
WT littermates at various stages of disease. The motor neuron count (mean±SEM) 
in WT/SOD1 mice at 90, 105, and 120 days were 433±7.8/264±10.5, 
422±8.9/189.2±5.0 and 439±2.3/125.5±5.6, respectively. (C) The percentage motor 
neuron death in SOD1 mice and levels of plasma NfHSMI34 (dark green squares) and 
NfHSMI35 (light green triangles) at each disease stage (indicated by arrows). 
Exponential regression lines are shown for NfHSMI34 (thick dark green line) and 
NfHSMI35 (thin light green line). Error bars:  ±S.E.M. Mann-Whitney U Test: ** p < 
0.01. 
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of SOD1G93A mice were treated with Arimoclomol (10 mg/Kg; i.p.; SOD1+A) from 35 
days and their plasma was collected at 65, 90, 105 and 120 days of age for analysis 
of NfH levels.  
3.3.3.1 Longitudinal assessment of disease progression in Arimoclomol-
treated SOD1G93A mice 
The effect of Arimoclomol on disease progression was determined by longitudinal 
assessments of body weight (BW) and grip strength (GS). The results are 
summarised in Fig. 3.8, which shows that Arimoclomol had no detectable effect on 
either BW or GS compared to vehicle-treated SOD1 littermates. 
3.3.3.2 The effect of Arimoclomol on muscle force, motor unit and motor 
neuron survival in SOD1G93A mice 
In order to determine if arimoclomol did improve disease progression in SOD1G93A 
mice as previously reported (Kalmar et al., 2008; Kieran et al., 2004), I next 
examined the muscle force, motor unit survival and motor neuron survival in 
Arimoclomol-treated SOD1 mice and vehicle-treated SOD1 littermates, at 105 and 
120 days of age. The results are summarised in Table 3.1 and confirm that there is 
a significant improvement in muscle force, functional motor unit survival and motor 
neuron survival in Arimoclomol-treated SOD1 mice compared to their vehicle- 
treated SOD1 littermates, both at a symptomatic (105 day) stage and more clearly at 
a late stage (120 day) of disease. These results confirm that Arimoclomol delays the 
decline in muscle function and motor neuron survival that occurs in vehicle-treated 
SOD1 mice between 105 and 120 days of age. 
3.3.3.3 Plasma NfH levels reflect the beneficial effects of Arimoclomol in 
SOD1G93A mice 
I next examined whether the improvements in disease observed in Arimoclomol-
treated SOD1 (SOD1+A) mice was reflected in a reduction in plasma NfH levels 
compared to their vehicle-treated SOD1 littermates (SOD1).  
 
Levels of plasma NfH in SOD1+A mice and SOD1 mice were determined between 
65 and 120 days of age. The results are summarised in Fig. 3.9, which shows that 
even at 65 days, a pre-symptomatic age, the effects of arimoclomol were reflected in 
a reduction in the plasma mean levels of NfHSMI34 in treated SOD1+A mice (red) 
compared to vehicle-treated SOD1 littermates (green). Thus, at 65 days, the  
133 | P a g e  
 
Figure 3.8 
 
 
 
134 | P a g e  
 
Figure 3.8. Longitudinal assessment of grip strength and body weight in SOD1 
and SOD1+A mice during disease progression. (A) Mean grip strength (GS) was 
determined weekly in mice of each group from 65-120 days of age. No significant 
difference was observed in GS in SOD1 and SOD1+A mice at any age (two-sample 
t-test, p>0.05 at all the time points). (B) Body weight (BW) was determined weekly 
from 65-120 days in mice of each group. In both SOD1 and SOD1+A mice, BW 
began to decline steadily from a maximum at 90 days, although there was no 
significant difference between SOD1 and SOD1+A mice at any age studied. (C) 
Mean grip strength was expressed relative to body weight (GS/BW) for SOD1 and 
SOD1+A mice during disease progression. In SOD1 and SOD1+A mice, there was a 
steady and similar decrease in the GS/BW ratio as disease progressed. Error bars: 
±S.E.M. Green circles, SOD1 mice; red triangles, SOD1+A mice. 
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Table 3.1. Arimoclomol delays disease progression in SOD1G93A mice. 
Age 
(days) 
Group Maximum TA 
Tetanic Force 
(g±sem) 
(n=muscle 
examined) 
EDL MU survival 
(n±sem)           
(n=muscle 
examined) 
MN survival 
(%WT)                
(n= sciatic 
motor pool 
examined) 
105 SOD1 21.1±3.0 (16) 12.6±0.5 (15) 44.8 (10)       
SOD1+A 49.2±9.9 (11) ** 14.8±0.5 (12) ** 58.0 (10) ** 
120 SOD1 19.5±3.5 (12) 10.7±0.7 (11) 29 (10)             
SOD1+A 36.9±9.0 (10) ** 14.0±0.6 (10) ** 65 (10) ** 
 
The Table shows the maximum TA tetanic force, EDL Motor Unit survival and Motor 
Neuron Survival in vehicle-treated SOD1 and Arimoclomol-treated SOD1+A mice at 
105 and 120 days of age. The results are the mean ± S.E.M. **p <0.01 
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Figure 3.9 
 
 
Figure 3.9. Longitudinal assessment of plasma NfHSMI34 levels in Arimoclomol-
treated SOD1 mice. The graphs show the mean plasma level (ng/mL) of NfHSMI34 in 
(A) individual values and in (B) group mean values in vehicle treated SOD1 mice 
(dark green; n=19) and Arimoclomol-treated SOD1+A mice (dark red; n=19), at 65 
(pre-symptomatic), 90 (early symptomatic), 105 (late symptomatic), and 120 (end 
stage) days of age. Error bars: ±S.E.M. A t-test was performed for direct comparison 
of the levels of NfHSMI34 in the two groups at 105 and 120 days, and a Mann-Whitney 
Test was performed for the other time points as the data was not normally 
distributed. Non-parametric analyses take the median value into account more than 
the mean value in the statistical analysis. Black lines depict the median values of 
plasma NfHSMI34 levels in each group. * p < 0.05.  
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mean±S.E.M of plasma NfHSMI34 levels were 17.8±8.8 ng/mL in SOD1+A mice 
compared with 46.2±13.1 ng/mL in SOD1 mice (Mann-Whitney test, p=0.035). As 
disease progressed, plasma NfHSMI34 levels continued to be lower in Arimoclomol- 
treated than in vehicle-treated SOD1 mice. Thus, the mean±S.E.M NfHSMI34 levels in 
SOD1+A mice compared with SOD1 mice were 66.3±23.7: 81.8±15.8 (SOD1+A: 
SOD1) ng/mL at 90 days; 124.8±18.8: 155.4±19.3 ng/mL at 105 days and 
231.7±23.9: 328.4±40.3 ng/mL at 120 days. However, the reduction in NfHSMI34 level 
in symptomatic SOD1+A mice compared with SOD1 mice only reached significance 
at 120 days (90 days p=0.154, Mann-Whitney test; 105 days, p=0.264, t-test; 120 
days, p=0.048, t-test; Fig. 3.9).  
 
Similarly, plasma levels of NfHSMI35 were also lower in SOD1+A mice (pink) 
compared with vehicle-treated SOD1 mice (light green) at all stages of the disease 
(Fig. 3.10). In contrast to NfHSMI34 levels, the assay for variably-phosphorylated NfH 
did not detect any significant effects of arimoclomol at pre-symptomatic stages. 
However, levels of NfHSMI35 in SOD1+A mice at 65 days of age were more consistent 
between different animals and at a lower level than observed in SOD1 mice, where 
there was a greater variation in plasma NfHSMI35 levels. Thus, the mean±S.E.M 
levels of plasma NfHSMI35 in SOD1+A and SOD1 mice (SODA: SOD) were 35.1±10.3: 
74.0±20.8 ng/mL at 65 days; 55.4±15.5: 68.8±14.8 ng/mL at 90 days; 77.0±10.1: 
104.8±17.0 ng/mL at 105 days and 92.0±15.5: 161.0±21.5 ng/mL at 120 days 
(Mann-Whitney test, p-values: 0.391; 0.327; <0.001 and 0.009 at 65, 90, 105 and 
120 days, respectively; Mann-Whitney test).  
 
These results show that the disease modifying effects of Arimoclomol in SOD1G93A 
mice are reflected in a reduction in plasma NfH levels compared to vehicle-treated 
SOD1 littermates. Furthermore, a comparison of the relative plasma levels of the 
two NfH phosphoforms, which is summarised in Table 3.2, revealed that NfHSMI34 
levels were significantly lower in SOD1+A mice than vehicle-treated SOD1 mice at 
65 days of age (Mann-Whitney test, p=0.015). Vehicle-treated SOD1 mice had 
smaller ranks for NfHSMI34 even at 65 days; the increase in NfHSMI34 levels started 
from 90 days, although it was not significant. In contrast, SOD1+A mice had a 
similar ranks for NfHSMI34 and NfHSMI35 at 90 days of age, and levels of NfHSMI34 
levels became significant greater than NfHSMI35 at 105 days (p=0.04). Further 
reduction of NfHSMI35 in SOD1+A mice was also observed at end-stage (p<0.0001). 
Thus, the disease modifying effects of Arimoclomol in SOD1 mice were reflected in  
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Figure 3.10 
 
 
Figure 3.10. Longitudinal assessment of plasma NfHSMI35 levels in 
Arimoclomol-treated SOD1 mice. The graphs show the mean plasma level (ng/mL) 
of NfHSMI35 in (A) individual values and in (B) group mean values in vehicle-treated 
SOD1 mice (light green; n=19) and Arimoclomol-treated SOD1+A mice (pink; n=19), 
at 65 (pre-symptomatic), 90 (early symptomatic), 105 (late symptomatic), and 120 
(end stage) days of age. Error bars: ±S.E.M. A t-test was performed for direct 
comparison of the levels of NfHSMI34 in the two groups at 105 and 120 days, and a 
Mann-Whitney Test was performed for the other time points as the data was not 
normally distributed. Non-parametric analyses take the median value into account 
more than the mean value in the statistical analysis. Black lines depict the median 
values of plasma NfHSMI35 levels in each group.  ** p < 0.01.  
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Table 3.2. A summary of the statistical analysis (Mann-Whitney test) of the 
difference in the plasma levels of the two NfH phosphoforms in vehicle-treated 
SOD1 and Arimoclomol-treated SOD1+A mice at 65, 90, 105 and 120 days of age. 
 SOD1 mice SOD1+A mice 
Age 
(days) 
NfH 
phosphoforms 
Mean 
Rank 
Sum of 
Ranks 
p-Value 
Mean 
Rank 
Sum of 
Ranks 
p-Value 
65 
SMI34 
SMI35 
18.83 
21.14 
376.50 
403.50 
0.507 
15.16 
23.84 
288.00 
465.00 
0.015 
90 
SMI34 
SMI35 
21.08 
18.87 
421.50 
358.50 
0.546 
19.66 
19.34 
373.50 
367.50 
0.930 
105 
SMI34 
SMI35 
23.25 
16.58 
465.00 
315.00 
0.068 
23.21 
15.79 
441.00 
300.00 
0.040 
120 
SMI34 
SMI35 
25.15 
14.58 
503.00 
277.00 
0.004 
27.42 
11.58 
521.00 
220.00 
<0.0001 
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lower levels of both NfH phosphoforms as well as a more even composition of 
plasma NfH phosphoforms than in vehicle-treated SOD1 mice.   
3.3.4 Using plasma NfH levels as a biomarker in a novel preclinical trial in 
SOD1G93A mice  
The above results have shown that the beneficial effects of a known therapeutic 
agent are reflected in a reduction in plasma NfH levels in SOD1G93A mice. In order to 
further test whether plasma NfH levels could be used as a good surrogate marker of 
treatment response in a clinical trial, I next examined plasma NfH levels as part of a 
novel preclinical study in SOD1G93A mice.  
 
In this study, blood samples were taken from SOD1G93A mice in which the potential 
therapeutic effects of a new drug, Cogane, were under investigation. In this study 
the following experimental groups were examined: 
 
i) Vehicle; 
ii) Cogane alone; 
iii) Congane in combination with Riluzole; 
iv) Riluzole alone.  
 
A Riluzole group was included in this study as most ALS patients are offered this 
option as the standard treatment for ALS. Treatment was initiated at 70 days of age, 
at symptom onset. NfH levels were examined at 105 and 120 days of age, when 
results presented in Fig. 3.9 and Fig 3.10 showed there were significant increases in 
plasma NfH phosphoforms in vehicle-treated SOD1G93A mice. The effects of these 
treatments on disease progression in SOD1G93A mice was determined at 120 days in 
treated and untreated mice by assessment of muscle force, motor unit and motor 
neuron survival. These physiological experiments were undertaken by Dr Bernadett 
Kalmar, a postdoc in our lab (Kalmar et al., 2012a). The results are summarised in 
Fig. 3.11, which shows that i) treatment with Cogane alone or in combination with 
Riluzole had beneficial effects and as shown in Fig. 3.11, there was a significant 
improvement in EDL muscle force and MU survival. In contrast, no improvement 
was observed in mice treated with Riluzole alone. However, as can be seen in Fig. 
3.11C, treatment with Cogane and Riluzole, alone or in combination, resulted in an 
improvement in motor neuron survival compared to vehicle-treated SOD1G93A mice. 
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Figure 3.11. Functional and morphological assessment of SOD1G93A mice 
treated with Cogane and Riluzole from onset of disease (70 days of age). The 
bar chart summarises (A) maximum tetanic force of EDL muscle, (B) motor unit 
survival in EDL, and (C) motor neuron survival in SOD1G93A mice treated with 
Cogane or Riluzole, alone or in combination. In mice treated with Cogane alone 
there was a significant improvement in EDL muscle force compared to vehicle- or 
Riluzole-treated mice. Riluzole treatment alone or in combination with Cogane had 
no effect on muscle force. (B) Treatment with Cogane alone or together with 
Riluzole increased motor unit survival compared to treatment with Riluzole alone. (C) 
Treatment with Cogane and Riluzole, alone or in combination, increased motor 
neuron survival compared to vehicle treatment. Error bars: ±S.E.M. Mann-Whitney U 
Test. *p<0.05. **p<0.01. The experiments shown in this Figure were undertaken 
by Dr Bernadett Kalmar and data reproduced from Kalmar et al., 2012a. 
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Interestingly, Cogane’s superior beneficial effect on EDL muscle force and motor 
unit survival over Riluzole was not replicated in plasma NfH levels. As can be seen 
in Fig. 3.12, Cogane had no effect on plasma NfHSMI34 levels in SOD1G93A mice 
compared to vehicle, and although NfHSMI34 levels were reduced in mice treated with 
Cogane in combination with Riluzole, this reduction was not significant either at 105 
days or 120 days. In contrast, mice treated with Riluzole alone had significantly 
lower plasma NfHSMI34 levels than either vehicle- or Cogane-treated mice at both 105 
days and 120 days (Fig. 3.12A and Fig. 3.12 B). As for plasma NfHSMI35 levels, 
Cogane alone also had no effect compared to Vehicle. In contrast, in mice treated 
with Cogane in combination with Riluzole plasma NfHSMI35 was largely reduced than 
Cogane alone at 105 days of age (Fig. 3.12C). In mice treated with Riluzole alone, 
there was a small, but insignificant reduction in plasma NfHSMI35 levels at 105 days 
(Fig. 3.12C), but by 120 days this reduction in plasma NfHSMI35 was significantly 
lower than in Cogane-treated SOD1 mice (Fig. 3.12D).  
3.3.5 Plasma NfH levels reflect disease progression in a slowly progressing 
mouse model of ALS 
The results presented in this Chapter have shown that plasma NfH levels correlate 
with disease progression and can be used to monitor this functional parameter in 
preclinical trials which utilize the SOD1G93A mouse model of ALS. However, the 
SOD1G93A mouse model has a very aggressive, rapid disease. Therefore, in the next 
set of experiments, I examined whether plasma NfH levels also reflected disease 
progression in a more slowly progressing mouse model of ALS, the SOD1G93Adl 
mouse, in order to establish whether this approach was applicable to models other 
than that in which it was developed. The SOD1G93Adl mouse has a significantly 
slower disease course than the SODG93A model. The earliest phenotypic change 
detected in these mice is mild tremor, detected at 18 weeks of age, followed by 
deficits in grip strength at approximately 21 weeks (Acevedo-Arozena et al., 2011). 
Analysis of muscle force, motor unit and motor neuron survival revealed that deficits 
of these parameters were first detectable at 24 weeks of age and by 34 weeks these 
defects had worsened significantly. These physiological and morphological 
experiments were undertaken by Dr Bernadett Kalmar, a postdoc in our lab 
(Acevedo-Arozena et al., 2011). These findings are summarised in Fig. 3.13A-C.  
 
In the same SOD1G93Adl mice used for analysis of disease progression, plasma NfH 
levels were determined between 15 and 38 weeks of age. The results are  
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Figure 3.12 
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Figure 3.12. Summary of plasma NfH levels in SOD1G93A mice treated with 
Cogane and Riluzole from onset of disease (70 days of age). The bar chart 
shows the mean plasma NfHSMI34 levels in (A) 105-day-old mice and (B) 120-day-old 
mice as well as plasma NfHSMI35 levels in mice at (C) 105 days and (D) 120 days of 
age. Figures (A) and (B) show that treatment of SOD1G93A mice with Cogane has no 
effect on plasma NfHSMI34 levels compared to vehicle, and although NfHSMI34 levels 
are reduced in mice treated with Cogane in combination with Riluzole, this reduction 
is not significant either at 105 days or 120 days. Mice treated with Riluzole alone 
have significantly lower plasma NfHSMI34 levels than either vehicle- or Cogane-
treated mice at both 105 days and 120 days. Figures (C) and (D) demonstrate that 
Cogane alone has no effect on NfHSMI35 levels at 105 and 120 days, although a 
significant reduction in levels is observed in the mice treated with Cogane in 
combination with Riluzole and Riluzole alone also decrease plasma NfHSMI35 levels 
at 105 days of age, which is not significant. However, by 120 days, Riluzole 
treatment results in a significant reduction in plasma NfHSMI35 levels compared to 
Cogane-treated mice. Error bars: ±S.E.M. Mann-Whitney U test. *p<0.05, **p<0.01. 
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Figure 3.13 
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Figure 3.13. The decline in neuromuscular function and motor neuron survival 
and change in plasma NfH levels during disease progression in SOD1G93Adl 
mouse model of ALS. The bar charts summarise data showing the decrease in (A) 
EDL tetanic force, (B) EDL motor unit survival, (C) Motor neuron survival at different 
stages of disease progression in SOD1G93Adel mice (green bars) and their WT 
littermates (black bars). (D) Mean plasma NfHSMI34 (bright green solid line) and mean 
plasma NfHSMI35 (light green dashed line) levels in SOD1G93Adl mice from 15-22 
weeks of age onwards are shown. Plasma NfH became detectable from weeks 24-
26, and increase largely during disease progression, particularly between weeks 28-
31 and weeks 32-34, the late disease stage in this model.  Error bars: ±S.E.M. 
*p<0.05, **p<0.01, ***p<0.001. The experiments in (A), (B) and (C) were 
undertaken by Dr Bernadett Kalmar and data reproduced from Acevedo-
Arozena et al., 2011. 
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summarised in Fig 3.13D. It can be seen that plasma NfH levels, both NfHSMI34 and 
NfHSMI35 phosphoforms, were undetectable up to 22 weeks of age. By 24 weeks, 
however, plasma NfH levels began to increase and increased further as disease 
progressed, particularly between weeks 28-31 and 32-34, a late stage of disease in 
this model. 
3.4 Discussion 
In this Chapter I examined i) the potential of phosphorylated NfH as a biomarker of 
disease progression in SOD1G93A mice; ii) the ability of this method to detect the 
disease modifying effects of therapies under study in preclinical trials, and iii) the 
use of phosphorylated NfH levels to monitor disease progression in an alternative  
mouse model of ALS. 
3.4.1 Plasma NfH levels are a biomarker of disease progression in the 
SOD1G93A mouse model of ALS and reflect the beneficial effects of a disease-
modifying therapy 
In this Chapter, plasma NfH levels were validated as a marker of late stage disease 
progression and treatment response in an animal model of ALS. Plasma is a readily 
available biological fluid that is easy to sample in longitudinal studies of progressive 
neurodegenerative disorders such as ALS. As shown in Fig. 3.1, the results show 
that plasma NfH levels increase significantly during disease progression, between 
65-120 days, in the SOD1G93A mouse model of ALS (Friedman test: p< 0.0001).  
Moreover, this increase in plasma NfH in SOD1G93A mice correlates with the loss of 
muscle force, the decline in motor unit survival and most significantly, with the extent 
of motor neuron degeneration that occurs during later stages of disease. 
Furthermore, the results also show that plasma NfH levels are a sensitive readout of 
late stage disease severity that can reflect the effects of a disease modifying therapy. 
Thus, in SOD1G93A mice treated with Arimoclomol, I observed a significant delay in 
disease progression as previously reported (Kalmar et al., 2008; Kieran et al., 2004),  
as reflected in an improvement in muscle force, motor unit and motor neuron 
survival, and these improvements were linked to a reduction in plasma NfH levels 
compared with vehicle treated age-matched SOD1G93A littermates. Arimoclomol is 
currently in a Phase II/III clinical trial in ALS patients with SOD1 mutations 
(Cudkowicz et al., 2008; Lanka et al., 2009; NCT00706147). The findings of this 
study therefore may represent an important step in the development of an easily 
accessible, comprehensive marker for disease progression in ALS that may have 
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utility in future clinical trials, particularly since patients are usually diagnosed and 
recruited into trials well after the onset of symptoms. 
3.4.2 The use of NfHs as a biomarker of disease 
Although previous reports have suggested that NfH levels may be a candidate 
biomarker for ALS and other progressive neurodegenerative diseases including AD 
and PD (Constantinescu et al., 2009; de Jong et al., 2007; van Eijk et al., 2010; 
Zetterberg et al., 2007), most of these studies have examined CSF as the target 
biological fluid. This approach necessitates the use of a relatively invasive 
procedure i.e. a lumbar puncture, which is not suitable for repeated sampling in 
longitudinal assessment of disease progression, particularly in individuals suffering 
from ALS, with significant physical and often respiratory impairment. Analysis of 
plasma NfH is the obvious solution to this problem, but this can be technically 
challenging due to the so-called NfH ‘Hook Effect’. This technical hurdle is caused 
by the tendency of proteins such as neurofilaments to aggregate, resulting in the 
masking of its epitopes and consequently, lower and un-representative yields in 
commonly used ELISA techniques (Lu et al., 2011). The NfH ‘Hook Effect’ has to 
date, therefore prevented the reliable measurement of neurofilament levels in ALS 
and other diseases where NfH aggregate formation occurs by standard 
immunoassay. In this respect, the methodology developed in Chapter 2 and used in 
this Chapter to determine plasma NfH levels is unique, in so far it is the first method 
specifically devised to overcome the NfH ‘Hook Effect’ (Lu et al., 2011).  
 
Although the anatomically defined blood-brain barrier (BBB) and the functionally 
defined blood-CSF barrier (BCB) limit CNS-to-blood transfer, molecules expressed 
in the CNS can still enter the blood under both normal and pathological conditions. It 
is therefore not surprising that neurofilaments leak into the circulation in both SOD1 
mice and ALS patients. The method I have developed (Lu et al., 2011) and used in 
this study was capable of detecting both hyperphosphorylated (NfHSMI34) and 
variably-phosphorylated (NfHSMI35) forms of NfH in plasma of WT animals at all ages 
studied. Although the two forms of NfH were present in approximately equal 
amounts, the detection of hyperphosphorylated NfH in the plasma of healthy WT 
mice shows that the presence of hyperphosphorylated NfH in the peripheral blood is 
not in itself indicative of pathology. Moreover, since NfH have been detected in 
several pathological conditions (Perrot et al., 2008), their presence is not disease 
specific and one of the important conclusions from this Chapter is that plasma NfH 
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cannot therefore be used as a primary diagnostic biomarker for neurodegenerative 
conditions such as ALS. However, increased plasma NfH levels do not reflect the 
earlier stages of disease in SOD1G93A mice, where NfH levels were similar in 
SOD1G93A and WT mice. Nonetheless, a far larger variation in plasma NfH levels in 
SOD1G93A mice than WT mice was observed, even prior to symptom onset (65 days).  
Plasma NfH levels increased significantly in SOD1 mice between 105 to 120 days of 
age (Fig. 3.1 and 3.2). Similarly in another SOD1G93Adl mouse model, a significant 
increase of plasma NfHSMI34 and NfHSMI35 were found in parallel with the decline in 
muscle force, motor unit survival and motor neuron survival. However, I did not have 
enough data/mice to correlate these disease progression markers with NfH levels in 
SOD1G93Adel mice, as tested in SOD1G93A mice. 
 
The sensitivity and reliability of the method used in the present study is highlighted 
by a comparison of our results with those of previous reports investigating plasma 
NfH as a potential biomarker of ALS. Thus, one study failed to detect any NfHs in 
plasma from WT mice and reported NfH levels in end-stage SOD1G93A  mice on 
average below 75 ng/mL (Boylan et al., 2009) and the other study only detected NfH 
in plasma of end-stage SOD1G93A mice at very low levels (on average, 8 ng/mL) 
(Gnanapavan et al., 2012). In contrast, using the method employed in the present 
study, plasma NfH levels can be detected in WT mice at all ages studied, as well as 
in pre-symptomatic and end-stage SOD1G93A mice, in which mean NfH levels rise to 
as high as 318.11 ng/mL (Lu et al., 2011).  
 
In addition to examining changes in plasma NfH levels in SOD1G93A mice, I also 
compared the relative levels of the two different NfH phosphoforms, NfHSMI35 and 
NfHSMI34. The results show that at 65 days of age, in both WT and SOD1 mice, the 
plasma levels of NfHSMI35 and NfHSMI34 were similar to each other. However, by 90 
days, a clear change in the relative levels of the two NfH phosphoforms was 
detected, with an increase in NfHSMI34 levels and a decline in NfHSMI35. It is possible 
that this change in the relative levels of hyperphosphorylated NfH is a better 
indicator of pathology than simply the presence of this phosphoform per se. Thus, 
the results i) demonstrate the early involvement of NfH in pathology in SOD1G93A 
mice, ii) reveal the true abundance of NfH in the plasma of these mice and iii) 
suggest that an increase in the ratio of hyperphosphorylated NfH: variably 
phosphorylated NfH is indicative of pathology, at least in the SOD1G93A mouse 
model of ALS.  
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3.4.3 Plasma NfH levels correlate with functional and morphological read-outs 
of neuromuscular decline in SOD1G93A mice  
In order to examine whether the increase in plasma NfH reflected the decline in 
neuromuscular function that occurs during disease progression in SOD1G93A mice, I 
performed a correlation analysis of plasma NfH levels with longitudinal and acute 
outcome measures. There was a strong-moderate inverse correlation between 
plasma NfH levels (both NfHSMI34 and NfHSMI35) and grip strength in SOD1G93A mice 
between 65-120 days of age (Fig. 3.4). Grip strength is a general functional test 
widely used to evaluate general motor function in mouse models (Crawley, 2008; 
Rogers et al., 1997; Rogers et al., 2001). However, grip strength is an overall 
measure of neuromuscular function that predominantly reflects the function of 
forelimb muscles, which are affected relatively late in disease progression in 
SOD1G93A mice. I therefore also correlated NfH levels with acute, quantitative, 
reproducible in vivo physiological assessments of neuromuscular function in 
hindlimbs. A moderate-strong correlation in the decline in muscle force and 
increased plasma NfH (Fig. 3.5D) and a mild correlation between plasma NfH and 
EDL motor unit loss (Fig. 3.6C) in SOD1G93A mice was observed. The mild 
correlation between NfH levels and motor unit survival is likely to be a reflection of 
the relatively late involvement of the EDL muscle in disease in SOD1 mice (Kalmar 
et al., 2008; Sharp et al., 2005). It is therefore possible that motor unit loss in other 
muscles such as TA, which is affected earlier and to a greater extent than EDL, may 
correlate better with NfH levels than EDL. However, it is technically more difficult to 
accurately estimate motor unit survival in large muscles such as TA, which has a 
large number of motor units. Instead, assessment of motor unit loss in any individual 
muscle may not be a good measure of overall disease progression, particularly in a 
disease such as ALS, where the site of disease onset and degeneration of different 
muscle groups varies.  
 
Among the most direct measures of disease progression in ALS is the extent of 
motor neuron survival. It has been proposed that the loss of motor neurons in ALS 
patients is linear (Chio et al., 2009) and in the present study, morphological 
assessment of motor neuron survival at different ages confirms that motor neuron 
survival appears to decline linearly in SOD1G93A mice. More importantly, we found a 
strong correlation between the extent of motor neuron degeneration and plasma NfH 
levels in SOD1G93A mice (Fig. 3.7C). These results show that plasma NfH levels, at 
least detected by the method described in this study, can be used to reflect the 
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extent of motor neuron degeneration. Thus, longitudinal measurement of plasma 
NfH levels in SOD1G93A mice reveals that plasma NfH levels increase as disease 
progresses, particularly in later stages between 105-120 days, the most critical 
period of disease progression in SOD1G93A mice, and this increase in NfH levels 
correlate with the decline in neuromuscular function and death of motor neurons, the 
defining phenotypic characteristics of ALS.  
 
However, it should be noted that, there is likely to be a significant delay between the 
time that the first physical manifestations of disease occur in ALS, such as muscle 
denervation (Fischer et al., 2004), and when these deficits result in functional, 
symptomatic deficits (such as reduced muscle force), and the eventual appearance 
of Nfs in the peripheral blood. Thus, when the timeline between muscle denervation, 
axonal degeneration, formation of NfH-containing aggregates, motor neuron 
degeneration and the eventual entry of NfH into peripheral blood is taken into 
account, it is not surprising that there is a discrepancy in the time between the 
detection of early physical manifestations of the disease (90 days) and the first 
significant elevation in plasma NfH levels (105 days). However, the invasive 
physiological and morphological approaches used to determine the extent of 
disease in SOD1G93A mice in this study, although very sensitive, quantitative and 
accurate, are irreversible and not practical for longitudinal follow-up in mice. 
Moreover, these measures are, in the mice, not clinically relevant for humans as 
they may not reflect the state of disease in patients when they first present to their 
physician with symptoms. Therefore, the correlations we report between the 
increases in plasma NfH levels and the decline in neuromuscular function may 
provide a safe and easy measure for the evaluation of later disease progression in 
ALS.   
3.4.4 Plasma NfH levels reflect the effects of disease-modifying therapies in 
SOD1G93A mice 
The results presented in this Chapter also show that plasma NfH levels reflect the 
disease modifying effects of Arimoclomol in SOD1G93A mice. In confirmation of our 
previous findings (Kalmar et al., 2008; Kieran et al., 2004), we found that treatment 
with Arimoclomol significantly delays the decline in neuromuscular function and the 
degeneration of motor neurons in SOD1G93A mice (Table 3.1). Furthermore, plasma 
NfH levels were in general lower in Arimoclomol-treated SOD1+A mice than vehicle-
treated SOD1 littermates at all ages studied, but most significantly at later stages of 
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disease, from 105-120 days of age (Fig. 3.9 and Fig 3.10). Hence, at 65 days, a pre-
symptomatic age, plasma levels of NfHSMI34 were significantly lower in Arimoclomol-
treated SOD1+A mice compared to vehicle-treated SOD1 littermates, possibly due 
to the early beneficial effects of Arimoclomol in the periphery, at the neuromuscular 
junction (NMJ) (Kalmar et al., 2012b). Arimoclomol acts as a co-inducer of the heat 
shock response, so that it only acts in cells under conditions of cellular stress to 
augment the heat shock response (HSR) (Hargitai et al., 2003). Thus, although the 
neuroprotective effects of Arimoclomol in SOD1G93A mice only manifest later in the 
disease when motor neurons are under considerable stress (Kalmar et al., 2008; 
Kieran et al., 2004), a recent study shows that its beneficial effects in the periphery 
manifest earlier in the disease, prior to symptom onset (Kalmar et al., 2012b). It has 
now been established that the earliest physical manifestation of disease in 
SOD1G93A mice occurs at the NMJ, where significant muscle denervation occurs 
prior to any motor neuron death (Fischer et al., 2004; Kalmar et al., 2012b). The 
recent work in our lab has shown that this early denervation is accompanied by an 
increase in the HSR and correspondingly, in Arimoclomol-treated SOD1G93A mice, 
this stress response is augmented, resulting in a delay in muscle denervation 
(Kalmar et al., 2012b). Therefore, since the levels of NfH remain steady in WT mice 
throughout the study, the difference in plasma NfH levels observed in SOD1+A and 
SOD1 mice at 65 days of age is likely to be the result of Arimoclomol’s early 
beneficial effects in the periphery and the maintenance of neuromuscular contacts. 
 
As shown in Fig. 3.9 & 3.10 and Table 3.1, the significant improvement in muscle 
force, motor unit and motor neuron survival observed from 105 days of age in 
Arimoclomol-treated SOD1+A mice compared to their vehicle-treated SOD1 
littermates is reflected in a decrease in plasma NfH levels. Although the significance 
of reduction of NfHSMI35 observed from 105 days was in line with the physiological 
improvement, the reduction of NfHSMI34 became significantly reduced only at 120 
days of age. However, further analysis of the levels of the two NfH phosphoforms 
showed that the relative increase in the more pathological plasma NfHSMI34 
compared with NfHSMI35 occurred later in Arimoclomol-treated SOD1+A mice than 
vehicle-treated SOD1 mice (Table 3.2). It is likely that the difference in the timing of 
the effects of Arimoclomol treatment on NfHSMI35 and NfHSMI34 levels may be related 
to their different levels of phosphorylation. Since the stability of NfH increases with 
the degree of phosphorylation (Petzold, 2005), it will take longer for proteases to 
cleave hyperphosphorylated NfH compared with variable-phosphorylated NfH. 
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Because neurofilament aggregates containing a large quantity of 
hyperphosphorylated NfH are a hallmark of disease in SOD1G93A mice, it will take 
longer for hyperphosphorylated NfH levels to decrease following treatment with 
Arimoclomol compared with variable-phosphorylated NfH.  
 
Furthermore, in this Chapter I also examined the utility of phosphorylated NfH 
measurements to detect the effects of therapeutic agents in a novel preclinical trial 
undertaken in the group. In this study, the efficacy of a new potential drug candidate 
called Cogane was examined. As part of this study, SOD1G93A mice were also 
treated with Riluzole either alone or in combination with Cogane, as Riluzole is the 
standard treatment for ALS and in any human ALS clinical trial it is likely that 
patients will be receiving Riluzole. The effects these treatments in neuromuscular 
function and motor neuron survival were analysed. In addition, blood was collected 
from these mice at key time points in disease when data collection from vehicle-
treated SOD1 mice had shown the most significant changes in phosphorylated NfH 
levels, i.e. at 105 and 120 days of age (Fig. 3.1 and Fig. 3.2). As can be seen in Fig. 
3.12, distinct plasma NfH levels were observed in mice treated with Riluzole and 
Cogane, in which Riluzole is more effective in reducing plasma NfH levels than 
Cogane. Together with the findings in Kalmar et al., 2012a, it is therefore possible 
that Cogane primarily improves muscle function, whereas Riluzole appears to have 
neuroprotective effects. The changes in phosphorylated NfH may therefore reflect 
the different therapeutic mechanisms of Cogane and Riluzole in disease progression 
in SOD1G93A mice.  
 
Lastly, a large difference in NfH levels was observed in the vehicle-treated 
SOD1G93A mice in the Arimoclomol trial (Fig. 3.1 & 3.2) and the Cogane trial (Fig. 
3.13). As the goal in the Arimoclomol trial was to investigate the possibility of NfH as 
a disease biomarker in SOD1G93A mice, male mice, which are usually only used for 
breeding in most of other studies, were used in order to obtain the maximal blood 
samples in serial blood samplings, while still complying with UK Home Office 
regulations. In contrast, female mice were chosen to investigate novel therapeutic 
effects on disease progression in SOD1G93A mice, the main goal in the Cogane trial. 
As there is a gender difference in body mass, disease progression, survival days 
and response to Arimoclomol in SOD1G93A mice (Kalmar et al., 2008), the difference 
in plasma NfH levels observed in these two trials in vehicle-treated SOD1G93A mice 
is likely to be due to gender differences.  
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3.5 Conclusions 
Taken together, the results presented in this Chapter show that the late stage 
decline in neuromuscular function and motor neuron survival in SOD1G93A mice and 
SOD1G93Adl mice is correlated with an increase in plasma NfH phosphoform levels. 
Furthermore, plasma NfH phosphoform levels reflect the improvement in disease 
phenotype induced by disease-modifying treatments such as Arimoclomol. Plasma 
NfH phosphoform levels may therefore be a useful marker to determine late stage 
disease progression in ALS and that may eventually be used as a sensitive outcome 
measure in clinical trials, particularly since ALS patients are likely to exhibit 
significant disease symptoms by the time of enrolment.  
 
The accurate and sensitive assessment of plasma NfH phosphoform levels may 
therefore provide a quick and easy readout of disease progression in individual 
patient in future clinical trials. In addition, plasma NfH levels may also serve as a 
safety biomarker as rapid increases in plasma NfH phosphoform levels following 
administration of test drugs might indicate a detrimental treatment effect (Petzold et 
al., 2010b). The use of plasma NfH as an outcome measure may therefore help to 
improve the safety of clinical trials by speeding up the time taken to detect 
deleterious effects. Furthermore, reductions in the time taken to complete these 
studies will reduce the costs of Phase III trials, which account for 70% of costs of 
clinical drug development in ALS (Cudkowicz et al., 2010). Whether the findings 
presented in this Chapter in animal models of ALS can be translated to ALS patients 
will become clear through further longitudinal investigation on cohorts of ALS 
patients. This is the focus of the experiments next presented in Chapter 4. If the 
results observed in this study in animal models of ALS are translated into patient 
samples, accurately measured plasma NfH phosphoform levels may become a 
valuable biomarker of disease progression, especially in later stages, for the ALS 
community. 
 
 Some of the results presented in this Chapter have been published:  
Ching-Hua Lu, Axel Petzold, Bernadett Kalmar, James Dick, Andrea 
Malaspina, Linda Greensmith. (2012). Plasma neurofilament heavy chain 
levels correlate to markers of late stage disease progression and treatment 
response in SOD1G93A mice that model ALS. PLoS ONE, 7(7):e40998. 
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Chapter 4 
Plasma neurofilaments as a biomarker of disease progression in ALS: 
Insights from a longitudinal study 
 
4.1    Introduction 
In Chapter 3, I examined whether plasma phosphorylated NfH levels may be used 
as a biomarker of disease progression in SOD1G93A mice. My results showed that 
plasma NfH levels correlate well with functional and morphological read-outs of 
disease progression in this well-characterised mouse model of ALS, which exhibits a 
homogenous disease phenotype. Moreover, my results also showed that plasma 
NfH levels were sensitive enough to reflect the disease modifying effects of known 
and novel therapies in SOD1G93A mice. In addition, analysis of plasma NfH levels in 
the more slowly progressing SOD1G93Adel mouse model of ALS established that the 
correlation between disease progression and plasma NfH levels was not restricted 
to the aggressive, rapidly progressing ALS phenotype observed in SOD1G93A mice. 
Taken together, these findings suggest that plasma NfH levels may be a biomarker 
of disease progression in human ALS. In this Chapter, I investigated the relevance 
of the findings outlined in Chapter 3 in ALS patients, by analysing the longitudinal 
pattern of plasma NfH levels in a heterogeneous group of ALS patients and 
examining its correlation with disease progression in these ALS patients. 
4.1.1 Current limitations and merits in biomarkers of disease progression in 
ALS 
Similar to other neurodegenerative disorders, it is generally accepted that the 
neurodegenerative processes driving ALS start long before the appearance of overt 
signs and symptoms of disease. In addition to this period of unrecognized pathology 
and of its detrimental effect to neuronal integrity, there is typically a 9-14 month 
delay between symptom onset and a final diagnosis of ALS (Cellura et al., 2012; 
Iwasaki et al., 2002). It is therefore reasonable to assume that this overall delay in 
the recognition of the disease may be a major obstacle to the development of 
treatments, whose efficacy largely depends on an early rescuing strategy for still 
healthy or partially functioning motor neurons (Ganesalingam and Bowser, 2010).  
 
Indeed, the diagnostic latency remains to date one of the strongest predictors of a 
worse prognosis in ALS (Chio et al., 2009; Turner et al., 2010a). The significant 
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clinical heterogeneity in ALS, which encompasses different anatomical sites of 
disease initiation as well as different patterns of disease progression, and overall 
survivals ranging from 6 months to 10 years, adds an additional layer of complexity 
in any effort to identify biomarkers of disease progression and of treatment response 
in ALS (Kiernan et al., 2011).  
 
The clinical diversity in the progression of ALS can be captured by clinimetrics such 
as the ALS Functional Rating Scale_Revised (ALSFRS_R) (Castrillo-Viguera et al., 
2010; Cedarbaum et al., 1999; Kollewe et al., 2008), which recapitulates the main 
components of the neurological impairment in ALS and provides a measure of the 
level of involvement based on commonly recognized disease milestones, such as 
the need for gastrostomy and for non-invasive ventilation. The ALSFRS_R score 
and its ratio have a strong correlation with disease progression and survival 
(Kaufmann et al., 2005; Kollewe et al., 2008), and have been widely used as primary 
or secondary outcome measure of efficacy in ALS clinical trials (Beghi et al., 2011). 
The ALSFRS_R score and its ratio have also been used as a parameter of disease 
progression in several biomarker development studies (Boylan et al., 2013; Keil et 
al., 2012; Tortelli et al., 2012; Zhang et al., 2011b). However, the ALSFRS_R is far 
from perfect and still requires refinement, as some of its rating categories were 
recently found not to be sensitive enough, with a reduced sensitivity of the raw 
scores in changes occurring in very high and very low functional ALS patients 
(Franchignoni et al., 2013). Therefore, it is possible that the ‘not-so-perfect’ 
ALSFRS_R, a clinimetric mostly used to validate the relevance of a developing 
disease progression biomarker in ALS, might also contribute to the uncertainty of 
current biomarker development in ALS.  
 
However, attempts to establish molecular indicators to predict or monitor the rate of 
disease progression in ALS have produced initial encouraging results, for example, 
evidence of a correlation between the numbers of regulatory T-lymphocytes (Tregs) 
& their FoxP3  protein expressions and disease progression rates in ALS (Beers et 
al., 2008; Henkel et al., 2013). With recent discoveries of new genetics and 
pathomechanisms in ALS as well as advances in technologies and platforms for 
biomarker development (discussed in Chapter 1 Section 5) it is still possible that 
novel biomarkers for disease progression in ALS may be identified in the near future. 
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4.1.2 Recent progress in developing neurofilaments as a biomarker of disease 
progression in ALS 
Nfs have emerged as one of the most promising candidates amongst potential 
biomarkers of disease progression in extracellular fluid (ECF), in cerebrospinal fluid 
(CSF), and in blood extracted from patients with ALS (Ganesalingam et al., 2013). 
The reported direct pathological involvement of Nf phosphophorms in ALS and the 
fact that Nfs are the main by-product of axonal loss and motor neuron degeneration 
clearly identify Nfs as a suitable target for any investigation into disease biomarkers 
of neurodegeneration. The CSF is in a privileged position to be the main bio-
repository for molecules synthetized or excreted during physiological or pathological 
events within the CNS. As a result, most of the biomarkers studies in 
neurodegenerative disorders, including the study of Nf, have been undertaken in 
CSF. In ALS, levels of Nfs in CSF have been found to be much higher than in other 
neurodegenerative disorders such as AD (Brettschneider et al., 2006c; 
Ganesalingam et al., 2011; Norgren et al., 2003; Rosengren et al., 1996; Tortelli et 
al., 2012) and to correlate inversely with disease duration (Zetterberg et al., 2007), 
inversely with diagnostic delay & ALSFRS_R score and positively with disease 
progression (Tortelli et al., 2012).  
 
However, due to the invasive nature of spinal taps, serial CSF sampling, although 
not impossible, is certainly not practical for the purpose of monitoring disease 
progression, particularly in frail and advanced ALS patients. Studies to uncover the 
Nf plasma profile in ALS patients have been undertaken in small cohorts of patients 
and have shown a 2-fold increase of pNfH in ALS, although both patients and 
controls display very low detection levels (Boylan et al., 2009).  Levels of pNfH in 
blood-based bio-fluids, serum and plasma, correlated well with CSF pNfH levels, 
although the correlation with ALSFRS_R slope was the best in CSF, followed by 
serum and then plasma, according to a recent study (Boylan et al., 2013). However, 
the major disadvantage with previous investigations into the bioavailability of NfH in 
peripheral blood is that they have been conducted in cohorts of rather small group 
size, which are unlikely to be representative of the heterogeneous ALS population 
(Chio et al., 2011a; Chio et al., 2011b).  
 
Both CSF and current blood-based Nf studies extrapolate prognostic information 
based on a single time point sampling followed by short follow-up periods, tracking 
only a fraction of the disease course from the baseline sampling. Large scale of 
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longitudinal investigations defining Nf expression at multiple time points in 
association with the observed rate of neurological decline would be a better 
approach to test the relationship between the bioavailability of a protein and the 
natural development of the disease. This approach would also help the study design 
of clinical trials which plan to use plasma NfH as a biomarker of treatment response. 
4.1.3 Hypotheses and Aims of this Chapter 
In this Chapter, I examined the hypothesis that plasma NfH levels may be a marker 
of disease progression in ALS. To test this possibility, I examined NfH levels in 
plasma samples collected from 136 ALS patients and 104 controls with the following 
Aims:  
 
i) To conduct a baseline cross-sectional examination of plasma NfH levels in ALS 
patients and controls;  
 
ii) To establish the longitudinal pattern of plasma NfH levels in ALS patients;  
 
iii) To examine whether the plasma NfH levels correlate with disease progression in 
ALS, using ALSFRS_R score;  
 
iv) To establish whether plasma NfH levels have any prognostic value in ALS;  
 
v) To explore a possible mechanism affecting NfH homeostasis in peripheral blood. 
4.2   Method and Materials 
4.2.1 Experimental participants 
Ethical approval for the study was obtained from the East London and the City 
Research Ethics Committee 1 (09/H0703/27) and patients were recruited at different 
clinics within the University College London Partner-Motor Neuron Disease (UCLP-
MND) Care Centres (St Bartholomew’s Hospital, London; Royal London Hospital, 
London; Basildon Hospital, Essex; National Hospital for Neurology and 
Neurosurgery, London) and at the Musgrove Park Hospital, Somerset. All subjects 
provided written informed consent. All subjects were evaluated in MND clinics. The 
study design involved study visits and blood samplings every 3 months in the follow-
up period, but time intervals varied between 2 and 4 months.  
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4.2.1.1 ALS patients 
In this project, we recruited only clinically sporadic ALS patients, who had a 
diagnosis of definite, probable, laboratory supported probable or possible ALS 
according to the El Escorial Criteria (Table 4.1) (Brooks et al., 2000). Only patients 
able to consent and to attend the designated out-patient clinics were included in this 
study. 90% of ALS participants were consented in the study either at diagnosis or 
within 2-3 months from diagnosis. Exclusion criteria included neurological co-
morbidity which are likely to affect Nf homeostasis including neurosurgical 
operations prior to enrolment, concomitant peripheral neuropathies (idiopathic, 
diabetes-induced or following chemotherapy) and recent history of significant 
neurotrauma (Petzold et al., 2010a; Petzold et al., 2006a; Petzold et al., 2006b; 
Petzold et al., 2008; Petzold et al., 2010b; Tisdall and Petzold, 2012). A total of 136 
ALS patients were recruited into the study. 
4.2.1.2 Control subjects 
Control subjects included healthy individuals and patients with a variety of 
neurological conditions, seen in the Neuromuscular Clinics within UCLP; these 
subjects were divided into two groups:  
i) Healthy controls (HC), mainly the unrelated spouse/partner of patients;  
ii) Neurological disease controls (NC); 
Group NC included 14 multiple sclerosis (MS) individuals with a diagnosis of 
relapsing remitting MS (n=5), secondary progressive MS (n=6) and primary 
progressive MS (n=3), 10 individuals with inflammatory demyelinating neuropathies 
including chronic inflammatory demyelinating polyneuropathy, paraproteinemia 
related and multifocal motor neuropathy, 15 individuals with a diagnosis of single-
level or multi-level compressive cervical or lumbar radiculopathy, 10 cases of 
idiopathic or genetically determined neuropathy including Charcot-Marie-Tooth and 
4 cases with benign fasciculations and cramp syndrome. It is important to 
investigate neurological disease controls as these NCs represent some ALS mimic 
conditions. A total of 104 control subjects were included into the study. 
4.2.2 Characterisation of disease progression ALS  
4.2.2.1 Change in function 
Disease duration was calculated from the reported symptom onset onwards. 
Disease progression was evaluated using the ALS Functional Rating Scale  
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Table 4.1 Diagnostic guidelines for ALS (Brooks et al., 2000). 
Diagnostic Criteria: 
(A) 
Presence 
1. Evidence of LMN degeneration by clinical, electrophysiological 
or neuropathologic examination; 
2. Evidence of UMN degeneration by clinical examination; 
3. Progressive spread of symptoms or signs within a region or to 
other regions as determined by history or examination. 
(B) 
Absence 
1. Electrophysiological or pathological evidence of other disease 
processes that might explain the signs of LMN and/or UMN 
degeneration; 
2. Neuroimaging evidence of other disease processes that might 
explain the observed signs. 
Diagnostic certainty categories: 
Definite ALS: Clinical evidence of UMN and LMN signs in three regions; 
Probable ALS: Clinical signs of UMN and LMN deterioration in at least two regions, 
with some UMN signs rostral to LMN signs; 
Probable Laboratory-Supported ALS: Clinical signs of UMN and LMN degeneration 
in one region, or UMN signs alone in one region and electromyographic LMN signs 
in at least two regions; 
Possible ALS: Clinical signs of UMN and LMN degeneration in only one region, or 
UMN signs alone in two or more regions, or LMN signs found rostral to UMN signs. 
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(ALSFRS_R) and disease duration over a specific period. The details of the 
ALSFRS_R, a composite functional outcome measure used for clinical trials and 
biomarker studies in ALS (Castrillo-Viguera et al., 2010; Chio et al., 2009; Kollewe et 
al., 2008), are shown in Table 4.2. In this study, the sum of scores from Questions 
1-12 of the ALSFRS_R is taken as the ‘score’ for that visit. The maximal score is 48, 
which represents no functional deficit, and is used as the pre-onset status. A 
number of parameters of disease progression derived from the ALSFRS_R score 
were used in this Chapter: 
 
i) Progression rate: the progression rate from onset to each evaluation is 
calculated as [48 - the ALSFRS_R score at an assessment/duration in month 
between the reported time of ALS onset and the evaluation].  
ii) Overall progression rate: the progression rate between the reported time of 
ALS onset and the last assessment in the study period, determined as [(48 - the last 
ALSFRS_R score)/ duration in month between reported time of onset and the last 
available assessment in our follow-up]. This parameter was used to characterize the 
speed of progression of the disease and to separate ALS individuals with a fast 
disease development (ALS-F) from ALS individuals displaying a slower rate of 
progression (ALS-S). In general, those patients with an overall-progression rate ≥1.0 
were considered as ALS-F, whereas those with an overall-progression rate of ≤ 0.5 
were considered ALS-S.  
iii)        ALSFRS_R slope: the change in functional score between two consecutive 
visits determined as [ALSFRS_R score/duration in months]; this value can be 
negative. 
4.2.2.1 Disease duration to baseline 
For the purpose of our cross-sectional and longitudinal analyses, the ALS cohort 
was divided into 4 sub-groups according to the disease duration to baseline: 1) <12 
months; 2) between 12-24 months; 3) between 24-36 months and 4) >36 months. 
4.2.3 Plasma collection 
All participants were evaluated in the out-patient clinics and blood samples were 
taken and processed within 1 hour. The interval between each visit was usually 3 
months, but could vary according to patients’ clinical progression. Blood was 
collected, into EDTA-coated tubes and spun down at 20°C 3500 rpm for 10 minutes,  
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Table 4.2 ALS Functional Rating Scale _ Revised (ALSFRS_R). 
0 Questionnaire 
collected: 
1 From patient in clinic 
 
2 From patient by phone 
3 
From carer by phone (patient response) 
Must be done by carer only when dysarthric patient 
cannot communicate by phone. Must be patient view. 
 
1 Speech 4 Normal speech processes 
 3 Detectable speech disturbance 
2 Intelligible with repeating 
1 Speech combined with nonvocal communication 
0 Loss of useful speech 
 
2 Salivation 4 Normal 
 
3 
Slight but definite excess of saliva in mouth; may have 
night-time drooling 
2 Moderately excessive saliva; may have minimal drooling 
1 Marked excess of saliva with some drooling 
0 
Marked drooling; requires constant tissue or 
handkerchief 
 
3 Swallowing 4 Normal eating habits 
 
3 Early eating problems – occasional choking 
2 Dietary consistency changes 
1 Needs supplemental tube feeding 
0 NPO (exclusively parenteral or enteral feeding) 
 
4 Handwriting 4 Normal 
 
3 Slow or sloppy: all words are legible 
2 Not all words are legible 
1 Able to grip pen but unable to write 
0 Unable to grip pen 
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5a Cutting food 
and handling 
utensils 
(patients 
without 
gastrostomy) 
4 Normal 
 
3 Somewhat slow and clumsy, but no help needed 
2 
Can cut most foods, although clumsy and slow; some 
help needed 
1 Food must be cut by someone, but can still feed slowly 
0 Need to be fed 
or 
5b Cutting food 
and handling 
utensils 
(patients 
with 
gastrostomy) 
4 Normal 
 
3 
Clumsy but able to perform all manipulations 
independently 
2 Some help needed with closures and fasteners 
1 Provides minimal assistance to caregiver 
0 Unable to perform any aspect of task 
 
6 Dressing 
and 
Hygiene 
4 Normal function 
 
3 
Independent and complete self-care with effort or 
decreased efficiency 
2 Intermittent assistance or substitute methods 
1 Needs attendant for self-care 
0 Total dependence 
 
 
7 Turning in 
bed and 
adjusting 
bed clothes 
4 Normal 
 
3 Somewhat slow and clumsy, but no help needed 
2 Can turn alone or adjust sheets, but with great difficulty 
1 Can initiate, but not turn or adjust sheets alone 
0 Helpless 
 
8 Walking 4 Normal 
 
3 Early ambulation difficulties 
2 Walks with assistance 
1 Nonambulatory functional movement 
0 No purposeful leg movement 
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9 Climbing 
stairs 
4 Normal 
 
3 Slow 
2 Mild unsteadiness or fatigue 
1 Needs assistance 
0 Cannot do 
 
10 Dyspnea 4 None 
 
3 Occurs when walking 
2 
Occurs with one or more of the following: eating, bathing, 
dressing (ADL) 
1 
Occurs at rest, difficulty breathing when either sitting or 
lying 
0 
Significant difficulty, considering using mechanical 
respiratory support 
 
11 Orthopnea 4 None 
 
3 
Some difficulty sleeping at night due to shortness of 
breath, does not routinely use more than two pillows 
2 Needs extra pillows in order to sleep (more than two) 
1 Can only sleep sitting up 
0 Unable to sleep 
 
12 Respiratory 
insufficiency 
4 None 
 
3 Intermittent use of BiPAP 
2 Continuous use of BiPAP during the night 
1 Continuous use of BiPAP during the night and day 
0 
Invasive mechanical ventilation by intubation or 
tracheotomy 
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with acceleration and deceleration set at 5 and 4 respectively. Plasma was then 
aliquoted and stored at -80°C until assayed. 
4.2.3.1 Cross-sectional study sampling 
Baseline plasma samples collected from the 136 ALS and 104 control participants 
were used for a cross-sectional study of plasma NfH levels. 
4.2.3.2 Longitudinal study sampling 
For longitudinal analysis, serial blood samples for plasma analysis were obtained 
from 74 of the 136 patients with a mean±S.E.M. follow-up period of 12.2±1.0 months 
(Max: 39.0, Min 1.1, 25%: 4.1, 75%: 17.9 months). The longitudinal study design 
involved visits and blood sampling every 3 months in the follow-up period, although 
time intervals varied between 2-4 months. 
4.2.4 NfH ELISA 
4.2.2.1 Analytical procedure using ELISA method originally designed for CSF 
samples 
For detail procedures, please refer to Chapter 2, section 2.2.5. 
4.2.2.2 Analytical procedure using ELISA method designed for plasma 
samples (developed in Chapter 2) 
For detail procedures, please refer to Table 2.3. 
4.2.2.3 ELISA data analysis 
Hyperphosphorylated NfH was detected with the SMI-34R capture antibody labelled 
as NfHSMI34 (averaged intra-assay coefficient of variation (CV): 3.11%, averaged 
inter-assay CV: 3.76% at 12.5 ng/mL, 1.94% at 50 ng/mL), while variably 
phosphorylated NfH was detected with the SMI-35R capture antibody, labelled as 
NfHSMI35 (averaged intra-assay CV: 2.97%, averaged inter-assay CV: 3.29% at 12.5 
ng/mL, 3.65% at 50 ng/mL). The sensitivity (blank + 3SD) of the assay calculates to 
0.74 ng/mL, with a detection limit of 1.56 ng/mL. Total NfH refers to the sum of 
NfHSMI34 and NfHSMI35. Measurements with a CV higher than 10%, the intra-assay 
CV in the ELISA method original designed for measuring NfH in human CSF, were 
repeated to keep up with the standard in the original assay (Petzold et al., 2003). 
Quality control samples were used throughout the analyses and absorbance 
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readouts from different microtitre plates were adjusted to the quality control readout 
to allow comparison of results across different plates (Petzold et al., 2010c). 
4.2.4 Western Blots 
4.2.4.1 Sample preparation 
Western blot (WB) analysis of NfHSMI34 was carried out using plasma from ALS 
patients and purified bovine NfH protein (USBiological; N2160-15B). Each set of 
samples contained plasma pooled from 3 patients. All sets of samples were filtered 
twice through the Amicon® Ultra Centrifugal filter (Millipore; UFC510024) to remove 
low molecular weight proteins in the plasma. Next, to check for presence of 
aggregates, concentrated plasma samples were divided into two groups: one with 1-
hour urea incubation prior protein denaturation and the other without incubation. The 
urea pre-incubation group was processed with a 1:1 dilution factor, with 0.5 M urea-
Barb2EDTA buffer incubation for 1 hour (RT), while the non-urea group was kept at 
4°C during that hour before diluting 1:1 with Barb2EDTA buffer prior protein 
denaturation. Samples were then mixed with lithium dodecyl sulfate sample buffer 
and 0.5 M dithiothreitol before being denatured at 70ºC in a water bath for 10 
minutes. Purified bovine NfH protein was incubated using the above conditions to 
have a final amount of 100 ng NfH in each denatured sample. 
4.2.4.2 Blotting procedures 
HiMark™ Pre-stained high molecular weight (MW) protein standard (ranged 
between 460-30 kDa; Invitrogen, LC5699), purified bNfH protein and plasma 
samples were loaded into 3-8% NuPAGE® Noves® Tris-Acetate gels (Invitrogen, 
EA0375BOX) and run at 150 V for 1 hours before transferred on a nitrocellulose 
membrane. The membrane was then blocked with Barb2EDTA buffer containing 5% 
skimmed milk at room temperature for 1 hour. After washing (4 x 10 minutes), the 
membrane was incubated in Barb2EDTA buffer containing 0.1% skimmed milk with 
SMI-34R (1:1000) at 4ºC overnight. The membrane was then washed (6 x 15 
minutes), followed by 2-hour incubation with HRP-labelled rabbit anti-mouse IgG 
(Dako, P0260, 1:1000, RT) and washed (6 x 15 minutes). The membrane was then 
treated with the chemiluminescence substrate (SuperSignal West Pico, Thermo 
Scientific, #34078) for 5 minutes. The dried membrane was visualised on an 
AlphaEase SP CCD camera.  
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Then, the blots were stripped of the antibodies and re-probed with HRP conjugated-
Anti-Human immunoglobulin G (IgG) (Dako, P0214, 1:1000, 4°C, overnight) 
following the manufacturer’s instructions (Abcam®). The membrane was then 
treated with the chemiluminescence substrate (SuperSignal West Pico, Thermo 
Scientific, #34078) for 1 minute and then visualized. Pre-absorption of the primary 
antibodies abolished all the bands at high MW. 
4.2.5 Statistical analysis 
Numerical variables were summarized by the sample mean±S.E.M., median and 
interquartile range (IQR). A Mann-Whitney U test was performed for group 
comparison between ALS patients and controls. The correlations between plasma 
NfH levels and the monthly rate of change in ALSFRS_R score, diagnostic latency 
in months and overall progression rate as well as plasma NfH levels and age were 
carried with Spearman’s rank correlation coefficient (rho). Fisher’s exact test was 
used to examine the dominant group of patients with different patterns of 
longitudinal plasma NfH levels and ALSFRS_R score. A p value of less than 0.05 
was considered as statistically significant. All analyses were performed using SPSS 
(V.20; IBM SPSS statistics, UK). 
4.3   Results 
In this Chapter, I examined whether the findings presented in Chapter 3, in which I 
showed that plasma NfH levels correlated with markers of disease progression in 
the SOD1G93A mouse model of ALS and increased towards end-stage disease, were 
reflected in plasma of ALS patients. I examined i) whether the NfH ‘Hook effect’ 
observed in SOD1G93A mouse model is present in human plasma, and ii) if so, can 
the ELISA method developed in Chapter 2 overcome this NfH ‘Hook effect’ in 
human plasma samples? Having established a suitable assay for the detection of 
NfH in human plasma, I next examined i) both the cross-sectional and the 
longitudinal pattern of plasma NfH in ALS patients, and ii) whether plasma NfH 
levels are of prognostic value in ALS. Finally, I investigated the possibility of that 
alternative mechanisms may affect plasma NfH homeostasis, aside from disease 
progression. 
4.3.1 A NfH ‘hook effect’ is present in human plasma 
In the first set of experiments, I examined whether the NfH ‘Hook Effect’ observed in 
the plasma of SOD1G93A mice is also present in human plasma. Samples selected 
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from a small number of healthy controls, and limb-onset ALS patients at an early 
stage (ALSFRS_R score ≥40) and a late stage (ALSFRS_R score ≤25) of disease 
were examined, using the method originally developed for human CSF samples 
which is described in Chapter 2 (Section 2.2.5).   
 
A NfH ‘Hook Effect’ was observed from the serial dilution of plasma samples from 
early-ALS (eALS), late-ALS (lALS) as well as in healthy controls (HC) (Fig. 4.1A). 
The resulting lack of parallelism between human plasma samples and standards 
introduced an analytical error averaging up to 46.9, 101.5, and 22.5 times higher 
levels for a 1:16 dilution (4th), when compared with 1:2 dilution (1st) for HC, eLAS, 
and lALS, respectively (Fig. 4.1B). Taken together, plasma NfHSMI34 levels in human 
can be up to 32.3 times higher at the 4th serial dilution than the 1st one (Fig. 4.1C).  
4.3.2 The NfH ‘Hook Effect’ in human plasma is overcome by urea 
A number of different approaches were tested as described in Chapter 2 Section 3.2 
to overcome the NfH ‘Hook Effect’ in human plasma. These tests showed that the 
same modification used for analysis of mouse plasma can overcome the NfH ‘Hook 
Effect’ in human plasma and subsequently improved parallelism (Fig. 4.2A-C). This 
involved incubation of the plasma samples in 0.5 M urea-Barb2EDTA buffer at a 
1:8 dilution for 1 hour at RT before adding to the ELISA plate.  Hence, the 
protocol described in Table 2.3 Chapter 2 was used for further experiments on 
human plasma described in this Chapter.  
4.3.3 Plasma levels of NfH in ALS patients and controls 
The demographic and clinical characteristics of the 136 ALS patients and 104 
Control subjects examined in the cross-sectional study are summarized in Table 4.3.  
The median (Interquartile range; IQR) of diagnostic latency in our ALS cohort was 
11.99 (7.03, 20.98) months, in line with other large-scale population studies in ALS 
(Cellura et al., 2012; Iwasaki et al., 2002). We observed a strong negative 
correlation between the Overall Progression Rate in ALS patients and their 
diagnostic latency (Spearman’s rho = -0.511, p<0.0001; Fig. 4.3). This confirms 
previous observations that short diagnostic latencies are generally associated with a 
worse prognosis in ALS (Chio et al., 2009; Turner et al., 2010a). 
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Figure 4.1 
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Figure 4.1. The Hook effect and lack of parallelism for NfH in human plasma. 
(A) Normalised optical density (NOD) in serial dilution of plasma samples from 
healthy controls (HC; red), early stage ALS (eALS; green), and late stage ALS (lALS; 
purple) showed a ‘Hook’ (arrow) and a lack of parallelism with the standard curve 
(blue), i.e. increase in NOD, while the NOD of the standard attenuated. (B) shows 
the percentage change of NfH concentrations obtained during serial dilutions 
normalised to the concentration obtained from the first dilution in HC, eALS and 
lALS. NfH concentration obtained from more diluted samples had much higher 
levels than the concentration obtained from less diluted samples in all three sample 
groups, with the maximum effect observed at 1:16 dilution. Note the effect seemed 
to be more prominent in eALS samples than lALS. (C) shows averaged percentage 
change of NfH concentrations during serial dilutions normalised to the concentration 
obtained from the first dilution, containing the three groups shown in (B). Error bars: 
±S.E.M. 
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Figure 4.2 
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Figure 4.2. The effects of 1 hour incubation of 0.5 M Urea-Barb2EDTA buffer at 
room temperature on plasma NfH levels in human plasma. (A) The ‘hook effect’ 
disappeared and parallelism was improved, using the urea-timed method 
(Incubation in 0.5 M Urea-Barb2EDTA buffer at room temperature for 1 hour). (B) 
Using serial dilution of samples, more consistent NfH levels were detected at the 1:8 
(16%) for both controls and ALS. However, plasma NfH levels degraded for controls 
and lALS at 1:16 dilution, respectively. (C) Urea pre-incubation delivered consistent 
levels for controls and ALS plasma (the three groups shown in B) up to 1:8 dilution, 
but not beyond. Error bar: ±SEM. 
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Table 4.3. Characteristics of ALS patients and controls in the cross-sectional study for plasma NfH levels.      
Groups Patient 
No 
Plasma 
NfH
SMI34
 
levels 
(ng/mL) 
Mean±SEM    
(1
st
 quartile, 
median, 3
rd
 
quartile) 
Plasma 
NfH
SMI35
 
levels 
(ng/mL) 
Mean±SEM    
(1
st
 quartile, 
median, 3
rd
 
quartile) 
Plasma pNfH 
levels 
(ng/mL) 
Mean±SEM        
(1
st
 quartile, 
median, 3
rd
 
quartile) 
Age at 
sampling 
(yrs) 
Mean±SEM        
(1
st
 quartile, 
median, 3
rd
 
quartile) 
Gend
er 
F/M 
Ethnicity 
% Non-
Caucasia
n 
Age of 
onset    
(yrs) 
Mean±SE
M        (1
st
 
quartile, 
median, 3
rd
 
quartile) 
Clinical 
onset 
sites 
Bulbar/Li
mb/Both 
ALSFRS_
R score at 
sampling 
Mean±SE
M (1
st
 
quartile, 
median, 3
rd
 
quartile) 
Progressi
on rate at 
sampling 
Mean±SE
M (1
st
 
quartile, 
median, 3
rd
 
quartile) 
Riluzole 
treatme
nt 
% on 
treatmen
t 
ALS
§
 136        
at Visit 
1    
17.4±1.4       
(8.6, 15.1, 
24.3) 
14.5±1.6       
(4.1, 10.8, 
20.7) 
32.0±2.5         
(15.2, 29.0, 
4.1) 
63.7±1.0        
(57.7, 65.1, 
70.6) 
48/88 6.62% 60.9±1.1        
(53.9, 63.8, 
68.2) 
29/104/3 35.3±0.7 
(29.0, 
37.0,42.0) 
0.68±0.06 
(0.23, 0.51, 
0.92) 
75 
All 
Controls
* 
104 16.7±1.4       
(5.0, 14.0, 
26.5) 
11.1±1.0       
(4.3, 9.1, 
16.3) 
27.8±2.1         
(11.5, 24.9, 
40.1) 
57.4±1.2        
(50.1, 59.1, 
64.8) 
60/44 1.92%      
HC 51 16.9±1.9       
(6.1, 14.5, 
27.4) 
11.8±1.2       
(6.5, 9.4, 
15.0) 
28.7±2.6        
(14.2, 27.7, 
40.1) 
55.3±1.8        
(45.5, 57.9, 
62.7) 
38/13 0% 
NC 53 16.4±2.2       
(4.0, 13.7, 
24.9) 
10.5±1.5       
(0.1, 7.7, 
17.8) 
26.9±3.3          
(6.9, 23.8, 
40.0) 
59.4±1.7        
(51.4, 60.3, 
67.3) 
22/31 3.77% 
§The ALS cohort includes 62 patients sampled only at baseline (visit 1) and 74 patients sampled longitudinally during disease progression (total 
136 patients). *Controls include i) HC: Healthy controls, ii) NC: Neurological disease controls. The NC group includes 14 MS individuals with a 
diagnosis of relapsing remitting MS (n=5), secondary progressive MS (n=6) and primary progressive MS (n=3) and 10 individuals with 
inflammatory demyelinating neuropathies including chronic inflammatory demyelinating polyneuropathy, paraproteinemia related and multifocal 
motor neuropathy, 15 individuals with a diagnosis of single-level or multi-level compressive cervical or lumbar radiculopathy, 10 cases of 
idiopathic or genetically determined neuropathy including Charcot-Marie-Tooth and 4 cases with benign fasciculations and cramp syndrome. 
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Figure 4.3 
 
 
 
Figure 4.3 A shorter diagnostic latency is associated with a poorer prognosis 
in ALS. A strong negative correlation was observed between the overall progression 
rate in ALS patients and their diagnostic latency expressed in months (from the 
reported onset of symptoms). Spearman’s rho= -0.511, p<0.0001. The best-fit trend-
line is shown in red. 
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4.3.3.1 Changes in plasma NfH levels in ALS patients 
Plasma NfH levels were determined in our cohort of ALS patients (n=136) and 
control subjects (n=104). The results were first analysed in a cross-sectional study 
in which plasma NfH levels in ALS patients and control subjects were compared. 
Next, a longitudinal study in a proportion of our ALS cohort (n=74) was undertaken, 
in which changes in total plasma NfH levels, as well as changes in the more 
pathological form of NfH, hyperphosphorylated NfHSMI34, during disease progression 
were examined.  
 
In the control subjects enrolled into this study, no significant difference in plasma 
NfH levels between Healthy controls (HC) and Neurological controls (NC) was 
observed (p=0.247, 0.507 and 0.195 for total NfH, NfHSMI34 and NfHSMI35, 
respectively; Mann-Whitney U test; See Table 4.3).  
4.3.3.1.1 Cross-sectional study of plasma NfH levels in ALS patients and 
control subjects  
I first undertook a cross-sectional study of plasma NfH levels in ALS patients and 
control subjects, to establish whether plasma NfH levels are distinct between ALS 
patients and controls at the time of enrolment into the study, irrespective of any 
disease parameter (e.g. disease duration, progression rate etc.). I determined levels 
of total NfH, as well as levels of the two NfH phosphoforms, hyperphosphorylated 
NfHSMI34 and less pathological NfHSMI35. 
 
4.3.3.1.1.1 There is no significant difference in plasma NfH levels between ALS 
patients and control subjects at baseline sampling 
The cross-sectional analysis comparing NfH plasma levels measured at baseline (1st 
sampling) in the ALS cohort and control subjects (HC plus NC), showed that there 
was no significant difference between these groups (p=0.202, 0.524 and 0.288, for 
total NfH, NfHSMI34 and NfHSMI35, respectively; Fig. 4.4A). This finding is in contrast to 
previous reports of NfH levels in smaller cohorts of ALS patients and controls 
(Boylan et al., 2009), possibly due to the high clinical heterogeneity of our large ALS 
patient cohort. 
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Figure 4.4 
 
 
Figure 4.4 Cross-sectional analysis of plasma NfH levels in ALS patients and 
controls at baseline. (A) Analysis of NfH levels showed that there was no 
significant difference in total plasma NfH or its phosphoforms in ALS patients and 
controls (HC + NC). (B) When ALS patients were grouped according to time of 
disease duration to Visit 1, patients with the shortest disease duration (n=31) 
showed higher NfH levels compared to controls, and the difference in NfHSMI35 and 
total NfH was very close to statistical significance (p=0.055 and 0.059, respectively). 
Mann-Whitney U test. ALS duration: 1= <12 months; 2= <24m; 3= <36m; 4= >36m. 
Error bars: ±S.E.M.  
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4.3.3.1.1.2 Plasma NfH levels may change during disease progression 
Since plasma NfH levels are likely to change throughout the course of disease 
progression, the time of plasma sampling with respect to the time of disease onset 
was considered to be a likely key determinant of NfH expression levels. Therefore, 
we undertook an additional cross-sectional analysis between the control subjects 
and sub-groups of ALS patients that were homogeneous with respect to disease 
duration, defined as the time interval between reported disease onset and baseline 
plasma sampling (Visit 1). In this analysis, the cohort of ALS patients was divided  
into four sub-groups according to the disease duration to Visit 1. Analysis of 
plasma NfH levels showed that only the sub-group with the shortest disease 
duration (less than 12 months) showed higher levels of plasma NfH levels compared 
to controls, with a trend towards statistical significance (p= 0.059, 0.175, 0.055, for 
total NfH, NfHSMI34 and NfHSMI35, respectively; Fig. 4.4B). In contrast, ALS patients 
with longer disease durations (greater than 12 months), had comparable levels of 
plasma NfH to control subjects. Since disease duration in our cohort of ALS patients 
was very close to the diagnostic latency (in most patients baseline sampling 
occurred within 3 months of diagnosis), this data suggests that patients with a 
shorter diagnostic latency (and disease duration) were likely to progress faster and 
to have higher plasma NfH levels in samples taken during the early stages of the 
disease, as previously described by others (Boylan et al., 2013).  
4.3.3.1.2 Longitudinal changes in plasma NfH levels in ALS patients  
On the basis of these observations, I next undertook a longitudinal analysis of NfH 
expression in a subset of our clinically heterogeneous ALS cohort. I examined the 
overall pattern of change in plasma NfH levels during the progression of disease in a 
subset of our ALS cohort, followed longitudinally for up to 2 years from first sampling, 
and assessed whether the pattern of NfH changes was related to the rate of disease 
progression. Plasma samples were collected longitudinally during the follow-up of 74 
ALS patients and the profile of total plasma NfH expression during the natural 
progression of the disease was first determined. Samples were collected at several 
time-points, ranging between 2 and 11 times, with the interval between visits ranging 
between 2 to 4 months. 
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4.3.3.1.2.1 Total plasma NfH levels in ALS patients are affected by the 
progression rate during disease 
Patients were grouped according to their overall progression rate and defined as 
having either fast progressing disease (ALS-F) or slow progressing disease (ALS-S), 
as defined by the monthly decline in the ALSFRS_R score. The characteristics of 
these patients are summarized in Table 4.4. The results shown in Fig. 4.5 
summarize the longitudinal pattern of plasma NfH levels from the baseline for 18 
ALS-F (overall progression rate >1.0/month) and 35 ALS-S (overall progression rate 
<0.5/month) patients followed-up longitudinally for up to 15 months from the first 
sampling. Plasma NfH levels were higher in both ALS-F and ALS-S patients at 
baseline than controls. In ALS-F patients, there was a decline in NfH levels over 
time towards end-stage disease. In contrast, plasma NfH levels in ALS-S patients 
remained stable during the first 6 months after baseline sampling and subsequently 
began to slightly increase with disease progression, although they remained above 
control levels throughout the study period (Fig. 4.5).  
4.3.3.1.3 Longitudinal changes in levels of hyperphosphorylated NfH in ALS 
patients: the change in expression from symptom onset 
The results presented in Fig. 4.5 suggest that the overall pattern of plasma NfH 
levels is different in ALS patients with different rates of disease progression. I 
therefore sought to examine plasma NfH levels in ALS patients in more detail, by 
undertaking an analysis of the changes in levels of the more pathological NfH 
phosphoform, NfHSMI34, in addition to taking into account both the time of disease 
duration as well as the rate of disease progression. Thus, I next examined the 
changes in expression of hyperphoshorylated NfHSMI34 in ALS patients during 
disease progression.  
4.3.3.1.3.1 Hyperphosphorylated NfHSMI34 plasma levels in ALS patients and 
the effects of disease duration and progression rate 
The characteristics of the ALS patients included in this analysis are summarized in 
Table 4.5, which also details the classification of the rate of disease progression in 
this analysis. The 74 ALS individuals followed up longitudinally were divided into 4 
groups based on disease duration, defined as the time interval from the reported 
clinical onset of ALS symptoms to the first sampling of plasma. 
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Table 4.4. Patient characteristics of the ALS patients studied longitudinally and sub-grouped according to their overall progression rates. Serial 
plasma NfH levels for all ALS patients were recorded from the baseline visit.  
 
 
ALS patients with overall progression rates of >1.0 and <0.5 were grouped as fast (ALS-F) and slow (ALS-S) progressors, respectively. There is 
a significant difference between the two groups of patients in the ALSFRS_R score at baseline, overall progression rate, duration to the 
baseline and the last sampling, as well as diagnostic latency. However, there is no difference between age of onset in these patients *p<0.05, 
**p<0.01, ***p<0.0001, N.S.: not significant. 
 
 
Pattern 2: 
Overall 
progression 
rate*** 
Patient 
n. 
 
Time 
points 
Age of 
onset
N.S.
 
Gender Duration: 
onset to 
baseline 
sampling*** 
Duration: 
onset to 
diagnosis** 
Duration: 
onset to the 
last 
sampling*** 
ALSFRS_R 
at baseline** 
 
Ethnicity Clinical onset 
 
(Mean±SEM)  
 
range 
 
(Mean±SEM) 
 
 
F/M 
(Months; 
Mean±SEM) 
(Months; 
Mean±SEM) 
(Months; 
Mean±SEM) (Mean±SEM) 
 
% non-
Caucasian 
 
 
Bulbar/Limb/Both 
ALS-F 
(1.258±0.06) 
18 2 to 8 65.9±1.1 7/10 12.2±1.6 7.9±1.0 20.8±1.6 34.9±1.7 none 5/12/1 
ALS-S      
(0.253±0.02) 
35 2 to 11 59.6±2.1 6/29 44.5±8.6 23.3±4.2 60.1±8.7 41.1±1.1 5.80% 8/26/1 
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Figure 4.5 
 
 
 
 
 
 
Figure 4.5.  The profile of total plasma NfH levels in a 15-month follow-up from 
baseline in ALS patients with different rates of disease progression. Mean total 
plasma NfH levels are shown in red for patients with a faster progression rate (ALS-
F) and in blue for patients with a slower progression rate (ALS-S). The dashed line 
represents the mean total plasma NfH level in control subjects. The two solid lines 
encasing the dashed lines represent the error bars for controls. Values in the 
parentheses are number of ALS-F and ALS-S patients at each time point (ALS-
F/ALS-S). Error bars: ±S.E.M. 
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Table 4.5. Characteristics of ALS patients followed longitudinally: ALS patients are sub-grouped according to the time interval between ALS 
onset and their first study visit.  
 
 
§ ALS patients were first sub-grouped according to the interval from symptom onset to their first sampling, and then further sub-divided 
according to their overall progression rate.  For sub-groups in Year 2 and beyond, slow progressing ALS patients (ALS-S) had an overall 
progression rate < 0.5; the remaining patients were grouped as fast progressors (ALS-F). For ALS patients with a baseline sampling within 12 
months of  ALS onset, the majority was ALS-F and had a progression rate > 1.0, the remaining  5 patients were grouped as ALS-S.   
 
Patient Groups§:  
time from ALS 
onset to sampling 
(overall progression 
rate (Mean±SEM)) 
Patients 
n. 
 
Time 
points 
range 
Age of 
onset 
(Mean±SEM) 
Gender 
F/M 
Duration: 
onset to 
baseline 
sampling 
(Months; 
Mean±SEM) 
Duration: 
onset to 
diagnosis 
(Months; 
Mean±SEM) 
Duration: 
onset to the 
last 
sampling 
(Months; 
Mean±SEM) 
ALSFRS_R 
at baseline 
(Mean±SEM) 
Ethnicity 
% non-
Caucasian 
Clinical onset 
Bulbar/Limb/Both 
< 1year ALS-Ft            
(1.29±0.08) 
13 2 to 8 63.9±1.9 4/9 8.8±0.7 6.0±0.8 19.3±1.6 37.8±1.6 none 5/8/0 
< 1year ALS-S          
(0.57±0.13) 
5 2 to 7 61.4±3.4 1/4 9.1±1.2 5.9±1.1 17.0±3.3 44.4±1.8 none 0/5/0 
1 to 2 years ALS-F     
(0.82±0.06) 
15 2 to 7 65.0±2.3 8/7 17.6±0.9 12.6±1.3 26.5±1.7 35.3±1.4 none 3/12/0 
1 to 2 years ALS-S   
(0.23±0.03) 
11 2 to 11 58.8±4.1 2/9 17.2±1.2 9.7±1.7 34.5±4.4 44.3±0.6 9% 2/9/0 
2 to 3 years ALS-F     
(0.73±0.06) 
10 2 to 8 64.7±4.5 4/6 29.3±1.2 20.6±2.4 38.2±2.0 30.2±2.0 none 1/8/1 
2 to 3 years ALS-S   
(0.34±0.04) 
10 2 to 11 65.9±2.6 3/7 28.0±1.0 19.2±2.1 45.0±4.2 40.8±1.5 none 3/7/0 
> 3 years ALS-S      
(0.31±0.05) 
10 2 to 10 57.7±3.3 1/9 47.7±2.3 27.9±4.3 62.0±3.3 34.1±3.3 none 4/6/0 
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As can be seen in Fig. 4.6, the profile of plasma NfHSMI34 expression in the follow-up 
period varied according to both disease duration (from symptom onset) and to 
overall progression rate. Patients with a fast progression rate (ALS-F) enrolled in the 
study within the first year from ALS onset (Fig. 4.6A; Year 1), had higher plasma 
NfHSMI34 levels than those with a slow progression rate (ALS-S), throughout the 
study period. Patients enrolled in the study more than 12 months after disease onset 
(Fig. 4.6B; Year 2), had similar levels of plasma NfHSMI34 in ALS-F and ALS-S 
disease, over the study period. However, for those ALS patients enrolled in the 
study more than 24 months after disease onset (Fig. 4.6C; Year 3), the longitudinal 
pattern of NfH expression of ALS-F and ALS-S appeared to diverge between 4-6 
months from the levels detected at baseline, with the ALS-F group displaying a 
gradual decline in NfHSMI34 levels and the ALS-S group showing an increase 
followed by stabilization of NfHSMI34 levels, which typically remained above the mean 
NfHSMI34 level detected in the control group (Fig. 4.6C). All ALS patients in our cohort 
enrolled during the 4th year after symptom onset were defined as ALS-S, and their 
mean plasma NfHSMI34 levels were consistently higher than control levels throughout 
the study (see Fig. 4.6D; Year 4).  
 
Taken together, these results show that in this heterogeneous ALS patient cohort, 
plasma NfH levels are dependent on both disease duration (from time of symptom 
onset to sampling) as well as the rate of disease progression. 
4.3.3.2 Do changes in plasma NfH levels have any prognostic value? 
The conclusions drawn from the data above come from an overall, retrospective 
analysis of plasma NfH levels in ALS patients. In order to examine whether plasma 
NfH levels could be of any prognostic value in a prospective study, I next undertook 
a correlation analysis between plasma NfH levels and disease progression.   
4.3.3.2.1 Plasma NfH levels correlate with progression of disease between 
visits  
In order to establish whether the changes in plasma NfH levels in ALS patients were 
a good indicator of the rate of disease progression, I examined the correlation 
between disease progression, determined by the ALSFRS_R slope between two 
consecutive visits (average interval of 2-4 months between visits) and the plasma 
NfH levels at the later visit, in patients from whom plasma samples and clinical  
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Figure 4.6 
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Figure 4.6.  The longitudinal profile of plasma NfHSMI34 levels in a 2 year follow-
up varies according to the rate of disease progression and duration. ALS 
patients were grouped according to the time of their first, baseline sampling of 
plasma relative to the time of symptom onset: (A) within the 1st, (B) 2nd, (C) 3rd and 
(D) 4th year from the reported onset of ALS. The graphs show the mean plasma 
NfHSMI34 levels in patients sampled at 3-month intervals, grouped according to their 
Overall Progression Rate. The results from patients with faster progression rates 
(ALS-F) are shown in red, and those with slower progression rates (ALS-S) are 
shown in blue. The dashed lines represent the mean plasma NfHSMI34 levels from 
Control subjects (HC plus NC); the two solid lines encasing the dashed line 
represent the variability of error bars in control samples. Error bars: ±S.E.M. Values 
in the parentheses are number of ALS-F and ALS-S patients at each time point 
(ALS-F/ALS-S). For patients recruited within the 1st year of symptom onset, patients 
classified as ALS-F have an overall-progression rate ≥1.0, and those patients 
classified as ALS-S have a progression rate of ≤1.0. For patients recruited after the 
1st year of symptom onset, patients classified as ALS-S have an overall progression 
rate of ≤ 0.5, and those defined as ALS-F have a rate of ≥0.5.  
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information were collected longitudinally. In this analysis, data from 206 ‘pairs’ of 
visits from 74 patients were examined. For each pair of visits (i.e. one visit and the 
next follow-up visit) the ALSFRS_R slope was determined and the level of plasma 
NfH at the follow-up visit was correlated with the ALSFRS_R slope for that period. 
The ALSFRS_R slope ranged between -9 and 3 per month [mean±S.E.M. = -
0.866±1.34; median (IQR) = -0.5 (-1.33, 0)]. As can be seen in Fig. 4.7, there was a 
mild positive correlation between the ALSFRS_R slope and NfHSMI34 levels 
(Spearman’s rho=0.186, p=0.009; Fig. 4.7A), but no correlation between the 
ALSFRS_R slope and NfHSMI35 levels (Spearman’s rho=0.076, p=0.281; Fig. 4.7B), 
in 206 pairs of consecutive visits.  
 
However, this correlation was strengthened for both NfHSMI34 (Spearman’s 
rho=0.256, p=0.01) and NfHSMI35 (Spearman’s rho=0.215, p=0.032), when only those 
patients with a relatively fast progression rate were included in the analysis, i.e. 
patients with a confirmed decrease in the ALSFRS_R score of >0.5 points per 
month. Lower plasma NfH levels correlate with a faster decline in the ALSFRS_R 
score, particularly in patients in whom a loss of >0.5 points in the ALSFRS_R score 
per month indicates a faster disease progression. This finding is similar to that 
observed in the longitudinal analysis of changes in plasma NfH levels during 
disease progression (Fig. 4.6) in which ALS-F patients had lower plasma NfH levels 
during the more advanced stages of disease, when the ALSFRS_R slopes between 
visits were more marked and mostly negative.  
 
These results therefore indicate that there is a correlation between plasma NfH 
levels and the rate of disease progression in ALS patients, where surprisingly, low 
levels of plasma NfH correlate with a poor prognosis. These findings are in contrast 
with previous reports which show that high levels of plasma NfH correlate with a 
faster disease progression (Boylan et al., 2013).   
4.3.3.2.2 Changes in plasma NfH levels do not predict patterns of disease 
progression  
I next examined whether a specific pattern of disease progression was reflected in a 
change in plasma NfH levels. 74 ALS patients followed-up longitudinally were 
assessed to establish the overall pattern of disease progression as determined by 
the ALSFRS_R score and sub-grouped these patients according to the pattern of 
plasma NfH changes. The pattern of disease progression, as determined by the  
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Figure 4.7 
 
Figure 4.7. NfH plasma levels correlate with the decline in the monthly 
ALSFRS_R slope. The ALSFRS_R slope between two consecutive visits correlated 
with the change in plasma NfHSMI34 (A) and NfHSMI35 (B) levels in the total of 206 
pairs of consecutive visits. A significant correlation was found between the 
ALSFRS_R slope and NfHSMI34 levels in the second visit of each sampling pair 
(Spearman’s rho=0.186, p=0.009), but not between the ALSFRS_R slope and 
NfHSMI35 (Spearman’s rho=0.076, p=0.281). For those pairs of consecutive visits in 
which the ALSFRS_R slope was less than -0.5 (patients who lost more than 0.5 
points per month, as shown to the left side of the blue dashed lines; 100 sampling 
pairs), the correlation between the ALSFRS_R slopes and both NfHSMI34 
(Spearman’s rho=0.256, p=0.01) and NfHSMI35 (Spearman’s rho=0.215, p=0.032) 
levels were strengthened. 
188 | P a g e  
 
 
ALSFRS_R score, showed that patients either progressed or stabilised during the 
follow-up period of this study. In each of these two groups of patients, we found that 
plasma NfH either increased in some patients or decreased/no change. Thus, as 
can be seen in Fig. 4.8, we identified 4 main patterns of combined behaviours of 
these two parameters: (A) deterioration of the ALSFRS_R score with increased NfH 
levels; (B) deterioration of the ALSFRS_R score with decreased/no change NfH 
levels; (C) stable ALSFRS_R score with decreased/no change NfH levels; and (D) 
stable ALSFRS_R score with increased NfH levels. The proportion of gender and 
onset site of patients in these four groups is also presented in Fig. 4.8, which shows 
that group (B) has the highest proportion of female and bulbar onset ALS patients. 
Statistical analysis of each group was undertaken to determine whether increased 
NfH levels could predict deterioration in function (as determined by a decrease in 
the ALSFRS_R score). As shown in Table 4.6, the results showed that there was a 
trend toward significance for plasma NfHSMI34 levels (Fisher Exact test p= 0.0704), 
but not for NfHSMI35 levels (Fisher Exact test p=0.1674).  
 
Taken together, these results show that changes in plasma NfH levels do not 
appear to predict disease progression in a large, heterogeneous population of ALS 
patients. However, if the patient cohort under study is relatively small or 
homogenous, it is more likely that one pattern of disease will predominate. This may 
lead to a false positive correlation between plasma NfH levels and rate of disease 
progression that is not representative of the heterogeneous ALS population. Thus, 
our results suggest that cross-sectional biomarker studies consisting of small 
sample sizes may be subject to sampling bias, since they may consist of a relatively 
high number of one particular group of patients.  
4.3.3.3 Sampling bias leads to misinterpretation of relevance of NfH levels in 
cross-sectional studies in ALS 
In order to establish how significant the sampling bias may be in cross-sectional 
studies, we next divided our cohort of 74 ALS patients studied longitudinally into two 
groups: (a) those in which plasma NfH levels increase from baseline during the 
course of the disease (n=45), and (b) those in which NfH levels decrease from 
baseline during the course of the disease (n=48). In these patients we compared 
plasma NfH levels at baseline sampling at Visit 1 (V1) to either the maximum level of 
plasma NfH (VMax) determined in Group (a) patients, or the minimum level of plasma 
NfH (VMin) determined in Group (b) patients.  
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Figure 4.8 
 
 
 
 
 
 
 
190 | P a g e  
 
 
Figure 4.8. Analysis of the change in plasma NfH levels and ALSFRS_R score 
during a follow-up period of up to 32 months identifies four main groups of 
ALS patients. The graphs show the four groups of ALS patients revealed by 
dividing the patients according to the pattern of change of plasma NfH levels and 
disease progression. The graphs on the left show the 4 main patterns of change in 
plasma NfH levels (Total plasma NfH=Triangles; NfHSMI34=Diamonds; and 
NfHSMI35=Squares); the graphs on the right show the corresponding pattern of 
change in the ALSFRS_R score. The 4 groups of patients represent Group (A): 
Increased NfH levels with deterioration of ALSFRS_R; Group (B): Decreased NfH 
levels with deteriorated ALSFRS_R; Group (C) Decreased NfH levels with a stable 
ALSFRS_R; and Group (D) Increased NfH levels with a stable ALSFRS_R.  
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Table 4.6. Change in plasma NfH levels and its prognostic value for disease 
progression: summary of the statistical analysis. 
 
  ALSFRS_R 
score  
Decrease 
ALSFRS_R 
score 
Increase or 
stabilised 
Fisher Exact Test 
(p value) 
Plasma 
NfHSMI34 
levels 
Increase  25 9 p=0.0704 
Decrease/no 
change 
23 17 
Plasma 
NfHSMI35 
levels 
Increase 19 12 p=0.1674 
Decrease/no 
change 
29 14 
 
The Table shows the number of ALS patients who fulfilled the criteria for sub-
grouping according to the change in NfHSMI34 or NfHSMI35 levels together with the 
change in the ALSFRS_R score during the study period. The p value obtained from 
Fisher exact test is also presented. No significant correlation between the change of 
plasma NfH and the change of ALSFRS_R score was observed in this cohort of ALS 
patients.  
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The plasma V1 and VMax NfH levels for ALS patients in Group (a) in which plasma 
NfH levels increased during disease are shown in Fig. 4.9A, where they are 
compared to mean NfH levels for healthy controls (HC; n=51). It can be seen that 
NfH plasma levels at VMax are significantly higher than NfH plasma levels at V1 and 
in HCs. In ALS patients in Group (b), in which plasma NfH levels decreased during 
disease progression to VMin, NfH levels at baseline (V1) are significantly higher than 
VMin levels and from HC levels (Fig. 4.9B). Thus, for both groups of patients, 
determination of NfH levels at a specific point in disease progression in a snap-shot 
cross-sectional study would result in a completely different estimation of NfH levels 
from samples taken at a different stage of the disease. For example, if the total NfH 
levels determined at V1 and Vmax are compared, it can be seen that if the sample at 
V1 was used in a cross-sectional study NfH levels would be taken as 25.3±2.7 
ng/mL (mean±S.E.M.), which is not different from HCs, in contrast to NfH levels at 
VMax, 49.6±3.6 ng/mL (mean±S.E.M.), which would be taken as significantly higher 
than HCs 28.7±2.6 ng/mL (mean±S.E.M.). These results therefore confirm that 
sampling bias can significantly affect the interpretation of cross-sectional studies of 
plasma NfH levels in ALS patients.  
4.3.4 The immune response to neurofilaments; NfH fragments co-localise with 
anti-human IgG immunoglobulin  
The results presented above show that plasma NfH levels do not always increase as 
disease progresses in ALS patients. This finding is in contrast to my previous 
findings in the SOD1G93A mouse model of ALS, which present a very homogenous 
pattern of disease progression and in which I observed a clear increase in plasma 
NfH levels during disease progression (Lu et al., 2012). I therefore next investigated 
a possible mechanism that may explain the contradictory patterns of plasma NfH 
levels in ALS patients during disease progression. It has been previously shown that 
auto-antibodies can be produced in response to the presence of neuron-specific 
proteins in peripheral blood (Couratier et al., 1998; Fialova et al., 2010). We thus 
undertook a preliminary study to examine whether auto-antibodies against NfHs and 
their proteolytic by-products could be detected in plasma of ALS patients, since 
these may affect the level of NfHs in plasma.  
 
High molecular weight NfH aggregates were detected in the plasma of ALS patients, 
as can be seen in the immunoblot in Fig. 4.10A (green dashed arrow; bands 
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Figure 4.9 
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Figure 4.9. A comparative cross-sectional analysis of plasma NfH levels in 
ALS patients and healthy controls: NfH levels vary according to the chosen 
sampling time. (A) In 45 ALS patients, NfH levels were significantly higher than in 
healthy controls at Visit 1 and were also much higher in a later stage of the disease. 
(B) In 48 ALS patients, NfH levels were significantly higher than in healthy controls 
at Visit 1, but later decreased to a much lower level compared to both healthy 
controls and to NfH levels at Visit 1.  Grey bars= Total NfH levels: light grey bars: 
Healthy Controls (HC), Dark Grey Bars: ALS patients from Visit 1, VMax and VMin. 
Blue bars= NfHSMI34 levels: Light Blue bars: Healthy Controls (HC), Dark Blue bars: 
ALS patients from Visit 1, VMax and VMin. Brown bars= NfH
SMI35 levels: Light brown 
bars: Healthy Controls (HC), Dark brown bars: ALS patients from Visit 1, VMax and 
VMin. Error bars: ±S.E.M. **p<0.01, ***p<0.0001. Kruskal-Wallis Test. 
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Figure 4.10 
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Figure 4.10. Immune response to NfH and NfH aggregates. (A) Immunoblots of 
plasma samples from ALS patients. Three sets of plasma samples, each containing 
plasma samples from 3 ALS patients were examined. Lane 1-3 and 1’-3’: samples 
pre-treated without and with 0.5M urea incubation, respectively. The blot on the Left 
is probed with NfHSMI34: bands at high molecular weight are present in ALS plasma 
(bands between 238-460 kDa; green dashed arrow) and endogenous binding of NfH 
cleavage products at lower MW areas (bands below ~205 kDa). Addition of 0.5 M 
urea partly dissolves the aggregates, particularly in lane 2’. On the right-side, the 
same blot re-probed with anti-Human IgG immunoglobulin is shown after stripping of 
the NfH antibody. Multiple bands showing intense staining for Human IgG were 
revealed; both the expected bands for the light chain (25kDa) and heavy chain (53 
kDa) (red arrows) as well as bands at the MW of NfH endogenous fragments can be 
seen (black arrows). (B) The image shows the enterokinase cleavage sites for NfH 
(as described in Petzold et al., 2011a). (C) The diagram illustrates a hypothesis of 
NfH aggregates complex, which contain i) NfH high MW aggregates, a mixture of 
NfH monomer and NfH low MW fragments (endogenous cleavage products by 
Enterokinase), ii) human autoantibody to NfH, and iii) other proteins. 
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between 238-460 kD in lanes 1-3 of the NfHSMI34 blot). In addition, endogenous 
binding of NfH cleavage products were detected (see Fig. 4.10A: NfHSMI34 blot, 
bands below the expected ~205 kDa in lanes 1-3, marked by asterisks). This result 
is similar to our previous findings in plasma of SOD1G93A mice (Lu et al., 2011). The 
addition of 0.5 M Urea partly dissolves the aggregates after one hour (especially in 
lane 2’ Fig. 4.10A, lanes 1’-3’ in the NfHSMI34 blot). The NfHSMI34 blot shown in Fig. 
4.10A was subsequently stripped of the NfH antibody and re-probed with HRP-
conjugated anti-Human IgG immunoglobulin. This revealed multiple bands stained 
intensely for Human IgG, both for the expected bands for its light chain (25kDa) and 
heavy chain (53 kDa) (Fig. 4.10A, red arrows) as well as bands at the same MW of 
the NfH endogenous fragments (Fig. 4.10A, black arrows). These findings suggest 
firstly, that NfH aggregates are present in ALS plasma, and secondly, that both the 
high MW NfH aggregates and low MW fragments appear to co-localize with human 
IgG. Fig. 4.10B illustrates the enterokinase cleavage sites for NfHs (Petzold et al., 
2011a) 
 
The molecular weight of the NfH fragments produced following enterokinase 
cleavage (Fig. 4.10B, bands marked by asterisks), were of the same MW as the 
bands observed in the blot shown in Fig 4.10A (bands marked by asterisks) in the 
NfHSMI34 blot. These findings are similar to those reported in SOD1G93A mice (Lu et 
al., 2011). Taken together the results shown in Fig. 4.10 support the hypothesis that 
NfH aggregates may be present in the peripheral blood of ALS patients. 
Furthermore, as shown in Fig. 4.10C, these results also suggest that NfH aggregate 
complexes may contain:  i) high MW NfH aggregates, a mixture of NfH monomers 
and low MW NfH fragments (endogenous cleavage products produced by 
enterokinases), ii) human auto-antibodies to NfHs, and iii) other possible proteins. 
The immune response to plasma NfHs and its proteolytic fragments may thus play a 
central role in the change in plasma NfH levels in ALS patients in different phases of 
the disease. 
4.4 Discussion 
In this Chapter I investigated whether plasma NfH levels may be used as a 
biomarker of disease progression in ALS.  I have: i) validated whether the method 
developed in Chapter 2 is suitable for analysis of human plasma samples; ii) 
conducted a baseline cross-sectional comparison of plasma NfH levels between 104 
control subjects and 136 ALS patients; iii) undertaken a longitudinal analysis of 
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serial samples from 74 ALS patients; iv) tested the prognostic value and functional 
correlation of plasma NfH levels in ALS patients; v) identified a potential sampling 
bias in ALS patients that may be a general practical challenge in biomarker studies 
of all neurodegenerative disorders that do not have a clear-cut disease onset; and vi) 
identified a possible additional mechanism that influences the plasma NfH levels in 
ALS patients. 
4.4.1 Plasma NfH levels are related to disease duration and disease 
progression in ALS and may also be affected by the immune response: NfH is 
not a ready-to-use biomarker of disease progression for ALS 
In this Chapter, I firstly confirmed the presence of the ‘Hook Effect,’ a technical 
obstacle caused by the form of NfH aggregates, which prevent accurate 
quantification of plasma NfH using ELISA methods. This hurdle was overcome by 
the use of a modified version of ELISA method for plasma NfH detection developed 
in Chapter 2. Next, using a large heterogeneous cohort of ALS patients, a cross-
sectional analysis of plasma NfH levels showed that there was no significant 
difference in plasma NfH levels between ALS patients and control groups at 
baseline, the time of the first sampling. This finding is in contrast to previous reports 
of NfH levels (Boylan et al., 2009). However, since these previous studies involved 
smaller cohorts of ALS patients and controls than the present study, it is likely that 
our results more closely reflect the high clinical heterogeneity of large ALS patient 
cohorts.  
 
Analysis of longitudinal changes in plasma NfH levels, showed that patients with a 
shorter diagnostic latency and disease duration, are not only more likely to progress 
faster, a finding that has been also described by others (Chio et al., 2009; Turner et 
al., 2010b), but to also have higher plasma NfH levels during the early stages of the 
disease (Fig. 4.6). Thus, in the ALS patient cohort examined in this Chapter, I found 
a correlation between plasma NfH levels and the rate of disease progression in ALS 
patients, where surprisingly, low levels of plasma NfH correlate with a poor 
prognosis. These findings also are in contrast to those reported by Boylan and 
colleagues, which suggested that high levels of plasma NfH correlate with a faster 
disease progression (Boylan et al., 2013), and may again be explained by the larger 
and more heterogeneous ALS population examined in the present study.   
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I also investigated whether a specific pattern of disease progression was reflected in 
a change in plasma NfH levels. Four main patterns of combined behaviors of these 
two parameters were identified, where patients either progressed or stabilised, 
accompanied by either an increase or decrease in NfH levels. These results show 
that changes in plasma NfH levels do not predict disease progression, in our large, 
heterogeneous population of ALS patients. It is possible, however, that in studies of 
small homogenous patient cohorts, one pattern of disease may predominate, 
resulting in an increased chance of detecting a false positive correlation between 
plasma NfH levels and rate of disease progression. Therefore, my results show that 
sampling bias may have a significant impact on the interpretation of cross-sectional 
biomarker studies, particularly those consisting of small sample sizes.  
 
My results also clearly show that, contrary to expectations, plasma NfH levels do not 
always increase as disease progresses in ALS patients. Since previous studies 
have detected the presence of auto-antibodies to other neuron-specific proteins in 
peripheral blood (Couratier et al., 1998; Fialova et al., 2010), it is possible that the 
rise of auto-antibodies may influence the levels of NfH in plasma of ALS patients. I 
therefore examined whether auto-antibodies against NfHs and their proteolytic by-
products could be detected in plasma of ALS patients. My results showed that NfH 
aggregate complexes in plasma of ALS patients may contain not only high MW NfH 
aggregates, a mixture of NfH monomers and low MW NfH fragments (endogenous 
cleavage products produced by enterokinases), but also human auto-antibodies to 
NfHs. The immune response to plasma NfHs and its proteolytic fragments may thus 
play a central role in the change in plasma NfH levels in ALS patients in different 
phases of the disease. 
4.4.2 Plasma NfH levels do not always increase as disease progresses in ALS 
The results presented in this Chapter have thus significantly increased our 
understanding of the relationship between disease progression in ALS, the 
bioavailability of NfH and the importance of the time of sampling in the disease 
course, which is key to the interpretation of case-control and cross-sectional studies. 
The large and heterogeneous cohort of ALS patients and controls subjects 
examined in this study is representative of the wider ALS population with regard to 
the delay from symptom onset to disease recognition, and the median (IQR) of 
diagnostic latency in our ALS patients is in line with other large population studies 
(Cellura et al., 2012; Iwasaki et al., 2002). For NfH detection, I have used an 
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efficient, sensitive and reproducible blood-based analysis, circumventing the need 
for invasive lumbar punctures. Using the immunoassay described in Chapter 2 for 
analysis of human plasma samples, I have significantly improved the sensitivity of 
NfH detection in plasma by overcoming the ‘hook effect’ created by NfH aggregates 
Fig 4.1 and Fig. 4.2). 
 
The longitudinal analysis of a biomarker throughout disease progression provides an 
unquestionable methodological advantage over cross-sectional studies. In this 
Chapter, I have obtained information which cannot be easily extracted from single 
time point measurements.  
 
In ALS, the invariably progressive nature of the condition may suggest a linear 
change in time of any biological signal that reflects the pathological process. This 
can be seen quite clearly in the SOD1 mouse model of ALS, where plasma NfH 
levels increase towards end-stage disease (Boylan et al., 2009; Lu et al., 2012). 
Furthermore, in this experimental model, we have been able to demonstrate a 
treatment effect of a known neuroprotective agent on plasma NfH levels (Lu et al., 
2012). However, the situation in the human pathology, as the present study 
demonstrates, is completely different. The profile of plasma NfH, at least within the 
disease time frame studied, varies significantly and depends on both the speed of 
disease progression and the delay from reported disease onset to baseline and 
subsequent NfH measurements, which may result from different expression levels of 
NfH mRNA in the neurons, different rates in the breakdown of NfH, and the reaction 
to the autoantibodies against NfH (Fig. 4.5). The differences in NfH bioavailability in 
sub-groups of ALS patients is likely to reflect not only the clinical heterogeneity of 
the disease, but also other unknown factors such as the rate of motor neuron and 
axonal degeneration in different disease phenotypes, NfH catabolism in biological 
fluids and possibly, as suggested in this study, the immune response to NfHs.  
4.4.3 Immune response against neuroglia-specific proteins in the peripheral 
blood 
My results also suggest that the rise of antibodies against NfH may accelerate the 
clearance of NfH and interfere with the detection power of antibody-based assays. 
Our immunoblotting results suggest a co-localisation of NfH fragments and human 
IgG components, which is in keeping with an immune response to the changing 
levels of NfH in plasma (Fig. 4.10A). Although we have not established the role of 
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these auto-antibodies in determining plasma NfH levels, these findings suggest that 
these antibodies may be responsible for a faster NfH clearance and may also 
interfere with the actual sensitivity of our antibody-based assay.  
 
The potential importance of auto-antibodies to NfHs in ALS has been discussed 
previously. Recent studies have re-addressed the findings of significant elevations in 
serum auto-antibodies against neuronal and glial specific-proteins such as tau, 
microtubule-associated protein-2, tubulin, myelin basic protein, glial fibrillary acid 
protein and Nfs in airline crews (Abou-Donia et al., 2013) and in serum/CSF against 
Nfs in early MS patients (Fialova et al., 2013). It is therefore possible that the 
humoral immune response to plasma NfHs may itself be the primary target of future 
exploratory studies into biomarkers of disease progression in ALS.  
4.4.4 Possible explanations for the discrepancy in plasma NfH levels between 
animal models and men  
The Results presented in Chapter 3 showed that plasma NfH increase as disease 
progresses in SOD1 mice. This finding is in contrast to the Results of this Chapter, 
which show that this is not the case in human ALS patients. There may be several 
reasons for this discrepancy between the mouse models of ALS. Firstly, in contrast 
to ALS patients, SOD1 mice exhibit a very well characterised, homogeneous pattern 
of disease, with minimal variation in disease onset, site of onset, duration and end-
stage, especially in colonies which are well maintained, managed, and monitored for 
gene copy numbers, fluctuations in lifespan of male stud mice. This homogeneity is 
enhanced when mice of a single gender are examined as in Chapter 3, as gender is 
known to affect disease progression in the SOD1 mouse model (Kalmar et al., 2008). 
Furthermore, disease progression in this model is extremely aggressive and 
SOD1G93A mice in our colony die, on average, by Day 130, showing for a clear 
neuromuscular deficit around 100-110 days. This phenotype, of homogeneity and 
rapid disease progression, is very different from the disease phenotype observed in 
a large cohort of ALS patients, which are clearly characterised by a significant 
heterogeneity in all aspects of the disease. Furthermore, it is possible that the 
rapidity of the disease observed in SOD1 mice is such that an immune response to 
plasma NfH is not initiated, unlike in ALS patients, where the prolonged duration of 
disease makes this more likely. 
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4.4.5 The impact of this study for biomarker studies in ALS 
In addition, whilst the transgenic animal model of the ALS provides the opportunity 
to study the very early stages of the disease process when the animal is largely 
asymptomatic, investigations in humans capture only the later stages of disease. 
Ultimately, the use of NfHs or other proteins as prognostic biomarkers for ALS will 
be best served by study designs that allow a preliminary longitudinal evaluation of 
their expression. The use of a biomarker as an outcome measure in clinical trials 
implies a projected change of the area under the curve of the longitudinal 
measurement reflecting a treatment response. This, as findings described in this 
Chapter shown, can only be achieved with prior knowledge of the expression profile 
of the biomarker in the natural course of the disease and of the specific expression 
profile that each phenotypic variant of the disease may entail. 
 
The data presented in this Chapter also suggest that the asymptomatic phase of 
ALS and the delay to diagnosis or plasma sampling have a significant effect on NfH 
measurements performed in the symptomatic phase. ALS patients in the study were 
sub-grouped according to the delay from ALS onset to baseline sampling. This time 
interval reflects the diagnostic delay, as baseline sampling in most of patients 
occurred either at diagnosis or up to 3 months later. Plasma NfH levels in ALS-F 
patients were higher during earlier stages of disease and reduce as the disease 
progresses, possibly as a consequence of the depletion of the motor neuron 
population. In contrast, ALS-S patients tend to have relatively low levels of NfHs 
during earlier stages of disease, which increase in the later stage of the disease. It is 
possible that plasma NfH levels may reflect neuropathological changes driven by a 
disease that proceeds at different speeds in different patients. The higher NfH levels 
detected in ALS-S patients may indicate the development of a level of 
neurodestruction that occurs earlier in ALS-F patients. Whether ALS-S subjects 
would exhibit, at later disease stages, a decrease of NfH levels as observed in end-
stage ALS-F cannot be determined from our study. However, it is clear that the 
results of the longitudinal study presented here show that the level of information 
that cross-sectional studies can provide is severely limited, as the results are subject 
to significant sampling bias and are critically dependent on the chosen sampling 
time in the study population.  Thus, cross-sectional studies alone cannot provide a 
comprehensive representation of the bioavailability of markers such as NfHs, whose 
expression changes throughout the disease course. 
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4.5 Conclusions 
Taken together, the results presented in this Chapter show that plasma NfH levels in 
ALS patients differ from the pattern observed in SOD1 mouse models of ALS 
(presented in Chapter 3). In the animal models, the materials used for investigation 
are homogenous and are also neatly time-controlled. However, in 
neurodegenerative disorders so heterogeneous as ALS, the pre-diagnosis variation 
between patients are still huge, even though researchers can achieve a short 
diagnosis-to-sampling/study delay. Cross-sectional studies with strict enrolment 
criteria can certainly reduce the heterogeneity in the study cohorts, although this 
approach simultaneously raises the concern of low representative such patient 
cohorts are. This is a dilemma commonly faced in ALS biomarker studies and 
clinical trials. 
  
My findings from the longitudinal analysis of plasma NfH levels in a large 
heterogeneous ALS cohort reveal several limitations that are not revealed in studies 
of small homogenous ALS cohorts. Although plasma NfH is correlated with disease 
progression in ALS, as shown in this Chapter, NfH levels are not only determined by 
the progression and disease course of ALS itself, but might also be affected by the 
immune response in individual patients. This is a very important finding in blood-
based biomarker research, as several studies have now shown that auto-antibodies 
against neuroglia-specific proteins are produced in the blood (Abou-Donia et al., 
2013; Fialova et al., 2013). Hence, for any blood-based neurochemical biomarker 
study, it is not possible to draw any positive or negative conclusions from small 
homogenous patient cohorts, particularly in studies involving proteins that are 
directly related to the pathology of ALS. Moreover, the findings of this study also 
highlight the role that the immune system may play in ALS biomarker studies.  
 
From this study I conclude that there are several ways by which blood-based 
biomarker studies for ALS could be improved: 
i) Studies should be undertaken longitudinally and in a large 
comprehensive cohort of ALS patients to gain an overview of the target 
biomarker as a function of disease progression. From such a study, 
patients sub-groups can be subsequently identified and analysed; 
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ii) The probability of an immune response to the target biomarker must be 
considered and investigated, as auto-antibodies may have a significant 
effect on the levels of the target molecules.  
 
 The Results presented in this Chapter was submitted to Neurology, under 
Review. 
Ching-Hua Lu, Axel Petzold, Jo Topping, Kezia Allen, Jan Clarke, Jens 
Kuhle, Gavin Giovannoni, Pietro Fratta, Katie Sidle, Mark Fish, Richard 
Orrell, Robin Howard, Linda Greensmith, and Andrea Malaspina. Plasma 
NfH levels and group-based trajectories of disease progression in ALS: 
Insights from a longitudinal study.  
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Chapter 5 
Discussion 
 
 
The experiments described in this Thesis have examined whether plasma NfH 
levels may be a biomarker of disease progression in SOD1 mouse models of ALS 
and in ALS patients.  
5.1 The development of a sensitive, reliable immunoassay for the 
quantification of NfH in plasma of SOD1 mice and ALS patients.  
In the experiments described in Chapter 2, I first evaluated the suitability of methods 
that have been previously used for measuring NfH in the CSF (Petzold et al., 2003) 
to be employed for the detection of plasma NfH in SOD1G93A mice. As can be seen 
in Table 2.2, the assayed values for serial sample dilutions of SOD1 plasma 
increased as the dilution factor increased, while NfH in the WT animals remained 
undetectable. A similar phenomenon was observed using plasma samples from ALS 
patients. The identification of the ‘Hook Effect’ and the presence of high MW NfH 
aggregates in the plasma of SOD1 mice and ALS patients, phenomena thought to 
be due to endogenous binding of protein fragments, were overcome by pre-
incubation of plasma samples with 0.5 M urea. This enables the accurate and 
consistent detection of NfH not only in plasma from diseased animals and from ALS 
patients, but also in plasma from healthy individuals. The sensitivity and reliability of 
the method developed in this study is clear if our results are compared with those of 
previous reports investigating plasma NfH as a potential biomarker of ALS. These 
studies have shown low or late detection of plasma NfH in SOD1 mice and 
undetectable plasma NfH in WT mice (Boylan et al., 2009; Gnanapavan et al., 2012). 
In addition, the detection in our study of hyperphosphorylated NfH in plasma from 
healthy WT mice and from healthy controls shows that the presence of 
hyperphosphorylated NfH in the peripheral blood is not in itself indicative of 
pathology. 
5.2 Plasma NfH levels in clinically homogeneous SOD1 mouse models of ALS 
As a proof of principle, serial experiments examining plasma NfH levels in different 
mouse models of ALS were undertaken and correlated with readouts of disease 
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progression and the therapeutic effects of various known and potential therapeutic 
agents.  
5.2.1 Plasma NfH levels increase during disease progression is detected in 
both rapidly-progressing SOD1G93A and slowly-progressing SOD1G93Adl mouse 
models of ALS 
SOD1G93A mice have a homogeneous, aggressive, rapidly progressing disease 
phenotype in which neurofilament pathology is a disease hallmark. The Results 
presented in Chapter 3 show that plasma NfH levels increase significantly in 
SOD1G93A mice between 105 to 120 days of age. Increased plasma NfH levels do 
not reflect the earlier stages of disease in SOD1G93A mice, where NfH levels were 
similar in SOD1G93A and WT mice. Nonetheless, even prior to symptom onset, there 
was a larger variation in plasma NfH levels in SOD1G93A mice than WT mice, 
suggesting the beginning of the release of NfH into the peripheral blood. Similarly, 
but not identically, in the slow-progressed SOD1G93Adel mice, plasma NfH levels 
increased in parallel with disease progression, although there was a limitation of 
small numbers of samples analysed in this set of experiments. These findings 
suggest that plasma NfH levels increase during disease progression not only in 
rapidly-progressing SOD1G93A mice, but also in the more slowly-progressing 
SOD1G93Adl model which may be more relevant to the pattern of disease progression 
in ALS patients.  
5.2.2 Plasma NfH levels correlate with readouts of disease progression in 
SOD1G93A mice 
In SOD1G93A mice, plasma NfH levels correlate well with functional and 
morphological readouts of disease progression. There is a good correlation between 
plasma NfH levels and the decline in grip strength in SOD1G93A mice in the 
longitudinal assessment presented in Chapter 3. Moreover, the increase in NfH 
levels parallels the loss of muscle force and motor unit survival in the acute, cross-
sectional physiological assessment of disease phenotype. Amongst the most 
important readouts, there is a good correlation between plasma NfH levels and the 
motor neuron death in the spinal cord of SOD1G93A mice in the morphological 
assessment.  
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5.2.3 Plasma NfH levels reflect the therapeutic effects of established and new 
agents in SOD1G93A mice 
In SOD1G93A mice, plasma NfH levels were found to reflect the therapeutic effect of 
several test drugs. The first drug tested in this Thesis was Arimoclomol, a co-inducer 
of the heat shock response, which has previously been shown to have beneficial 
effects in SOD1G93A mice, improving neuromuscular function and prolonging lifespan 
(Kalmar et al., 2008; Kieran et al., 2004). The Results presented in Chapter 3 show 
that lower plasma NfHSMI34 levels are observed during the pre-symptomatic stages in 
Arimoclomol-treated SOD1 mice, suggesting a beneficial effect of Arimoclomol 
which is reflected in the reduction in NfHSMI34 levels in the blood. In the later disease 
stages, Arimoclomol-treated SOD1 mice tend to have lower levels of plasma NfH, 
although the difference in treated and untreated mice only reach significance at end-
stage.  
 
Interestingly, in the preclinical study of Cogane and Riluzole, mice treated with the 
two drugs have very different morphological and physiological profiles as well as 
plasma NfH levels. For example, in Riluzole-treated SOD1 mice, although their 
muscle strength and motor unit survival were not different from Vehicle-treated mice, 
these mice presented with an improved motor neuron survival and a reduction of 
plasma NfH levels. In contrast, in Cogane-treated SOD1 mice, there is an 
improvement in muscle strength, motor unit survival and motor neuron survival, 
compared to untreated mice, and these mice also present with significantly higher 
plasma NfH levels than those treated with Riluzole. These results suggest it is likely 
that Riluzole and Cogane target two very distinct mechanisms so that their 
neuromuscular profiles and plasma NfH levels are therefore different. These findings 
also imply that plasma NfH levels may be a potential candidate to be used as an 
outcome measure in clinical trials of new agents.  
5.3 Plasma NfH levels in a cohort of clinically heterogeneous ALS patients 
The Results presented in Chapter 3 from homogenous SOD1 mouse models of ALS 
suggest that plasma NfH levels a promising biomarker of disease progression in 
ALS, at least in these mouse models. In Chapter 4, I next examined the possibility 
that plasma NfH may also be a biomarker in a large, heterogeneous cohort of ALS 
patients. 
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5.3.1 Plasma NfH levels are influenced by disease duration, rate of disease 
progression, composition of study cohorts, and likely auto-antibody to NfH as 
well  
The pattern of plasma NfH levels in ALS patients were not as straightforward as 
those detected in SOD1 mice as a function of disease progression. The Results 
presented in Chapter 4 show that there is no significant difference in plasma NfH 
levels between ALS (n=136) and control subjects (n=104) in a cross-sectional study 
at baseline sampling. However, if ALS patients are further sub-grouped according to 
the disease duration from the reported onset of symptom to their baseline sampling, 
patients sampled within the first year of disease onset tend to have higher plasma 
NfH levels than the controls and those sampled in the second year. These results 
suggest that disease duration may play a role in determination of plasma NfH levels.  
 
The analysis of the longitudinal pattern of plasma NfH from baseline sampling 
amongst our 74 patients who had serial samplings showed that fast-progressing 
ALS patients (ALS-F) had plasma NfH levels that declined during disease 
progression while the levels in slowly-progressing ALS patients (ALS-S) remained 
steady, then increased later during the follow-up. These results suggest that plasma 
NfH levels are dependent on the rate of disease progression. Furthermore, the 
analysis of the longitudinal pattern of plasma NfH from the onset of symptoms, with 
further sub-grouping according to the overall disease progression rate, revealed 
distinct patterns between ALS-F and ALS-S patients at different disease durations. 
These results suggest that plasma NfH levels are influenced not only by the rate of 
disease progression but also by the disease course.  
 
A correlation between plasma NfH levels and the disease progression rate, 
determined by the ALSFRS_R, is more likely to be observed over short periods, i.e. 
between visits in the study rather than overall, from onset to baseline sampling or to 
the last available visit. However, this correlation is dependent on the composition of 
the patient cohort in the study as patients with different disease progression rates 
and disease durations at the time of sampling will affect the pattern of plasma NfH 
and hence its correlation with disease progression.  
 
Since plasma NfH levels do not always increase during disease progression in a 
large cohort of ALS patients, unlike in SOD1G93A mice, I examined the possibility that 
other factors/mechanisms may be influencing plasma NfH levels. Previous studies 
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have shown that an immune response to neuroglial specific proteins can be 
detected in the peripheral blood (Abou-Donia et al., 2013; Couratier et al., 1998; 
Fialova et al., 2010). I therefore examined whether there was any evidence of an 
immune response to the presence of NfH in plasma ALS patients. In the preliminary 
study, western blot, bands stained for anti-human IgG strikingly co-localised with 
bands stained for NfH, at high MW aggregates, monomers and proteolytic fragments, 
suggesting a possible role played by auto-antibodies against NfH in the peripheral 
blood in the determination of plasma NfH levels.  
5.3.2 Sampling bias is likely in small homogeneous cross-sectional studies of 
ALS patients: The need to re-think the use of baseline sampling 
The Results presented in Chapter 4 have shown that plasma NfH levels in ALS are 
influenced by the progression of ALS itself. Hence for neurochemical markers that 
are pathologically relevant to ALS, it is likely that small homogeneous cross-
sectional studies at baseline, particularly in studies targeting patients with an 
aggressive phenotype which enables them to be diagnosed as definite ALS with a 
short diagnostic interval, are un-representative of the clinical heterogeneity of ALS.  
Results from such studies may cause sampling bias, which can lead to a false 
conclusion about this marker. Moreover, the value of the data obtained at baseline 
should also be re-examined, as the baseline is an arbitrary time-point and could 
reflect very different stages of disease for different patients with different disease 
course. Only by increasing the number and the heterogeneity of patients in the 
cohort is it possible to further sub-classify patients in order to examine ALS as a 
whole disease, rather just a limited disease phenotype as currently undertaken in 
most of cross-sectional studies of ALS biomarkers. 
5.4 Conclusion 
In this Thesis, I have presented the results of experiments which resulted in the 
development of an improved immunoassay for the sensitive and reliable detection of 
NfH levels in plasma of mice and humans. In SOD1 mouse models of ALS, plasma 
NfH levels correlate well with disease progression and were a good outcome 
measure of the therapeutic effects of test drugs. In spite of the technical 
improvements and the promising results from SOD1 mice, the findings in a large 
heterogeneous ALS patient cohort are in contrast to the findings in the animal 
models. Figure 5.1 summarises the timeline of key clinical events and the use of  
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Figure 5.1 
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Figure 5.1. Timeline of key clinical events and the use of biomarkers in SOD1 
mice and in ALS patients. Schematic illustrations show the timeline of key events 
and the potential use of biomarkers in clinically homogeneous SOD1 mice (A) and in 
clinically heterogeneous ALS patients (B). SOD1 mice have well-characterised 
disease phenotypes, age of onset, rates of disease progression and duration of 
survival. In longitudinal biomarker studies in mice, it is possible to develop 
biomarkers for disease progression, prognosis, treatment effect and toxicity due to 
their disease homogeneity, as observed with plasma NfH levels in the experiments 
presented in this Thesis (Chapter 3). In contrast, ALS patients are highly 
heterogeneous with regard to initiating events, age of onset, disease phenotypes, 
rates of disease progression and disease duration. Therefore, the baseline in clinical 
trials and cross-sectional biomarker studies is arbitrary and may represent different 
disease stages amongst individual patients. Nonetheless, it is still possible to 
develop biomarkers of disease progression when patients are sub-classified 
according to disease phenotype in large comprehensive longitudinal biomarker 
studies, as observed in the study presented in Chapter 4, for plasma NfH levels in 
ALS patients. 
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biomarkers in SOD1 mice and in ALS patients, according to the results obtained 
from this Thesis. These results provide new insights into biomarker studies in ALS.  
 
Several important lessons have been learned from the experiments presented in this 
Thesis, including: 
 
i) Blood-based biomarker studies in ALS should be undertaken longitudinally and in 
a large comprehensive cohort of ALS patients in order to gain an overview of the 
target biomarker as a function of disease progression. From such a study, patient 
sub-groups can be subsequently identified and then analysed; 
 
ii) The possibility of an immune response to the target biomarker should be 
considered and investigated, as auto-antibodies may have a significant effect on the 
levels of the target molecules;  
 
iii) Despite the promising results observed in SOD1 mice and the correlation with 
disease progression in ALS patients shown both in Chapter 4 and in previous 
studies (Boylan et al., 2009; Boylan et al., 2013), plasma NfH levels are not a simple 
marker of disease progression in ALS patients. However, with the insights obtained 
from this Thesis, it is possible that the correlation between plasma NfH and disease 
progression may be revealed in further studies. 
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